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The genus Glycyrrhiza, encompasses several species exhibiting complex structural 
diversity of secondary metabolites and hence biological activities. The intricate nature of 
botanical remedies, such as licorice, rendered them obsolete for scientific research or medical 
industry. Understanding and finding the mechanisms of efficacy or safety for a plant-based 
therapy is very challenging, yet it remains crucial and warranted. 
The licorice plant is known to have Selective Estrogen Receptor Modulatory effects 
(SERMs), with a spectrum of estrogenic and anti-estrogenic activities attributed to women’s 
health. On the contrary, licorice extract was shown to induce pregnane xenobiotic receptor 
(PXR), which may manifest as a potential route for deleterious effects such as herb-drug 
interaction (HDI). While many studies attributed these divergent activities to a few classes of 
compounds such as liquiritigenin (a weak estrogenic SERM) or glycyrrhizin (weak PXR 
agonist), no attempt was made to characterize the complete set of compounds responsible for 
these divergent activities. A plethora of licorice components is undermined, which might have 
the potential to be developed into novel phytoSERMS or to trigger undesirable adverse effects by 
altering drug metabolizing enzymes and thus pharmacokinetics. 
In this work, we explored the mechanism associated with the efficacy and safety of 
components reported in the licorice plant. We utilized smart screening techniques such as 
cheminformatics tools to reveal the high number of secondary metabolites produced by licorice, 
which are capable of interfering with the human Estrogen Receptors (hERs) and/or PXR or other 
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vital cytochrome P450 enzymes.  
After the validation of our in silico models by using the previous knowledge in this area, 
the alerting phytochemicals from two Glycyrrhiza species (G. glabra and G. uralensis) were 
clustered. Exhaustive computational mining of licorice metabolome against selected endocrinal 
and metabolic targets led to the discovery of a unique class of compounds, which belong to the 
dihydrostilbenoids (DHS) class appended with prenyl groups at various positions. To the best of 
our knowledge, this interesting group of compounds has not been studied for their estrogenic 
activities or PXR activation. In addition, some of the bis-prenylated DHS have been reported to 
be present only in G. uralensis.  
Thus, we have ventured to synthesize a set of constitutional isomers of stilbenoids and 
DHS (archetypal of those found in licorice) with different prenylation patterns. Sixteen 
constitutional isomers of stilbenoids (M2-M10) and DHS (M12-M18) were successfully 
synthesized, of which six of them (M8, M9, M14, M15, M17, and M18) are synthesized for the 
first time to be further tested and validated with cell-based methods for their estrogenic activities. 
 We have unveiled a novel class of compounds, which possess a strong PXR activation. 
These results, which were in accord with the in silico prediction, were observed for multiple 
synthesized prenylated stilbenoid and DHS by the luciferase reporter gene assay at µM 
concentrations. Moreover, this activation was further validated by the six-fold increase in mRNA 
expression of Cytochrome P450 3A4 (CYP3A4), where three representative compounds (M7, 
M10, and M15) exceeded the activation fold of the positive control. 
Another aspect of the current project was to predict the phase I primary metabolites of 
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compounds found in both species of Glycyrrhiza and assess them with computational tools to 
predict their binding potential against both isoforms of hERs or drug metabolizing enzymes such 
as (CYP) inhibition models. Our investigations revealed estrogenic character for most of the 
predicted metabolites and have confirmed earlier reports of potential CYP3A4 and CYP1A2 
inhibition. 
Compilation of such data is essential to gain a better understanding of the efficacy/safety 
of licorice extracts used in various botanical formularies. This approach with the involved 
cheminformatic tools has proven effective to yield rich information to support our understanding 
of traditional practices. It also can expand the role of botanical drugs for introducing new 
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CHAPTER I                                                                                                                         
INTRODUCTION 
 
I.1 Natural product research remodeling: Medical research and clinical practice 
perspectives 
 The inherently complicated nature of an herbal remedy usually precludes the full 
understanding of its activity or safety. The polypharmacology represented by modulation of a 
network of targets and the infeasibility of the experimental testing of every reported secondary 
metabolite denotes the major hurdles in botanical research. This is coupled with the natural 
products chemical complexity, which imposes vast difficulties regarding their supplementation 
and progression in medical research. Therefore, in the past few decades, we have witnessed a 
biased investment into focused small molecule libraries generated by combinatorial chemistry as 
the mainstream for drug development. Unfortunately, the results were seemingly   
contradictory.1-5 
The clinical attrition of the vast majority of the new chemical entities was devastating and 
described as “productivity crises.”6-7 In part, this situation has been correlated to the phasing out 
of NPs from the drug discovery pipeline.8 On the other hand, one analysis revealed that 60% of 
the registered chemical entities in 1981 to 2010 are either natural products or natural products 
related molecules including NP derivatives or NP synthetic mimics.9 Undeniably, natural 
products are the ideal primary resource of new chemical entities by natural selection. The 
interactive environment in which these natural products have evolved should have indulged them 
with exceedingly incomparable therapeutic potentials. Therefore, they are predicted to harbor 
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chemical pharmacophores with preferred interactions toward surrounding biological 
targets.10-11 One interesting example is the blockbuster drug rosuvastatin, which is used for 
hypercholesteremia. This drug is considered as a synthetic mimic of mevastatin, a natural 
product from Penicillium citrinum fungus but with a less intricate scaffold for chemical synthesis 
(Figure 1).12  
In addition to the above, NPs are still used as a basic therapeutic option side by side as 
traditional medicine worldwide. In general, there was a global drift towards the use of natural 
products supplements, which was driven by the perception that they are safe and efficacious.13 
Correspondingly, the sales of these supplements peaked to $7.45 billion in 2016.14 The current 
cliffs where both the medical research and clinical practices stand has created a chain reaction in 
the natural product field. At this moment, it became a requisite to understand the drawbacks of 
the existing strategies and practices in this field, and to improve their competences. For instance, 
although coupling the biological assays to the chemical investigation of the NP was meant to 
rationalize the process of isolation in this field, but soon it was clear that it failed to prove their 
efficacy in the clinical trials in many occasions.15-16 In fact, these practices were incomplete to 
draw the complete picture of how these systems operate. Some of the reasons behind these 
failures are summarized in Figure 2.17-18 
These concomitant conclusions in both fields pointed out to the necessity of 
understanding the mechanism of action of NP or herbal remedy as to a priority to prove their 
efficacy and safety in the clinical practice and to eliminate the difficulties that undermined their 
engagement into the pipelines of the medical research. In silico investigation of natural products 
provides a versatile toolbox to deal with its complexity.4 In the past few decades, virtual 
screening (both structure-based and ligand-based approaches) has been utilized as a basic tool to 
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capture novel scaffolds out of diverse chemical libraries against known pharmacological targets. 
19-20  
Additionally, the growing field of genome mining, chemogenomics and molecular 
networking constitute a promising avenue to approach novel and effective NPs leads by 
application of multiple sophisticated computational tools.21 Nevertheless, in this context, natural 
product libraries are only partially and passively integrated into this procedure. However, to 
enrich their engagement in the process they should be treated separately before their direct 
employment. Creating this shortcut will inspire drug design and development effectively by 
capturing NP hits or generating natural product fragment libraries as fingerprints of active 
motifs, specifically, with the accumulating knowledge and computational tools to predict the 
pharmacodynamics and pharmacokinetic properties of molecules along with the growing 
numbers of NP entries in the databases. Moreover, it would also help us to explore novel 
candidates as natural-product-lead-structures in a time and cost-effective manner                   
(Table 1.).4, 12, 22 
 Figure 1. Natural products as a source of NCEs: Application of novel 





However, searching for lead compounds from NP origin is not the sole application of in 
silico procedures and virtual screening. They should be utilized for understanding the  
multi-targeted (polypharmacology) and off-targeted effects (toxicity) of the known plant therapy, 
defining the best components, which are capable of interacting with specific targets including 
enzymes involved in drug metabolism. The prediction of macromolecule targets for molecules of 
natural origin (reverse pharmacognosy), might solve the long lasted debate about the efficacy of 
herbal remedies. These concepts came along with the growing paradigm of reverse virtual 
screening or inverse docking, which is a direct consequence of thousands of accumulating solved 
protein crystal structures into data banks. Other approaches explored feature and similarity 
searches for target fishing.23-24  
 
Figure 2. An overview of BGF drawbacks that might lead to sub-clinical significance of 




 In the context of plant therapy, this would achieve the ultimate goal of defining a 
spectrum of potential activities and spotting the possible natural products candidates behind 
them. Conversely, it might predict or explain in early stages why such therapies end up with 
controversial conclusions when extrapolating to in vivo settings. For instance, adapting such 
methodologies have unveiled both peroxisome proliferator-activated receptor gamma and 
cyclooxygenase-2 as the main targets of Meranzin. Interestingly, the latter molecule was shown 
to have a potency comparable to their conventional drug therapies, rosiglitazone, and 
indomethacin.20 By the application and benchmarking of such methods, we should be able to 
define and rationally prioritize the targets, which should be screened.  
The diverse nature of plant secondary metabolites and their natural resources 
inconsistency has also dampened the study of their pharmacokinetic interaction with 
conventional therapeutics. They are the major contributors to why these effects are left 
underestimated and thus understudied. Although several HDIs are well known in the literature, 
the study of these events is still retrospective. This is quite concerning as one study showed that 
4 out of 10 adults in the US engage alternative and complementary medicines in their life. 
Around 20% of these are natural products.25-28 Moreover, concerning the HDI, it became clear 
that the NP entities play a complex role at the molecular level. Besides the direct interaction with 
the metabolizing enzymes and transporters, recent studies uncovered the significant role played 
by PXR mediating or exaggerating these effects.13  
The recent development of a systematic approach by the FDA to prioritize the natural 
supplements with the high-risk potential of precipitating an HDI is still dependent on the ranking 
and scoring of gathered information. However, there is a clear basic need for adapting 
prospective methodologies.25 In this context, the in silico oriented approaches, which try to 
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tackle the human-xenobiotic disposition system should take the lead. This trend has been 
motivated by the low-cost and the efficiency of such approaches, and it is aggravated by the 
clinical attrition of drug candidates in the clinical trials. In fact, the latter events along with 
several cases of FDA “approved drugs” withdrawals (because of CYP enzymes related drug-drug 
interaction) have escalated the need to screen for drug safety at an early stage of any drug 
development. This situation has created a surge of in vitro data measuring different metabolic 
endpoints such as metabolic stability or inhibition for thousands of chemical entities. In addition, 
the last few years have witnessed crucial advancements in the knowledge of metabolic pathways 
and their regulation as well as the structural and functional understanding of their operating  
machinery.29-30 
 In all, these events have created a momentum to develop multiple computational models 
to screen for different metabolic endpoints. Similar to the efficacy predictions, these 
computational approaches are also classified as ligand-based and structure-based models. On the 
grounds of reality, metabolism is among the most complex properties to predict. Unlike 
conventional targets, metabolic processes recruit a variety of enzymes with multiple isoforms 
and transporters, which are created to process a diverse group of chemical structures known as 
“xenobiotics”.   
Table 1: Selected natural product databases and number of entries  
 
Database NPs entries Content 
Dictionary of 
Natural products 
40,000 NPs found in the literature 
SymMAP 19,595 
NPs from listed in Chinese medical texts with target 
prediction 
SuperNatural II 326,000 NPs with the description of toxicity and target prediction 
Zinc 15 80,617 NPs found in the literature with a purchasable list 
CheMBL >75,000 NPs structures from the literature 
MarinLit 26,490 Marine NPs  found in the literature 
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Hence, making them usually larger, more flexible and promiscuous.31 Additionally, their 
expression is further regulated by several chemical, genetic and environmental factors. 
Nevertheless, assessing these properties is vital for developing NCEs as well as for herbs in order  
to avoid drug-drug or HDI that may lead to suboptimal dosing of accompanying drugs or even 
adverse effects.  
Thus, the best rationale in such a scenario is “to divide and conquer.”  Incorporation of 
multiple computational models including the CYP enzymes and their regulators such as PXR or 
CAR, which are most involved in drug disposition, would be a better practice. Particularly the 
CYP enzymes, where multiple models can measure different aspects of the process such as 
substrate/inhibition properties, substrate selectivity, regioselectivity (the site of metabolism the 
expected metabolites), and the rate or extent of metabolite generation or inhibition. The vast 
majority of metabolism occurs via CYP enzymes, particularly, CYP3A4, which is solely 
responsible for the metabolism of nearly half of the prescription drugs.31-33  
As a direct result of this discussion and to approach the pharmacokinetic and metabolism effects 
of herbal drug therapy with a known multicomponent system, the in silico models offer a good 
starting point to untangle the complexity of the situation. 
I.2 Cheminformatic approaches to unravel the biological functions and potential safety 
issues associated with herbal drugs.  
Application of cheminformatics to solve the complexity of an herbal remedy is enticing. 
Cheminformatics offers a diverse set of tools, which includes physics-based models comprising 
both quantum chemistry and molecular dynamics simulations. In addition, it encompasses the 
machine learning approaches that apply certain algorithms to recognize similar patterns and to 
find mathematical relationships between empirical observations. This could be applied to small 
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molecules in order to predict their properties (chemical, physical or biological). Furthermore, 
these techniques can be classified into structure-based and ligand-based approaches depending 
on the experimental design. Some of the commonly applied approaches include docking, 
pharmacophores, quantitative structure-activity relationships, similarity searches, and machine 
learning.  
 In fact, such approaches have proven to be effective in multiple research areas in 
medicine and drug design, which emphasizes the expansion of these terms to the phytochemical 
field in various applications such as activity profiling, mechanism of action and ADMET 
prediction including safety issues and HDI. The exponential increase in computational power 
represented by speed, accuracy, and cost, reinforces the importance of such techniques in every 
project agenda. 
 The following will be a brief overview of the implemented approaches in our study.  
I.2.1 Structure-based approaches: Molecular Docking  
 
The three dimensional and structural information extracted from biological targets forms 
a fundamental aspect of the structure-based approaches, which mainly includes molecular 
docking, virtual screening, and molecular dynamics. Exploring the transient interactions between 
small molecules and their targets became more and more feasible with the increasingly 
accumulating solved protein crystal structures in the databases. Moreover, the prediction of these 
interactions became sufficiently accurate with the advent of more sophisticated algorithms and 
scoring functions.34  
The process of docking is a multistep procedure that will predict the posing of the ligand 
by defining specific conformation and orientation within the binding site of a certain target. The 
aim of this process is to predict a correct pose and to estimate the binding energy of the small 
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molecules toward their targets. Docking procedures involve three premises. The first one is the 
flexibility of small molecules. The second premise is the flexibility of the protein followed by the 
scoring method.35 Small molecules usually have multiple degrees of freedom.  
The conformational sampling algorithm will provide a multi-conformer database to find the best 
conformation, which matches the binding site. The sampling procedure could be systematic, but 
most often it is stochastic to comply with the high throughput nature of the docking virtual 
screening. This ligand sampling procedure could be a separate step, or it can be embedded within 
the docking protocol.  
However, protein flexibility is a bit more challenging issue due to its huge nature and 
complexity. Docking procedures differ in the degree of freedom allowed for the binding site 
flexibility which could be advantageous in multiple occasions, especially where the key and lock 
principle fails to explain the protein-ligand interaction. Accordingly, the docking procedure 
could be rigid, or semi-flexible. In the first case, the protein is restricted to one conformation 
while in the second case the protein is treated as a soft body by relaxing the potentials of the van 
der Waals radii, or by considering a rotamer library for the protein side chains. In fact, these 
protocols may or may not adequately select a true or active conformation of the protein. 
An alternative approach that we have adopted in this research is to consider multiple rigid and 
known active conformations of the protein-ligand complexes, which is known as ensemble 
docking.23, 35-36 
 For the third premise of the docking procedure, the direct evaluation and comparison 
between various ligand conformers inside the protein pockets are required. Most docking 
programs generate potential energy grids. In this context, grid points are set as reference points 
to store information about the binding site such as steric, electrostatic and van der Waals 
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potentials that will be used for scoring the ligand pose using atomic pair-wise interactions. 
However, the overall success of the docking procedure does not end by identifying the correct 
binding conformation. Rather, it will be judged for the correct pose prediction, differentiating 
between actives and inactives and the correct estimation of the binding energy. In fact, the latter 
aspect is not easily achieved in the regular setting, which relies on the scoring functions solely.  
Most often, the scoring function is inherently deficient for oversimplification of the energetic 
terms.35, 37-39 Accordingly, to achieve true binding energy calculations both enthalpy and entropy 
terms such as desolvation, translational and rotational entropy of the binding process should be 
considered. Alternatively, quantum mechanics or mixed approaches might be adapted. 
Nonetheless, the scoring methods are usually sufficient to rank the small molecules according to 
their simplified predicted energies.35  
I.2.2 Ligand-based approaches: Quantitative structure-activity relationships (QSAR) 
 
 Although it is reasonable to think of the protein’s 3D structure as a straightforward way 
to get information about the ligand-binding process, this technique comes to the sheer 
complexity of multi-factorial drawbacks. These are related to the X-ray crystal structure itself, 
the nature of the target protein or to the interactive binding process. For instance, some of the 
major problems of crystallographic structures are their explicit waters, their resolution and other 
artifacts related to the crystallization process. Hence, the computational chemist should decide 
which waters to keep and which ones to discard.  
Moreover, the inherent limitation of their resolution makes them blind to the hydrogen 
atoms. Then, it becomes problematic to decide if the ionizable groups inside the pocket are in 
their ionized form or not. Nevertheless, careful treatment and examination of these drawbacks in 
the structure-based approach will increase their rate of success. However, the docking process 
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could become more and more challenging with proteins, having large binding sites or greater 
flexibility. Experimentally, proteins could be heterogeneously expressed with different ligands or 
they could bind to multiple ligands at the same time. In addition, some of them have multiple 
isoforms, which mostly will create selectivity challenges.40 
 In such cases, considering single conformation of the protein, especially in a highly 
flexible one, would certainly undermine the dynamic process of a ligand interacting with a 
protein. In fact, there are multiple proposed solutions for such problems such as considering 
multiple protein structures, the soft docking, or by considering rotamer libraries of the protein 
side chains. On the other hand and as we have envisaged in this research with regards to the 
critical targets, combining an orthogonal approach along with the above mentioned would 
increase the true positives and decrease the false positives rates.36, 41  
 The ligand-based approaches provide an alternative solution to reach out for the best 
understanding of ligand-target interactions in the absence of the experimental structure of a 
protein or in the case of a challenging protein. Even though both approaches are divergent, they 
serve the same role of finding a true binder. The building blocks of ligand-based approaches are 
the QSAR and pharmacophore models. Emanating from the concept that actives should share 
common features or physicochemical properties that would yield similar bioactivity. 
Furthermore, better solutions (potent ligands) could be found in the neighborhood of good 
solutions (actives). Thus, a QSAR model is simply the mathematical representation that discerns 
and correlates the best physicochemical properties or “the descriptors” that can explain the 
affinity of ligands toward a biological target.  
The first step in this method is data mining. The availability of diverse and reliable 
experimental data is a fundamental step in this method. After which, energy minimization and 
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calculation of diverse structural and physicochemical descriptors should take place. 
Consecutively, the researcher should find the best combination of descriptors that can explain the 
variation in the biological activity followed by the statistical examination of the model power in 
predicting the activity of an external testing set. This approach uses 2D and 3D information 
embedded in the ligands. For instance, it could be coupled to a pharmacophore model which can 
enrich the 3D conceptual match of how active molecules could bind to their targets. A 
pharmacophore is defined as “the 3D spatial orientation of various features, such as hydrogen 
bond donors or acceptors, which are essential for the desired biological activity”.40, 42  
There are two general classes for the derivatization of structure-activity relationships, the 
linear and the nonlinear methods. In fact, there is no method superior upon the other; it is more 
related to the researcher choice and preference. Linear methods include multiple linear 
regression and partial least squares while the non-linear includes mainly the support vector 
machines and artificial neural networks.  
I.3 Cheminformatic approaches to understanding the efficacy and safety of herbal 
remedies - Licorice plant as a proof of concept  
The licorice plant is among the most popular medicinal plants that are marketed in the 
U.S. to alleviate multiple ailments, including cough, asthma and menopausal complaints, etc. In 
addition, it is recognized as one of the most studied herbs in the contemporary alternative 
medicine. Nevertheless, significant research gaps are still found. For instance, there is no definite 
explanation or even an appropriate recommendation of either its efficacy or safety. This includes 
its use as an alternative medicine for hormone replacement therapy, and as a chemopreventive 
agent, or adjuvant therapy in cancer treatments.17, 25In addition, consumed licorice supplements 
are prepared from different mixed species. Every species has its distinctive chemical profile, 
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which will yield a diverse spectrum of biological effects. This situation warrants the use of more 
sophisticated methods to empower and delineate activity endpoint detection in clinical trials or to 
detect pharmacokinetic liabilities as well. 
I.3.1 Licorice plant origin and medicinal use  
 
Licorice plant was recognized as a medicinal plant since the genesis of early civilization. 
The use of licorice is predated to the ancient Assyrians, Chinese and Egyptians and documented 
as a folk remedy in both Greek and Roman empires. The name Glycyrrhiza is a combination of 
two Greek words, which means the sweet (glycos) root (rhiza). In addition to its healing 
properties and as the name indicates this plant has been used as a sweetener, which was usually 
mixed with other bitter therapeutic herbs. This herbaceous, perennial herb is native to the 
Mediterranean region but it is also found in other parts of the world such as China, Russia, and 
India. The Glycyrrhiza genus belong to the family Fabaceae and consist of more than 28 species. 
However, three clinically relevant species are employed in the pharmacopeias namely 
Glycyrrhiza glabra L., Glycyrrhiza uralensis Fisch. and Glycyrrhiza inflata Batal. 
 The roots and rhizomes are the most widely used parts in both industry and therapeutic 
settings.43 Traditionally, the roots are used to treat cough, diabetes, stomachache, ulcers, and 
tuberculosis. In addition to the fresh leaves were used to treat wounds. In the past few decades, a 
variety of pharmacological activities have been described for licorice or its secondary 
metabolites such as antioxidant, anti-inflammatory, antitussive and expectorant, antimicrobial, 
antiviral, anti-carcinogenic, neuroprotective, estrogenic and antidepressant. The astonishing 
diverse spectrum of activities is not surprising since more than 400 compounds have been 




I.3.2 The licorice secondary metabolome: a vast interspecies diversity 
 
The secondary metabolites of medicinal herbs comprise a large reservoir of bioactive or 
toxic compounds.11 Generally, a substantial group of compounds might be shared between 
closely related species. However, their abundances would not be the same. In addition, different 
species usually express species-specific or marker compounds.46 As a result, a variation in 
therapeutic effect is expected when different species are used. In fact, it is of great importance to 
address the dissimilarities between plant species to assure safe and efficacious delivery of their 
therapeutic effects.  
Licorice species are among the richest and diverse plants in terms of secondary 
metabolites, producing triterpene saponins and a variety of phenolic compounds such as flavons, 
flavonols, isoflavones, isoflavenes, coumarines, and chalcones, and others.47-48 Multiple species 
are, usually, mixed and used without discrimination in the preparation of licorice based herbal 
supplements. For instance, G. uralensis, G. glabra, and G. inflata are used in Europe and China 
interchangeably as licorice. Whereas, in the United States and Japan only G. uralensis and G. 
glabra are used. The identity of the constituents is directly correlated to the efficacy or safety of 
the supplement, which emphasizes the significance of understanding the secondary metabolite in 
each species, the correct labeling of the herbal supplements and the standardization of the 
botanical to their active components rather than to their marker compounds. Fortunately, the 
licorice metabolome has been vigorously investigated by both targeted and untargeted 
analysis.46-47, 49-53 One recent study, analyzed 95 plant samples of the three species of licorice (G. 
uralensis, G. glabra, and G. inflata) and targeted 151 pure compounds known for licorice, has 
identified 12 and 13 species-specific marker compounds in both G. uralensis and G. glabra.54 In 
addition, they have deduced characteristic biosynthetic pathways in each kind. Based on their 
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findings, the 3-aryl-5-methoxyl coumarins, the isoprenyl isoflavanes and the 2’-H chalcones 
were expressed discriminatively in G. uralensis, G. glabra, and G. inflata respectively. This 
interspecies diversity can remarkably affect the intended medicinal use (Figures 3 and 4).54 
 
















I.3.3 Licorice plant for woman health  
 
There is a growing tendency among women to consume botanical supplements for a 
variety of reasons.17 This trend is predominant in older women for the chemoprevention or the 
relief of postmenopausal symptoms such as vaginal atrophy, hot flashes, bone loss, and 
cardiovascular and metabolic functional changes. Popular opinion drifted to natural sources after 
the findings that pharmaceutical hormone replacement therapy (HRT), represented by estrogen 
pills or the available selective estrogen receptor modulators, may induce or exacerbate already 
existing uterine or breast cancer.55 Moreover, several other studies encouraged the use of 
botanicals for their chemopreventive properties or protective effects against osteoporosis. 
However, none of these herbal treatments was carefully studied for their safety.17, 56-58 
Glycyrrhiza is commonly encountered in herbal supplements intended for 
postmenopausal symptoms relief in the United States. Many studies detected the estrogenic 
behavior of the clinically relevant licorice plant as well as for other defined phenolics isolated 
from them.17, 55, 59-63 In one recent study, G. inflata was shown to have the maximum efficacy for 
hERα activity in Ishikawa cells followed by G. uralensis and G. glabra respectively. On the 
other hand, G. uralensis was ranked first for the maximum efficacy toward hERβ followed by G. 
inflata and G. glabra.62 
 Liquiritigenin, a ubiquitous and major component in different licorice species was shown 
to produce weak estrogenic activity. However, several other compounds were also characterized 
by mixed estrogenic and anti-estrogenic behavior. Apparently, the estrogenic behavior of these 
species is a blend of multiple factors and can be traced back to many compounds that show a 




 A direct comparison between these species is intricate. Nevertheless, rigorous 
identification of these compounds is critical and further evaluation of their long term interaction 
with the estrogenic receptors is required in order to guarantee the safety of their use.             
I.4  Overall aims 
The grand challenges in botanical research starting from efficacy issues (how effective 
are extracts, marker compounds, and potent active constituents?) or safety issues (off-target 
effects, toxicity, HDIs, and other adverse effects) warrant the implementation of new strategies 
such as physiologically-based models and informatics. The analysis of multicomponent herbs 
using cheminformatics logic may be one of the effective, innovative tools that could be used. An 
approach that includes identification of active component(s) with computational tools, validation 
with cell-based methods will facilitate the identification of component(s) that could explain the 
activity of the botanical drugs. Such an approach could lead to a method to provide a mass 
comparison between multiple plant species.  
In view of the above discussion, we have envisaged that licorice plant would serve as the 
perfect demonstration in how to deal with a botanical issue of different levels or multiplicities. In 
this research, we have investigated the utility of cheminformatics methodologies as new 
strategies to identify the pool of the possible chemicals that could be attributed for certain 
activities or safety issues related to a plant species. 
1. Deconvolution of Estrogenic Potential of PhytoSERMs in Licorice (Chapter II) 
2. Synthesis of Unique Chemical Entities and their Estrogenic Activities (Chapter III) 
































CHAPTER II                                                                                                             
DECONVOLUTION OF ESTROGENIC POTENTIAL OF                                      
PhytoSERMs IN LICORICE  
 
II.1 Introduction  
II.1.1 PhytoSERMS: Chemoprevention vs endocrine disruption  
 
The recent term of “PhytoSERMs” came after two consecutive serendipities. The first 
one was the red clover disease, which was reported in the 1940s. Remarkably, a “botanical” 
estrogenic behavior was inferred from the observed infertility of the sheep grazed on grasslands 
that had the red clover.57 The second one was the discovery of tamoxifen in the 1960s, upon 
which the concept of “SERM behavior” was born. Tamoxifen had transformed from a failed 
contraceptive to the gold standard of the targeted chemotherapy of breast cancer in that era.56 
The estrogenic behavior of tamoxifen was puzzling; it showed different agonistic/antagonistic 
behaviors depending on the analyzed specific tissue. It has triggered antagonism and agonism in 
the breast and bone tissue respectively.64 The main underlying mechanisms behind this non-
classical activity involved the presence or absence of certain coactivators/corepressors proteins 
as well as the abundance of specific estrogen receptor isoform in the targeted tissue.56, 65   
 In fact, SERM tissue selectivity serves a multi-targeted therapy by antagonizing the 
estrogen-driven carcinogenesis in the breast tissue, while at the same time mimicking and 
maintaining the beneficial bone health. However, large-scale studies showed later that tamoxifen 
and other synthetic SERMs have detrimental effects on the uterine and endometrial tissues, 
which might lead to carcinogenesis. Consequently, to solve this estrogen paradox, the search for 
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alternatives SERMs with improved profiles was commenced. Finding novel SERMS with 
unique downstream expression events is extremely important, especially for the genes distinctly 
regulated by unique estrogen isoform.66-67  
Over time, phytoestrogens were recognized as a vital source of natural estrogens and 
multiple studies have verified their SERM behavior. Many of the first generation phytoestrogens 
belong to the isoflavonoids and flavonoids classes, but other structural types such as lignans, 
coumestans, and stilbenes or their prenylated congeners share the same properties.56 The 
significance of these phytoSERMS has grown immediately after the epidemiological studies 
among the Asian women. These studies found an interesting correlation between the 
phytoestrogen-rich diets and the diminished incidence of breast cancer as compared to the typical 
western women (These events have encouraged the western community to consume isoflavone-
rich diets in addition to other nutraceuticals prepared for this purpose (Figure 5).68 Presently, the 
debate about the efficacy and safety of these trends is still going on. The clinical studies 














Figure 5. Comparison of the incidence of breast and prostate cancer 
among the Asian and American people. 
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A recent study has shown that isoflavones -like genistein- are capable of inducing 
proliferation in cancer cells by altering the NFkβ (nuclear factor kappa-light-chain-enhancer of 
activated B cells) and AKT (Protein Kinase B) pathways in addition to hERs. This study 
revealed that they are capable of upregulating the gene expression associated with tumor 
proliferation via hERs.71 Conversely, many other studies concluded appealing results, where they 
recommended their use in both pre and post-menopausal women.68, 72  Taken together, there has 
been a steady conceptual buildup that phytoSERMs have the potential to act as chemopreventive 
agents, or as an estrogen surrogate to relief the vasomotor complications and to avoid 
osteoporosis.73  
Since then, the targeted population has free access to these phytoSERMs nutraceuticals 
and herbal preparations without any rigorous attention. This situation has undermined the safety 
of these products, where they might behave as endocrine disruptors. In addition, it underscores 
the potential harms of transforming these products from regular diets to every day pills. It 
ignores the fact that these products are mixtures of chemicals with high capability of 
manipulating the estrogenic receptors and their various gene expression responses. Actually, the 
short-term and small-sized studies are incompetent to rule out any possibilities. Moreover, 
although the FDA divines the potentials of these therapies, it recommends people and special 
population to take some precautions when consuming such products.74 On the other hand, these 
botanicals are considered as reservoirs of estrogens or estrogenic scaffolds each with a unique 
matrix of tissue, coregulator, gene, and isoform selectivity. A demanding requisite here is the 





II.1.2 The Human Estrogen Receptors 
 
 The first step to capture novel phytoSERMs from botanicals, which will aid in designing 
better SERMs, is to understand their mechanism of action. The estrogenic receptors belong to the 
nuclear receptor family, which are described as gene transcription regulators. Estradiol is the 
native ligand, which is responsible for triggering a cascade of gene transcriptional events that 
control the growth, proliferation, differentiation and the function of different tissues.75 There are 
two isoforms of estrogen receptors (hERα and hERβ); both are widely distributed in our bodies 
and both can be stimulated by estradiol. Higher hERα ratios found in the breast, ovarian, 
endometrial and hypothalamus tissues. On the other hand, higher hERβ ratios are found in the 
heart, kidney, lung, bone, brain, prostate, intestine and endothelial tissues.56, 75-76  
Additionally, unique tissues selectively express the specific type or concentration of 
coregulator proteins, which could act as coactivators or corepressors. hERβ has been shown to 
exert regulatory functions over hERα, while at the same time, they are both triggered by estradiol 
and share many target genes, indicating high similarity.76-77  Similar to other nuclear receptors, it 
consists of five main domains but the most important ones in terms of transcriptional activity are 
the N-terminal (DNA-binding Domain, DBD) and the C-terminal domain (ligand-binding 
domain, LBD).  
The LBD consists of 12 helices (H) and 4 β sheets, where the core layer that is in direct 
contact with the ligand is formed by H5, H6, H9, and H10. Three polar residues are established 
for receptor activation, in one side E353 (305 in hER β) and R394 (R346) and on the other side 
H524 (475). Generally, to fulfill the best H-bond network required for activation, the ligand 
should have a hydrophobic scaffold flanked with two polar sides separated by 11 Å. The amino 
acids lining the LBD of both hERs isoforms are almost identical except for two residues.77-81 
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Only two residues among those that line the binding pocket are found to be different: L384 
(hERα) vs. M336 (hERβ) and M421 (hERα) vs. I373 (hERβ).82-83  
Interestingly, ligands, which interacts with hERs, can direct the function of these 
receptors toward their active or inactive states. Previous experimental data correlated the 
conformation of the LBD of hER crystal structures to the ligand-induced activity. They can 
modulate the flexible helix H12 (one part of the active functional region 2 (AF-2) in the LBD), 
which allows variant conformations to take place as shown in Figure 6. Of note, the agonist, 
partial agonist and the antagonist conformations which will determine whether or not and which 
type of coregulator (coactivator or corepressor) might be hosted in the hydrophobic groove found 





























Figure 6. (Upper right) Open conformation of hER in brown cartoon (PDB: 2P15) 
with helix 12 in maroon. (Bottom left) Open conformation of hER in grey cartoon 
(PDB: 1L2J) with helix 12 in light pink. (Upper right) Helix 11 flexibility as shown 
by different orientations of the key residue histidine H524 (475). (Bottom right) Open 













II.1.3 Available cheminformatic information for the prediction of estrogenicity. 
 
Since the discovery of hERs in the 1960s up to date, the estrogenic behavior of synthetic 
and natural compounds became a hot topic in the scientific arena. This has been further 
aggravated by the emergence of the endocrine disruptors.84 Essentially, the world has witnessed 
an increasing number of exogenous chemicals that can interfere with the human endocrine 
system and induce adverse effects.  
This group of heterogeneous compounds includes many pesticides, herbicides, and fuel 
combustion by-products. This high burden of thousands of chemicals emerging has created a gap 
that exceeds the capacities of the regulatory agencies and the industrial sectors to follow and to 
evaluate their endpoint toxicities. Hence, to address this issue, the incorporation of multiple in 
silico and cheminformatic-based techniques have been created for the prediction of estrogenicity 
as well as other toxicity endpoints.85-87   
Among the list, there are two commercially available models viz., ADMET Predictor™ 
and MetaDrug™, and other open access sources viz., the free docking software the Endocrine 
Disruptome.88-90 Other free QSAR-based models are VEGA (Virtual models for property 
Evaluation of chemicals within a Global Architecture)91 and OCHEM (Online Chemical 
Environment).92 The first two models were generated from the same data set; the DSSTox 
database (Distributed Structure-Searchable Toxicity).93 In addition, they both offer a qualitative 
and a quantitative assessment for the estrogenic activity built by QSAR models of nonlinear 
analysis such as ensemble neural networks or recursive partitioning algorithms, respectively. The 
OCHEM model was generated using a different dataset; the CERAPP database (Collaborative 
Estrogen Receptor Activity Prediction) which involved a diverse set of estrogenic activity 
endpoints that could not be modeled using regular linear methods.94 Instead, they have applied a 
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network modeling with two-dimensional hierarchical clustering to get a consensus decision for 
their assessment, which provides both qualitative and quantitative measures. The VEGA model 
is only a classification model, which has applied the CART algorithm (Classification and 
regression tree) on a data set published from the Japanese Ministry of Economy, Trade, and 
Industry database.  
The last free tool is the Endocrine Disruptome, which offers a structure-based solution 
rather than a QSAR based analysis. This tool provides a free platform for the assessment of 
potential activity toward fourteen nuclear receptors including the estrogenic receptors. It is a 
classification model that provides the illustration of the docking protocols and the data sets used 
for building the model, in addition to the sensitivity thresholds that would be applied for 
identification.85  
One recent study has compared the performance of these five tools against the CERAPP 
database. As expected, the performance of OCHEM was the best since it has been trained with 
the same data set. However, the predictability of all models was described as convenient for 
selecting high priority chemicals that could alter the ERs. Even though they have shown low 
sensitivity (ratio of the true positive rate ~ 0.50), a higher specificity (ratio of the true negative 
rate ~ 0.80) was accomplished. The reason being that they were trained using imbalanced 
training sets that have incorporated more inactives. However, the addition of applicability 
domains would enhance the reliability and appropriateness of use according to the chemical 
structure similarity to the training set. The study concluded that these models would have more 
power to identify inactives and the combination of multiple models will be more advantageous to 




II.1.4 Ensemble docking technique  
 
Docking and virtual screening are increasingly engaged in multiple processes of drug 
discovery, design and development. To speed up the docking processes, the flexibility of the 
protein is overlooked or partially considered.36 However, the proteins are intrinsically dynamic 
structures that experience perturbations between high and low energy levels expressed as 
multiple conformations.  
Apparently, in this environment, the ligand-binding event itself could not be explained by 
the key and lock model anymore; instead, a conformational selection or induced fit model will 
take place. In fact, overlooking a profound characteristic as protein flexibility will definitely 
compromise the predictability of the 3D model under consideration. On the other hand, 
implementing these properties will sensitize the performance of the model and permit the 
exploration of novel chemospheres for potential target-ligand pairs. The applicability of these 
models exceed the classic task of hit identification; it has open the doors to explore toxicity, 
selectivity profiling, target fishing, polypharmacology and drug repurposing.95  
To overcome the limitations of rigid docking, multiple receptor docking or “ensemble 
docking” has been proposed. An experimental sampling of protein-ligand complexes will track 
back true active or inactive snapshots among the infinite number of possible protein 
conformations.96 Furthermore, molecular dynamics offer another source of probable relevant 
conformations.97  
One addition in this area is the “Pocketome” search engine. This engine is a collection 
(3313 entries in the last update in 2018) of conformational ensembles of druggable protein 
pockets for major biologicals targets pathways such as kinases, nuclear receptors family, 
CYP340 family, G-protein coupled receptor 1 family, etc. Treatment of protein flexibility within 
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the context of conformational ensembles has proven effective.23 In one benchmarking study, the 
applicability of the conformational ensembles libraries for virtual screening was investigated by 
utilizing thirteen nuclear receptors (66 structures) and a focused library of known nuclear 
receptors modulators (157 structures).98 The selectivity of active ligands was found to be high, 
where the area under the receiver operating characteristic curve (ROC curves) averaged to 85% 
and peaked to 99%. Compared to single receptor mode, there were major improvements in 
specific cases such as the estrogen receptors or at least keeping a high-level of detection.  
Specifically, the ensemble docking mode has increased the docking accuracy from 78% to 89% 
as measured by the selection of the near-native pose as one of the top three (out of a list of scored 
and ranked poses). This study concluded that the application of the ensemble strategy would 
enhance the performance of docking and virtual screening by careful selection of a limited 
number of distinctive conformations.98 
For the assessment of licorice compounds for their estrogenic potential, we have 
incorporated the docking technique, which was elaborated with the ensemble of available 
receptors of both ER isoform. Additionally, we have investigated the commercially available 
QSAR model “estro-model” that is found in (ADMET Predictor™) to empower the performance 
of our predictions. 
II.1.5 PhytoSERMs in licorice: A case study 
 
Licorice (Radix Glycyrrhizae) is one of the herbs endowed with estrogenic character. 
Indeed, it is increasingly used both as a natural substitute for endogenous estrogens in case of 
menopause or as a chemopreventive agent.17 However, licorice extract is derived from various 
species of Glycyrrhiza. Yet, most often, the identity of the botanical material in the licorice 
herbal product is not well characterized. The most common variety of licorice is Glycyrrhiza 
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glabra, commercially cultivated throughout the US and Europe, but other varieties are often used 
in various regions, such as G. glabra var. glandulifera (Russian and southwestern Asian), G. 
echinata (Russian licorice) and G. uralensis Fisch. Ex DC. (Chinese licorice/Manchurian 
licorice).49 In addition to the presence of species-specific secondary metabolites, different 
licorice species demonstrate a wide spectrum of chemovariation. Metabolic profiling of multiple 
licorice species has shown widely heterogeneous chemical profiles. These distinct chemical 
patterns are expected to elicit variable biological responses. To date, more than 20 triterpenoids 
and 300 flavonoids have been isolated from different Glycyrrhiza species.46, 52-53, 99 
 A common phytoestrogen to all licorice species is liquiritigenin, which displays weak 
estrogenic activity with moderate selectivity for hERβ.55 Previous studies have shown 
significantly higher concentrations of liquiritigenin and its analogs; liquiritin or isoliquiritin in G. 
uralensis as compared to those found in G. glabra or G. inflata.63 Species-specific compounds 
are also identified, such as glycycoumarin in G. uralensis, glabridin in G. glabra, and 
licochalcone A in G. inflata.100 To elucidate the estrogenic behavior of these plant species, many 
researchers compared their efficacy for stimulating an estrogenic response in cell-based assays. 
One recent study showed that the estrogenic activity decreased in the order G. uralensis > G. 
inflata > G. glabra with a higher preference toward hERβ.62, 101  
This study and several previous ones encouraged researchers to carry out the bioactivity-
guided fractionation to identify the compounds responsible for this estrogenic activity. Besides 
liquiritigenin, researchers identified other phytoestrogens in licorice such as (glabridin, glabrene, 
vestitol, calycosin, methoxychalcone, vestitol, glyasperin C, glycycoumarin, and glicoricone) 
demonstrating the estrogenic activity with moderate ERβ selectivity (Figure 7). Screening the 
estrogenic activity of the latter compounds via transcriptional assays in breast cell lines (MCF-7) 
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and liver cancer cell lines showed a unique mixed agonist/antagonist character for each 
compound in different tissue/target gene subsets, indicating a selective estrogen receptor 
modulating (SERM) behavior toward hERs.55, 59, 102 
 However, there is enough evidence in the literature that crude plant extracts have greater 
estrogenic activity compared to the isolated constituents at an equivalent dose. In many cases, 
there is evidence of synergy including pharmacodynamics interactions, but the exact mechanisms 
have not been elucidated. Several mechanisms may also be operating in parallel.55 Generally, 
phytoestrogens are estrogen mimics capable of interacting with the estrogenic receptors (hERα 
and hERβ) but in a discriminative fashion. They were shown to be hERβ selective in multiple 
levels of action including binding affinity, co-regulators recruitment, and gene transcription. The 
licorice SERM activity can be explained by the distinct ability of its components to stabilize the 
different conformation of hERs, which will preferentially recruit different types of 
coregulators.101  
Nevertheless, none of the individual identified components matches the activity of the 
extract. From the above discussion, it is clear that only a few licorice components were tested for 
their estrogenic behavior mostly due to their minor presence in the fractions. Likewise, they 
might have different unique phytoSERMS profiles and they could be involved in the observed 
activity. The aim of this study was to dissect the estrogenic behavior of licorice components by 
the application of comparative ensemble docking study. Hence, validating an exciting 
methodology to identify active compounds in complex mixtures and to understand the 
mechanism of action behind an herbal remedy.  
By the application of such a method, we anticipate circumventing some of the 
shortcomings accompanied by the classic bioactivity-guided fractionation. Particularly, when the 
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tested fraction includes multiple compounds with potential paradoxical estrogenic effects or in 
the opposite scenario where you have the additive effect of multiple weakly active components. 
Furthermore, selecting the right measures of certain activity for screening would certainly 
influence the results. For instance, if the screening assay seeks activation of certain function 




























Alternatively, the application of new techniques of cheminformatics will shed light onto 
new phytoestrogens with unique profiles that would not be detected by the classic methods. To 
demonstrate the utility of ensemble docking for the deconvolution of active compounds in a 
complex mixture, two species of commonly used licorice, Glycyrrhiza glabra and Glycyrrhiza 
uralensis, were selected. Using several computational tools along with crystal structures of two 
isoforms of human Estrogen Receptors (hERs), phytochemicals from Glycyrrhiza were probed 
for their isoform preference along with their putative functionality as agonists/antagonists of 
estrogen receptors.  
II.2 Results 




Initially, we have explored the binding site of six distinct hER conformations using 
sitemap calculation in order to evaluate their diverse characteristics as shown in Table SI 1, 
Figure 8, and Figure 9. In general, the pocket of hER receptors is highly hydrophobic with few 
polar residues at the sides of the binding site. Obviously, the active (closed) and the inactive 
(open) conformations of hERs differ widely in the total surface area. This is modulated by H12 
perturbation when it binds to an antagonist or a SERM, which will result in releasing one side of 
the binding site. One exception is 2P15 that has a large total surface area but it is still active, 
indicating that hERα can accommodate larger hydrophobic compounds by adopting a unique 
conformation. On the other hand, hERβ in its active form (4J24) exhibited the least surface area 
indicating its preference for smaller ligands. Next, we have considered an internal and external 
validation test as a measure of the accuracy of the docking procedure. The Glide SP docking 
protocol was reliable enough to reproduce the poses of the co-crystallized ligands with low 
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RMSD values. We also found that the ensemble docking approach was able to correctly pick the 
parent crystal structure for each native ligand as shown in Table SI 2. Regarding the focused 
library of known estrogenic compounds, the SP docking scores and the isoform preference are 
compared to the results of their actual experimental data as summarized in Table 2. Ten out of 
twenty listed compounds are licorice components that have been already tested toward hERs. We 
found that the active compounds score below −10 kcal/mol generally. This protocol had 85% 
efficiency in the functional selectivity task (ER (+) for agonist vs ER (−) for the antagonist), but 
it had lower efficiency in isoform selectivity (65%). In fact, this is expected since it is already 
established that ER selectivity is hard to gain because of the high similarity between the two 
isoforms.   
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Figure 9. A) Binding sitemaps of hERs with co-crystallized native ligands ((upper) hERα 
PDBs, left: 1GWR, middle: 2P15, right: 3ERT, (lower) hERβ PDBs, left: 4J24, lower middle 
1X7J, and lower right 1L2J). Hydrogen-bond acceptor sites are indicated by red color, 
hydrogen-bond donor sites are indicated by purple color and hydrophobic sites are indicated by 
yellow color. Key residues are shown in green.  
 
II.2.2 Docking of Glycyrrhiza compounds library into the ER ensembles 
 
As described in the Experimental, we were interested in the identification of Glycyrrhiza 
compounds that might modulate the estrogenic activity, as we believed that correlation of their 
estrogenic activity to a couple of compounds is an oversimplification for the plant estrogenicity. 
Hence, a library of 368 compounds reported from both Glycyrrhiza species (glabra and 
uralensis) was docked to six hER crystal structures. Apart from the known estrogenic modulators 
reported from licorice and evaluated in our validation test, this study has uncovered a larger 
group of phenolic compounds (78 structures), which have the same potential and yet has not 
   





















been explored. Firstly, to compare the predicted estrogenic compounds in both species we have 
plotted the highest glide score among the whole ensemble of six hERs crystal structures for each 
compound against the preferred crystal structure (Figure 10). For Glycyrrhiza glabra, 49 
compounds out of 177 scored above 10 and 65% of them preferred hER beta isoform. 
 
 
Figure 10. Ensemble SP docking scores in kcal/mol for the secondary metabolites of both G. 
glabra (triangles) and G. uralensis (circles) against six different crystal structures. For hERα: 
1GWR in green, 2P15 in blue and 3ERT in yellow. For hERβ: 1L2J in red, 1X7J in grey and 
4J24 in orange 
  
For G. uralensis, 43 of the compounds out of 191 scored below −10 and 63% of them 
preferred hERβ crystal structures. Our data suggest the preference of isoform β for both species. 
The analysis of such results revealed at least 50 compounds in each species that bear the 
potential of interfering with both hERs α and β in different modes of action. Secondly, for the 
search of novel phytoSERMS candidates, we also challenged the compounds by following 
various methods described in the experimental section. The top twenty compounds along with 
their docking results, which are nominated by this model, belong to several classes as 
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summarized in Figure 11, Figure 12, and Figure 13.    
II.2.3 The qualitative and quantitative estimation of the estrogenic character of licorice 
secondary metabolites via Estro-model (QSAR model from ADMET Predictor™ 
software)  
 
It has been established that the estrogenic activity is one of the complex bimolecular 
events that involve multiple levels of small molecule-protein-protein-DNA interaction. However, 
this process is sparked by the ligand (the small molecule-protein) interaction. To enhance our 
prediction of such an intricate system, we decided to test the licorice components with the 
orthogonal ligand-based model provided by ADMET Predictor™. Hence, we fed all the 
collected compounds from both species in the estro_filter model to calculate many atomic and 
molecular descriptors and eventually gain a consensus vote by the neural network that this model 
provides for classification. The compounds, which were selected as estrogenic, have been 
submitted to affinity estimation model (the estro_RBA model). The top 20 nominated estrogenic 
compound in each species are summarized in Table SI 7.  Interestingly, many of the top 
compounds were shared in both models indicating a high chance of interference with this nuclear 











Figure 11. Top scoring compounds of G. glabra nominated by ensemble docking (structures 
highlighted in red are: top scoring compounds which belong to DHS class, identifiers in blue 
are those in agreement with top scoring compounds identified by the QSAR model) 
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Figure 12. Top scoring compounds of G. uralensis nominated by ensemble docking (structures 
highlighted in red are: top scoring compounds which belong to DHS class, identifiers in blue 









1GWR 3ERT 2p15 1L2J 1X7J 4j24 1GWR 3ERT 2p15 1L2J 1X7J 4j24
G6 0 0 -11.04 -10.34 0 0 -11.88 -5.63 -10.33 -9.89 -9.07 -10.25 U63
G50 -9.91 0 -10.95 -10.59 -10.74 -9.99 -8.23 -8.11 -11.49 -9.65 0 0 U15
G38 -10.35 0 -10.87 -10.52 -10.92 -9.88 -10.96 -8.18 -11.15 -10.49 -8.64 -10.23 U66
G174 -8.48 -6.55 -10.84 -10.64 -9.47 -7.43 0 -6.48 -11.05 -10.47 0 0 U77
G40 0 -6.19 -10.83 -10.43 0 0 -8.11 -7.42 -10.95 -9.94 -9.51 0 U106
G47 0 -7.23 -10.82 -10.3 -8.55 0 -8.09 -7.42 -10.84 -9.01 0 0 U191
G127 -8.04 0 -10.8 -9.67 0 0 0 -5.34 -10.66 -10.3 0 0 U127
G163 -10.39 -8.21 -10.79 -11.35 -10.84 -11.08 0 -5.98 -10.39 -8.66 -9.04 0 U24
G138 -9.81 -7.23 -10.55 -10.01 -10.75 -10.3 -10.31 -5.76 -9.63 -9.99 -9.63 -9.3 U89
G106 -8.86 -8.26 -10.54 -9.31 0 0 -10.28 -6.88 -10.01 -9.9 -10.23 -10.1 U105
G108 -10.27 -5.71 -10.53 -10.39 -10.42 -10.2 0 -6.78 -10.26 -9.86 0 0 U22
G33 -10.45 -8.51 -10.49 -8.94 -9.82 -9.85 0 -6.25 -10.19 -10.06 0 0 U78
G21 -10.17 -8.45 -10.47 -9.43 -10.4 -10.1 -6.75 -7.68 -10.12 -9.73 -9.24 -9.11 U177
G28 0 -8.27 -10.43 -10.54 -8.41 0 0 -5.69 -10.02 -10.08 0 -7.18 U99
G112 -9.84 -7.55 -10.41 -9.72 -10.34 -9.99 -8.5 -3.91 -9.95 -9.12 0 -8.84 U189
G176 -10.41 -8.34 -9.58 -10.71 0 0 -9.94 -8.56 -9.92 -7.96 -10.09 -9.18 U190
G156 -9.59 -8.86 -10.38 -10.34 0 0 -9.66 -5.23 -9.92 -8.8 -7.77 -9.01 U25
G30 -10.37 -7.44 -10.06 -8.99 -9.43 -9.98 -9.63 -7.21 -9.78 -9.46 0 -10.08 U61
G171 -10.33 -7.38 -10.2 -9.93 -10.88 -9.63 0 -5.32 -9.76 -10.47 -6.49 0 U115
G154 -7.76 -6.86 -10.32 -8.8 0 0 0 -5.31 -9.7 -8.41 0 0 U2
G158 0 -6.51 -9.93 -11.73 0 0 0 -5.36 -8.25 -11.14 0 0 U23
G163 -10.39 -8.21 -10.79 -11.35 -10.84 -11.08 0 -7.45 -8.87 -11.03 0 0 U16
G100 -9.7 -8.13 -9.88 -10.42 -11.06 -9.61 0 -7.54 -8.9 -10.91 0 0 U117
G99 -9.64 -7.06 -9.84 -11 0 0 0 -3.37 -9.5 -10.85 0 0 U175
G38 -10.35 0 -10.87 -10.52 -10.92 -9.88 0 -5.1 -8.41 -10.72 0 0 U88
171 -10.33 -7.38 -10.2 -9.93 -10.88 -9.63 -9.02 -5.97 -9.18 -9.28 -10.59 -9.69 U69
G60 0 0 0 -10.83 0 0 0 -6.08 -9.09 -10.58 -6.05 0 U86
G170 0 -7.99 -10.3 -10.75 -8.46 0 -9.68 -9.44 -9.61 -9.6 -10.49 -9.56 U165
G138 -9.81 -7.23 -10.55 -10.01 -10.75 -10.3 -10.96 -8.18 -11.15 -10.49 -8.64 -10.23 U66
G50 -9.91 0 -10.95 -10.59 -10.74 -9.99 0 -6.48 -11.05 -10.47 0 0 U77
G75 -9.43 0 -10.08 -9.7 -10.74 -9.89 0 -5.32 -9.76 -10.47 -6.49 0 U115
G176 -10.41 -8.34 -9.58 -10.71 0 0 0 -6.07 -8.7 -10.33 0 0 U176
G125 -9.09 -7.34 -8.8 -9.17 -10.68 -9.37 0 -5.34 -10.66 -10.3 0 0 U127
G174 -8.48 -6.55 -10.84 -10.64 -9.47 -7.43 0 -8.17 -7.52 -10.29 0 0 U39
G111 -8.33 -7.7 -10.03 -10.58 -8.8 0 -11.88 -5.63 -10.33 -9.89 -9.07 -10.25 U63
G28 0 -8.27 -10.43 -10.54 -8.41 0 -10.28 -6.88 -10.01 -9.9 -10.231 -10.1 U105
G2 0 0 -9.84 -10.45 0 0 0 -6.18 0 -10.22 0 0 U57
G40 0 -6.19 -10.83 -10.43 0 0 0 -7.78 -8.83 -9.08 -10.15 -8.98 U119
G108 -10.27 -5.71 -10.53 -10.39 -10.42 -10.2 0 -5.73 -7.57 -10.15 0 0 U62
G144 -9.68 -8.61 -8.83 -9.01 -10.42 -9.4 -9.94 -8.56 -9.92 -7.96 -10.09 -9.18 U190
α-ensemble β-ensembleβ-ensembleα-ensemble
Figure 13. Top 20 compounds (white color) by SP docking scores in hERα ensemble 
compared to all crystal structures to visualize selectivity (G. glabra: upper left, G. uralensis 
upper right). Top 20 compounds by SP docking scores in hERβ ensemble (G. glabra: 
lower left, G. uralensis lower right) 
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II.2.4 ADMET Metabolite prediction and estrogenic evaluation via QSAR models  
 
The data revealed a small number of bio-activated metabolites (Figure 14). This is 
exemplified mostly by O-demethylation and/or hydroxylation processes. This is not surprising 
since most of the compounds are oxygenated phenolic structures. Nevertheless, the data suggest 
an estrogenic character for the majority of these metabolites. This preliminary investigation 
should be complemented with physiologically based pharmacokinetic models and secondary 
phase metabolism models to evaluate the effect and time of exposure of each route.   
II.3 Discussion: 
 Licorice (Glycyrrhiza spp.) is well known for its wide spectrum of estrogenic activity, 
which presumably adds to the beneficial effects of this plant. Both species of licorice– G. glabra 
and G. uralensis are commonly used in the marketed botanical products without any respect to 
their soundly different chemical composition. Many studies tried to identify the phytoestrogens 
found in these plants. Some compounds, which belong to the classes of flavonoids, isoflavonoids 
or chalcones, such as liquiritigenin, vestitol, calycosin and isoliquiritigenin have demonstrated 
estrogenic activities. Others, such as glabrene, glabridin, glyasperin C, glabrol, glicoricone, 
showed antagonism or partial agonism of estrogenic activities. By contrast, compounds like 
hispaglabridin A and hispaglabridin B have no activity to either estrogen receptors. In fact, 
licorice plant provides a versatile and powerful SERM toolbox. The advent of ESR1 mutations 
that lead to (30-50%) resistance of the available therapies call for an urgent search for novel 
hERα partial antagonists or SERMs of  highly favorable kinetics profiles.67 Paradoxically, in the 
case of highly estrogen-deprived tissue such as in case of exhaustive and long endocrine 
treatment of breast cancer or in the case of menopause, recent studies revealed the clinical 
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Figure 14. Comparison of ADMET QSAR Predicted RBA for both parent compounds 
and their putative metabolites originated from G. uralensis (up) and G. glabra (down) 
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As a result, a new-targeted SERM category with hERα partial agonistic effects in cancer 
tissue but devoid of proliferative activity elsewhere is highly acquired. In this study, we were 
interested in understanding the estrogenic potential of two licorice species by the application of 
multiple cheminformatic techniques such as molecular docking and QSAR analysis. In addition, 
our attempt sought the validation of these tools as a basic approach for cheminformatic-guided 
investigation of herbal remedy.  hERs are nuclear receptors that are known for having a flexible 
ligand-binding domain. Moreover, the ligand-directed transcriptional activity of hERs is 
correlated to the conformation of this particular region of the protein. Careful analysis of the 
conformational space of hERs suggests variable degrees of H12 flexibility leading to different 
states of open and closed conformation.75, 104  
Obviously, this suggests variable geometric and electronic features of the binding site in 
each specific conformation. That was evidenced by our analysis of the LBD pockets using 
sitemap calculations. To compensate for this flexibility for both hERα and hERβ and to avoid 
misleading information guided by one rigid receptor we have considered an ensemble docking 
with multiple protein conformations. To avoid any bias in the ensemble docking protocol and to 
improve the predictability, the same compounds were also evaluated using a readily available 
QSAR model from ADMET Predictor™ software for both qualitative and quantitative estimation 
of estrogenic nature.105 In the latter approach, the ‘hits’ which scored above 70% confidence 







II.3.1 Validation   
 
Modeling the estrogenic activity of multicomponent systems such as licorice extracts that 
are targeting a physiologically versatile target such as hERs is not straightforward. 
This situation warrants a careful use of the precise computational methods to address more 
complicated protein features such as flexibility. In our modeling, we have considered six hER 
protein structures and we have drawn out four ensembles to target both hER isoform selectivity 
(α vs β) and conformation preference (active (hER+) vs inactive (hER−)). Cognate ligands were 
redocked using flexible SP protocol, which was able to reproduce the binding geometry of each 
ligand. By considering the focused library, the application of ensemble docking allowed us to 
detect SERM ligands that cannot fit into the agonist conformation but instead they prefer the 
inactive conformation. In this manner, Glycyrrhiza compounds such as (glabridine, glabrol, 
glicoricone, and glyasperin C) could be detected where they have achieved relatively high scores 
(−9.40, −10.34, −9.67, and −10.85 kcal/mol respectively) in at least one of the inactive 
conformations   
Moreover, our ensemble model showed high recognition of the isotype-selective ligands 
by considering the simple SP raw scores. This model could not identify 8-prenyl-naringenin and 
vestitol as hERα selective. Maybe this is due to the low selectivity index of these two compounds 
(0.5-0.6). On the other hand, all hERβ selective agonists or partial agonists, which show better 
selectivity (genistein, daidzein, equol, dehydroequol, liquiritigenin, isoliquiritigenin, calycosin, 
and glabrene) and the antagonist (glabridin), were classified correctly as hERβ selective. 
Interestingly, both isoform ensembles were able to rank the known phytoestrogens compounds in 
agreement with their experimental binding affinities. For instance, previous studies have shown 
that 8-prenyl-naringenin is the most estrogenically active phytoestrogen.106  
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In addition, hERα agonistic activity declines in the order: 8-prenyl-naringenin> 
liquitrigenin> isoliquitrigenin> calycosin> vestitol when tested under identical assay 
conditions.55, 63 By considering the docking results in the hERα ensemble, we can notice a very 
similar trend. Moreover, 
 both binding affinity assays; the relative binding affinity (RBA) and efficacy assays; the 
concentration at the half maximum efficacy (EC50) toward hERβ showed a higher activity for the 
isoflavone genistein (13, 6 nM) followed by dehydroequol (4.3, 7.2nM) > equol (1.66, 74 nM) > 
(0.04, 100 nM).107 hERβ ensemble SP scores have also similar ranking. Of note, our docking 
algorithm did not yield any favorable docking pose for either hispaglabridin A or hispaglabridin 
B, which is in agreement with the previously reported cell-based data.59, 79 
II.3.2 Estrogenicity of Glycyrrhiza secondary metabolites via hER ensembles and 
estro_filter 
 
Computational tools provide a versatile knowledge about the interactions of small 
molecules with their target proteins. For this purpose, we have analyzed 368 known secondary 
metabolites in licorice plant against ensemble hER crystal structures of both isoforms. Our model 
suggests hERβ selectivity for both G. glabra and G. uralensis extracts, where more than 60% of 
the highest scoring compounds (those scored higher than the cut-off −10.0 kcal/mol) preferred 
hERβ sites. Interestingly, these results are consistent with the recent analysis, which showed that 
both G. glabra and G. uralensis extracts have similar potencies and both preferring hERβ.  
The top 20 compounds out of 368 are summarized in Figure 13. The model was able to 
identify many known phytoestrogens that are part of licorice in agreement with the reported 
literature. Among the top 20 compounds, known compounds were present such as glabrene 
(G38) the isoflavene and glycerol (U86) the 6-prenyl coumestrol, which are documented for their 
high experimental binding affinity toward hERα (RBA of 0.22 and 0.11 respectively).108  As 
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anticipated, most of the top scoring compounds are tethered with at least one prenyl group. This 
is due to the hydrophobic nature of the LBD, which will increase the value of the hydrophobic 
terms in the SP scoring function. 
 In fact, the experimental data in the validation set supports this prediction, where we 
noticed multiple prenylated compounds (G3, G35, G38, G127, and U175) that show sufficient 
RBA to exert hER activity. However, the prenylation of isoflavonoids is known to change their 
pharmacology.109 Although they show high affinity for hER receptors in the binding affinity 
assay, these compounds show hER inhibition response at least in one specific cell-based assay, a 
behavior that suggests a SERM activity. This is true for the monoprenylated isoflavones at 8, 6, 
5’ positions found in glabridine (G35), glyasperin C (U175) or glicoricone (G127) 
respectively.55 On the other hand, prenylation at 3’ position in flavonoids such as apigenin and 
liquiritigenin or a di-prenyl at 3’ and 5’ position such as breviflavone A and B kept their 
estrogenic character in the range of other known phytoestrogens.110       
However, in our results, we found several compounds, which belong to the 
dihydrostilbenoid (DHS) class appended with prenyl groups at various positions, to be an 
interesting group of compounds that has not been studied for their estrogenic activities. In 
addition, the model suggests that these prenylated DHS are amenable to occupying available 
chemical space composed of L346, T347, L354, W383, and L540, hence had the potentials to 
tightly interact with hERs. Interestingly, some of the bis-prenylated DHS U15 and U16 have 
been reported to be unique to G. uralensis. Not only these compounds scored high (< −11 
Kcal/mol), but also the position of the prenylation is predicted to change their selectivity, where 
U15 preferred hERα in the active form, while U16 selectively preferred hERβ in the inactive 
form (Figure 15 and Figure 16). As shown in the figures, the bad interactions between the 
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prenyl group of U16 and H524 in the closed form might be the main reason behind this predicted 
selectivity. Both compounds showed interactions with the key amino acids E353, R394, and 
H524.   
The present computational study revealed interesting features that might be gained with 
the introduction of prenyl groups onto the stilbenoid and dihydrostilbenoid scaffold. As 
described in the next chapter, we sought to synthesize this representative class of compounds 
including various prenylated constitutional isomers to analyze their structure-activity-
relationships and their activation against both isoforms of hERs. The number and the position of 



















Figure 15. (Up left) Docking pose of U16 (yellow ball-and-stick) in the LBD of PDB:ID: 1L2J 
(grey cartoon). (Up right) Docking pose of U15 (green ball-and-stick) in the LBD of PDB:ID: 
2P15 (grey cartoon) both showing major interactions with key residues (brown tubes). (Bottom 
middle) The docking poses of U16 (yellow) and U15 (green) and 8-prenyl-naringenin (grey) 
overlaid in PDB structures (1L2J in cyan, 2P15 in orange and 1GWR in light pink), the position 



























Figure 16. Docking pose of U15 in PDB 2P15 (green ball-and-stick) and U16 in PDB 1L2J 
(yellow ball-and-stick) overlaid with the protein crystal structures (up) and showing different 














II.3.3 In silico evaluation of estrogenic activity for the predicted metabolites  
 
It is now established and supported by literature reports that metabolism changes the 
parent compounds to a set of metabolites that might have their own spectrum of bioactivities.111-
112 A classic example is a phytoestrogen, daidzein. The intestinal microflora converts daidzein 
into two different metabolites. One of them is equol, which has stronger estrogenic activity, 
while the other one is O-desmethylangolensin, which is devoid of estrogenic activity compared 
to the parent compound, daidzein. It is obvious that inactive chemicals that bear a possible 
estrogenic metabolite would not be detected in a regular in vitro set up.113 Consequently, it is 
significant to pre-screen for metabolite estrogenicity.114 Thus, application of cheminformatic 
techniques such as QSAR models should be implemented in any early drug discovery programs. 
In the present study, we utilized an integrated in silico approach linking metabolite prediction 
with qualitative and quantitative assessment of estrogenic activity of both the parent and the 
predicted metabolites. 
ADMET Predictor™ provides both qualitative and quantitative models related to 
estrogenic activity. Only the compounds classified as estrogenic with “estro_filter” (compounds 
with a high likelihood to bind to the estrogenic receptors) were submitted to the second model 
“estro_RBA”.105 The endocrine regression models developed to estimate the numerical values of 
receptor binding affinity in ADMET Predictor™ were trained using U.S. EPA's Distributed 
Structure-Searchable Toxicity (DSSTox) database. Competitive binding assays in rats were used 
as the quantitative measures for building the model. As such, running the calculation for the 
provided molecule would estimate the degree of binding to the estrogenic receptors expressed as 
the relative binding affinity %RBA (100%*(IC50 for 17β-estradiol/IC50 for the query 
compound). Higher predicted %RBA value indicates higher affinity. The qualification test of 
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estrogenicity using ADMET Predictor™ would provide the output data with confidence 
estimation. The output of the metabolite estrogenic character was further filtered according to the 
provided confidence ratios. Only those that scored > 70% confidence were further sorted and 
ranked for their predicted %RBA.  
By carrying out this model using our licorice generated libraries, we found that most of 
the selected estrogenic metabolites with a high level of confidence for estrogenicity are coming 
from estrogenic parents. While we could not detect a high number of bio-activated compounds, 




The known secondary metabolites of two licorice species, G. glabra (179 compounds) 
and G. uralensis (189 compounds) were retrieved from several scientific databases, such as the 
Dictionary of Natural Products (DNP) and several other publications by a text search in 
SciFinder Scholar.115 For the external validation, a focused library of twenty compounds was 
considered, which included seven known phytoestrogens along with eleven compounds isolated 
from Glycyrrhiza that were already tested for their estrogenic activity. In order to validate the 
efficiency of incorporating multiple rigid protein crystal structures in our docking procedure, we 
have considered a diverse group of SERMS and phytoestrogens in the focused library. In 
addition to the co-crystalized ligands, we have considered hERα selective agonists based on their 
binding affinity assays (8-prenyl-naringenin, vestitol), or hERβ selective agonists or partial 
agonists (genistein, daidzein, equol, dehydroequol, liquiritigenin, isoliquiritigenin and calycosin, 




II.4.2 Ligand preparation 
 
The structure libraries were sketched using ChemDraw software and were saved as 
spatial data files (SDF) using Chem3D. After which, they were imported by Maestro 
(Schrödinger, LLC) for ligand preparation and data curation. Tautomeric and ionization states 
were generated at target pH7.4. The chirality of the molecules was determined from the 3D 
structure input. 
II.4.3 Protein preparation 
 
The following protein crystal structures were downloaded from the RCSB protein 
database.  For hERα ensemble, we have considered the following structures: the agonist 
conformation, estradiol, bound to LBD (PDB:1GWR) 116 , the antagonist conformation or 
SERM, 4-OH tamoxifen, bound to LBD (PDB: 3ERT), 77  and the hydrophobic agonist 
conformation, ortho-trifluoromethylphenylvinyl estradiol, bound to LBD (PDB: 2P15).80 For 
hER beta ensemble, the structures included the agonist conformation, estradiol, bound to LBD 
(PDB:4J24) 117, the antagonist conformation, (R,R)-5,11-cis-diethyl-5,6,11,12-
tetrahydrochrysene-2,8-diol, bound to LBD (PDB: 1l2J), 118 and the partial agonist conformation, 
genistein bound to LBD represented by (PDB: 1X7J)119. For each protein crystal structure, only 
one monomeric form was kept and prepared by the protein preparation wizard in Maestro. 
Hydrogen atoms were added after deleting the original ones. The protein was checked for 
missing residues and loop segments that were added using Prime. Water molecules with no 
hydrogen bond were removed. The protonation state and tautomeric state of protic amino acids 
were adjusted to match a pH 7.4. Possible orientations of side chains were generated and 
checked in the binding site to match the reported protein-ligand interaction. Finally, the protein-
ligand complex was subjected to geometry refinement for hydrogens only, using an OPLS2005 
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force field. 120   
II.4.4 Sitemap protein binding site analysis 
 
The PDB crystal structures were further studied using sitemap module in Maestro to 
explore the surface-type characteristic of each LBD.120 Through the protein analysis panel, the 
evaluation of a single binding site region was selected to encompass the native ligand in each 
crystal structure plus 3Å buffer. The binding site examination was set to require at least 15 points 
with the application of a more restrictive definition of the hydrophobicity and utilizing a standard 
grid.  
II.4.5 Ensemble Docking 
 
For each crystal structure, the grid was calculated using Glide, (Maestro, 10.3.015; 
Schrodinger).120 The binding site of each grid was defined by the native ligand with no 
constraints. The prepared ligands of both species were docked flexibly into the six generated 
grids of the rigid protein of the ensemble with the help of the virtual screening workflow in 
Maestro. For each compound, only one docking pose was kept against each crystal structure and 
scored by Glide SP (standard precision) score. Out of six protein structures, we have mainly 
considered two ensembles. The first ensemble inclined for active conformation (1GWR, 2P15, 
and 4J24) or inactive conformation (3ERT, 1X7J, and 1L2J). The highest docking score was 
considered to assign the preferred conformation in each ensemble. The second ensemble inclined 
for isoform selectivity. For each compound, only the highest score was kept for each isoform to 
determine the preferred isoform. To identify the best binders in each species we reviewed the key 
interactions known for activity and we have computed the simulated binding energy for the top 
20 scoring compounds in each isoform ensemble by the molecular mechanics − generalized born 
surface area model (MM-GBSA). Forty compounds for each species were ranked upon their 
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MM-GBSA energy allowing the challenge of isoform selectivity to take place. Of note, the top 
30 compounds were kept for each species (Table SI 5 and SI 6). Similarly, the top 20 
compounds ranked by the predicted RBA values are shown in (Table SI 7).  
II.4.6 Metabolite prediction and estimation of estrogenic activity via Estro-model 
 
A commercially available software, ADMET Predictor™ 9.0 (Simulations Plus Inc.), 
provides a friendly interface with a robust prediction environment. Molecular descriptor values 
are calculated and used to generate independent mathematical models by application of nonlinear 
machine learning techniques.105 The built-in trained QSAR models allow the prediction of 
metabolic oxidation sites mediated by various CYP enzymes. In this work, a pool of primary 
putative metabolites based on nine cytochrome P450 enzymes (CYP1A2, CYP2C9, CYP2C19, 
CYP2D6, CYP3A4, CYP2A6, CYP2B6, CYP2C8, and CYP2E1) were generated. To launch the 
metabolite generation in this QSAR package, compounds from licorice were imported as the 
basic 2D SMILES (simplified molecular-input line-entry system) notations.  
Curation of the data included removal of duplicate structures to get the unique 
compounds for each species as well as sugar hydrolysis using the MedChem Designer module. 
As such, the number of compounds from G. glabra and G. uralensis were refined to 146 and 158 
respectively. Upon execution of the program with the above parameters, a total of 601 and 708 
metabolites were generated for both glabra and uralensis, respectively. The generated 
metabolites were used as input for estrogenic activity prediction to analyze the importance of 
bio-activation as well as for comparison between the two species. ADMET Predictor™ provides 
both qualitative and quantitative models related to estrogenic activity.  
Only the compounds classified as estrogenic with “estro_filter” (compounds with a high 
likelihood to bind to estrogenic receptors) were submitted to the second model “estro_RBA”.  
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Consequently, the output of the metabolite estrogenic character was further filtered according to 
the provided confidence ratios. Only those that scored > 80% confidence were further sorted and 






























CHAPTER III                                                                                                                                     
SYNTHESIS OF UNIQUE CHEMICAL ENTITIES                                                                            
AND THEIR ESTROGENIC ACTIVITIES 
 
III.1 Introduction 
The previous in silico study of licorice against hERs, selected prenylated stilbenoids and 
DHS as potential components capable to interact differentially with the estrogenic receptors. In 
fact, plant secondary metabolites tethered with isoprenoids appendages provide an immensely 
rich diversity of biological activities that captured the interest of many scientific communities.121-
123 The vast number of research papers on the chemistry and the biology of many compounds 
have reflected this impact in the past two decades. From an evolutionary and functional 
perspective, the interplay between the plants and the surrounding harsh environment has 
amazingly selected the simplest methods, which coin for diverse effects. The addition of the 
iconic five carbon units on phenolics or alkaloids systems display the effects of a 
physicochemical change such as increased hydrophobicity. From a pharmacological point of 
view, this is usually accompanied by changes in pharmacokinetics and pharmacodynamics of the 
parent molecule.112  
Undeniably, the prenylated stilbenoids isolated from a variety of plant sources, have been 
described as phytoalexins, which show antibacterial, antifungal and antioxidant effects, are 
indispensable for the plant survival under stressful situations. In fact, these isoprene motives are 
not exclusive for plant, bacteria or fungi phylogenies, but also they are known to exert vital 
cellular processes roles in mammals via prenyl transferases.124 Unsurprisingly, this underpins the 
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viable crosstalk of prenylated plant secondary metabolites across the living organism. 
Many prenylated stilbenoids occur in the coniferous species such as Morus species, Rheum, 
Abies, Picea, pine, Rheum, and Juniperus but also found in many other plants.125 Stilbenoid 
produced in this line may differ in the number, position, and the type of the prenyls attached 
(furan and pyran type).126 Since the prenylated compounds were shown to have profound effects 
influencing their activity, potency, selectivity, and functionality compared to their parent 
molecules, the chemical installation of these units is a valued investment.  
We have identified the prenylated stilbenoids and prenylated dihydrostilbenoids, (Figure 
17) found in licorice species as one of its major components that are capable to interact 
differentially with the estrogenic receptors. To validate our computational data as well as to 
explore the influential aspects of these appendages to the stilbenoid scaffold, we have envisioned 
a regiodivergent chemistry that provides multiple isomers in a one-pot reaction. Despite the fact 
that a regiocontrolled synthesis is preferred, it has proven challenging and multi-step process, 
usually with low yields. However, in the early stage of pharmacological evaluation of such 
constitutional isomeric constructs, the straightforward regiodivergent installation of the alkyl 
group is a viable option. Interesting observations are found in the literature, in how these 
positional variants may profoundly affect the activity or selectivity of the compounds. 
A well-known example is the 8-prenyl naringenin. The presence of the prenyl group at 
the 8-position converted the flavanone from estrogenically inactive molecule into a highly 
estrogenic one. The same prenyl group added at 6 position acquired anticancer and androgenic 
characteristics.106, 127 On the other hand, the presence of the prenyl group at 8-position 
transformed the estrogenically active isoflavone or isoflavan structures, genistin and glabridin, 




Figure 17. Examples of stilbenoids and DHS reported in different licorice species. 
 
Furthermore, the displacement of the prenyl group from position 3 to 6 in one of the 
pawhuskin A methylated analog has changed the selectivity of the compound from kappa opioid 
receptor to a selective delta antagonist.128 In this study, we report the regiodivergent prenylation 
of the stilbenoid resveratrol and its dihydro-analog including multiple chemical strategies such as 
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Friedel-Crafts, ortho-metallation alkylation or the bio-inspired alkylation. During the course of 
this work, we have identified the plausible analogs in each reaction including major and minor 
products as well as the new analogs.  
III.2 Chemistry 
To append/tether a prenyl group on the stilbene scaffold, a flexible synthetic scheme was 
envisioned to accomplish the synthesis of a diverse set of prenylated stilbenes and 
dihydrostilbenes starting from commercially available resveratrol.  
Access to such analogs is expected to provide ample information on the number of prenyl groups 
necessary along with the preferred regioisomeric positions related to a specific estrogenic 
activity along with the isoform selectivity. 
III.2.1 Initial attempts: O-alkylation & Claisen rearrangement and ortho metalation 
alkylation 
 
The presence of the phenolic group in stilbenes makes them amenable to carbonylation 
via the carbonate exchange reaction, which could potentially afford several isomeric mono or 
multiple ether alkyl adducts as precursors for Claisen rearrangement. As shown in (Scheme 2), 
the readily available propargyl alcohol was converted to the carbonate with Buli and methyl 
chlorformate. Trans-etherification of the carbonate with the O-anion of resveratrol, followed by 
partial reduction with Lindlarl’s catalyst would have resulted in allyl ether.129 Microwave-
assisted Claisen rearrangement of allyl ether would have furnished the prenylated resveratrol. 
However, we were not able to prepare initial O-alkylation with carbonate, which prompted us to 
search for an alternative synthetic route. 
Our second attempt was to employ the nucleophilic addition with ortho metalation, which 
was inspired by chiricanine A synthesis.130 The protection of the phenolic moiety in stilbene with 
methoxymethyl is anticipated to increase the selectivity and stability of the resulting anion under 
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basic condition. Next, the addition of the prenyl bromide (24) will trap the generated anion to 
furnish the prenylated stilbene. As depicted in scheme 3 route I, the hydrogenation of 
resveratrol under condition (a) proceeded with excellent yield (92%).  
The emerged dihydroresveratrol was treated with methoxymethyl chloride (MOM) in the 
presence of the hydride anion (NAH) or triethyl amine (TEA) to gain access to the tri-protected 
product. Unfortunately, our attempts failed; it gave only a slight amount of the required product 
with NAH and only the mono-protected product was noticed with TEA. Similarly, only trivial 
amounts of the tri-protected version were detected in the interchange of MOM chloride with 
methoxyethoxymethyl (MEM) chloride. 
 
Scheme 2. Reagents and conditions: (a) nBuLi, anhyd. THF, 0 oC (b) CuCl2, DBU, THF at r.t. 
(c) H2, Lindlar cat (d) µ-wave, DMF, 180 
oC (e) Pd/H2, EtOH, r.t. 
 
Alternatively, in route II, we started with the stilbene 1 directly to forge the tri-MEM protected 
product 23 in good yield (70%). Next, Product 23 was subjected to catalytic hydrogenation to 
afford the intermediate 25 (tri-MEM protected dihydroresveratrol) in 90% yield. Next, the prenyl 
donor was added under condition c or d to get the final product.  
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Unfortunately, the reaction did not proceed in either case.    
 
Scheme 3. Reagents and conditions. (a) Pd/H2, EtOH, r.t. (b) MOMCl/MEMCl/, HNa/DMF or 
TEA/DCM, RT, 12 hrs. (c) Prenyl bromide, nBuLi, anhydrous THF, −70 to r.t. °C (d) Prenyl 
bromide, HNa, anhydrous THF, 0 to r.t. °C. 
 
III.2.2 Optimized regiodivergent synthesis of prenylated resveratrol and 
dihydroresveratrol. 
 
In order to get the target compounds, we have applied both biomimetic and semisynthetic 
prenylation methods either via electrophilic or nucleophilic additions starting with resveratrol. 
As depicted in Scheme 4. (Condition b), heating resveratrol (1) or dihydroresveratrol (2) with 
prenyl alcohol (26) in acidic conditions led to a regio, divergent installation of the prenyl group 
at C2, C4 or C6 in different ratios but in low yields. The bio-inspired reaction takes place in 
acidic aqueous solution through the emerged allylic cation. This reaction resulted in a complex, 
most diverse set of prenylated analogs along with the corresponding tetrahydropyrano analogs 
due to harsh, low pH conditions. Formation of the latter analogs is inevitable in this reaction, 
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where the decrease in time or temperature of the reaction will end up only with the mono-
prenylated isomers in low yield. Nevertheless, two new diprenylated (C2 and C4) resveratrol 
analogs (compounds M8 and M9) were generated under these conditions with a mixed pattern of 
linear prenyl chain (C2) and cyclized tetrahydropyran products (C4). The generated compounds 
differ in the mode of cyclization, where compound M8 dehydrated with C3 hydroxy and 
compound M9 is dehydrated with C5 hydroxy as shown by HMBC and NOESY spectra (Table 
4, Figure 20, and Figure 21).  
Alternatively, the Lewis acid-catalyzed “electrophilic addition” (Friedel-Crafts 
alkylation) was explored as a milder condition (c). As anticipated, the addition of 2,2-
dimethylbutenol (27) to 1 or 2 at 0 oC in the presence of BF3.OEt2 led to the formation of 
multiple mono- and di-prenylated analogs (with substitution onto positions C2, C4, and C6). 
This route provided higher yields compared to the previous one and did not lead to cyclization 
products (tetrahydropyrans moieties). An improved product selectivity was observed as we 
changed the (substrate: reagent) ratio. Of note, a major C2 monoprenylated product (compound 
M2) was observed at (1:1) ratio. On the other hand, we were pleased to see higher ratios of 
diprenylated product M6 (C2, C4) followed by M7 (C2, C6) preferentially produced at higher 
ratios as (1:3) or (1:4). As an alternative to electrophilic addition, and to reduce the number of 
prenylated products, the nucleophilic substitution was explored as outlined in condition d. We 
noticed from the prelude reactions in our initial attempts that we can approach the nucleophilic 
addition without protection. Thus, direct nucleophilic prenylation of 1 and 2 were investigated 
under multiple basic conditions including DBU, NaH and basic alumina (Al2O3) but they ended 




However, deprotonation with n-butyl lithium at low temperature followed by the addition of 
prenyl bromide resulted in mono-prenylated or di-prenylated products.  
 
Interestingly, this route showed higher selectivity profiles compared to the previous ones 
as the diprenylated resveratrol M7 (C2, and C6) emerged in higher amounts. Along with the 
required C-alkylation products, easily separable O-alkylated products and cyclized products were 
also noticed under this condition but in very low yields. However, starting with 2 under these 
conditions, the mono-tetrahydropyran versions (compounds M14 and M15) and a minor double 
tetrahydropyran dihydroresveratrol became a major product (compound M18) upon purification. 
Overall, 16 different analogs of both resveratrol (M2-M10) and dihydroresveratrol (M12-M18) 
were prepared; five of them were synthesized for the first time (Figure 18 and Figure 19). The 
overall yields and selectivities are summarized in Table 3. 
Scheme 4. Reagents and conditions: (a) Pd/H2, EtOH, r.t. (b) Prenyl alcohol, 
EtOH, pH 2.6, 120 °C, 7 hrs. (c)  2,2-Dimethylbutenol, BF3.OEt2, dioxane, 0 






















































































































































































































































































































































































































































































































































Figure 20. Energy-minimized structures M8 (cyan tubes) and M9 (green tubes) with the    
measured distances between the olefin proton of the straight chain prenyl and the methyl proton 































Figure 21. Lack of NOE correlation between olefin proton and the methyl group on 
the THP ring in M9 compared to M8  
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Table 4. NMR data for compounds M8 and M9   
 
                    
C/H no M9 M8 
δC δH, mult. 
(JHz) 
HMBC δC δH, mult. 
(JHz) 
HMBC 
1 135.39, C   134.84, C   
2 117.43, C   118.69, C   
3 152.62, C   153.31, C 152.29, C  
4 108.10, C   107.93, C   
5 152.65, C   152.29, C   
6 105.51, CH 6.63 (s, 1H) a, 2, 4, 5 102.33, CH 6.71 (s, 1H) a, 2, 4 
a 123.69, CH 7.20 (d, J = 
16.1 Hz, 1H) 
b, 2, 6 124.07, CH 7.24 (d, J = 
16.1 Hz, 
1H) 
6, 2, 1′ 
b 129.00, CH 6.93 (d, J = 
16.1 Hz, 1H) 
 128.63, CH 6.84 (d, J = 
16.3 Hz, 
1H) 
1, 2′, 6′ 
 
1′ 129.84, C   129.66, C   
2′ 127.75, CH 7.44 (d, J = 
8.5 Hz, 2H) 
b, 1′, 4′, 5′ 127.63, CH 7.40 (d, J = 
8.6 Hz, 2H) 
6′, 4′ 
3′ 115.48, CH 6.86 (d, J = 
8.5 Hz, 2H) 
 115.38, CH 6.85 (d, J = 
8.6 Hz, 2H) 
4′ 
4′ 157.13, C   157.21, C   
5′ 115.48, CH 6.86 (d, J = 
8.5 Hz, 2H) 
 115.38, CH 6.85 (d, J = 
8.6 Hz, 2H) 
 
6′ 127.75, CH 7.44 (d, J = 
8.5 Hz, 2H) 
 127.63, CH 7.40 (d, J = 
8.6 Hz, 2H) 
 
1″ 24.49, CH2 3.49 (d, J = 
6.6 Hz, 2H) 
1 ,2, 2″ 24.11, CH2 3.41 (d, J = 
7.0 Hz, 2H) 
1, 2, 3,  2″, 
3″ 
2″ 124.3, CH 5.14 (t, J = 6.7 
Hz, 1H) 
 124.52, CH 5.12 (t, J = 
7.0 Hz, 1H) 
 
3″ 129.66, C   128.72, C  1″, 4″, 5″ 
4′′ 17.21, CH3 1.83 (s, 3H)  17.30, CH3 1.83 (s, 3H) 2″, 3″ 
5′′ 25.00, CH3 1.67 (s, 3H)  25.07, CH3 1.65 (s, 3H) 2″, 3″, 4″ 
1‴ 17.53, CH2 2.71 (t, J = 6.8 
Hz, 2H) 
2′′′, 3′′′, 3, 4 17.27, CH2 2.68 (t, J = 
6.9 Hz, 2H) 
2‴, 3‴, 4, 5 
2‴ 32.17, CH2 1.83 (t, J = 6.8 
Hz, 2H) 
3′′′, 4 31.88, CH2 1.79 (t, J = 
6.9 Hz, 2H) 
1‴,4 , 3‴  
3‴ 72.80, C   73.27, C  3‴, 2‴,1‴ 
4‴ 25.99, CH3 1.30 (s, 6H) 2′′′, 3′′′ 26.16, CH3 1.32 (s, 6H) 5‴, 3‴ 






III.3.1 Conformational analysis of compounds M8 and M9 
 
The conformational search was applied with MacroModel (Schrodinger, LLC) utilizing 
advanced search with Low-frequency-Mode and OPLS2005 for energy minimization. The 
probability of TORS/MOLS steps was set to 0.5 with a maximum number of steps was equal to 
1000. The energy window for saving a structure was set to 5.02 kcal/mol to eliminate the higher 
energy conformations that could be generated. The maximum deviation between conformers was 
set to a cutoff of 0.5Å to eliminate the redundant structures.  The number of structures generated 
by this method was 1387 structures, out of which 888 were successfully minimized. The sampled 
conformational populations were assembled based on the Boltzmann potential energy-weighted 
populations (relative Potential-Energy-OPLS-2005 in KJ/mol at 298.15 K).  
III.3.2 General experimental procedures  
 
All the reactions were monitored using thin layer chromatography. All the chemicals and 
reagents were purchased from Sigma Aldrich (MO, USA). Agilent 630 FTIR (Agilent 
Technologies, CA, USA) was used to record the IR spectra. 1H and 13C NMR spectral data were 
recorded on Bruker (400 and 500 MHz; Bruker AU III, MA, USA) spectrometers and chemical 
shifts were expressed as p.p.m. Agilent UHPLC 6200 series (Agilent Technologies) was used to 
acquire Mass spectra. Column chromatography was performed on (Merck, MA, USA) silica gel 
60 and Sephadex LH20 (sigma). Flash silica gel (40μm, 60 Å, J. T. Baker) and reversed phase 
RP-C18 silica (Polarbond, J.T. Baker). Preparative-TLC plates were used for extra purification 







Condition b: Biomimetic prenylation of stilbenoids and dihydrostilbenoids using prenyl 
alcohol  
The stirred solution of resveratrol (500 mg or 2g) or dihydroresveratrol (250 mg or 500 
mg) in ethanol was adjusted to pH 2.6 using 500 mg of citric acid dissolved in 5 ml of water,then 
prenyl alcohol (2 or 4 equivalents) was added. The reaction mixture was heated up to 120 °C 
gradually in a sealed vessel using silicon oil bath for 7 or 24 hours. The reaction mixture was 
quenched with aqueous NaHCO3 and the water layer was extracted three times (15 ml) with ethyl 
acetate. The combined organic layer was dried over MgSO4 and concentrated under reduced 
pressure. Column chromatography (SiO2, EtOAc−Hex = 15:85 to 50:50) provided compounds 
M2-M10 and M12-M15.  
Condition c: Prenylation of stilbenoids and dihydrostilbenoids via electrophilic addition 
(Friedel-Crafts alkylation) 
To an ice cooled solution of resveratrol or dihydroresveratrol in dry dioxane was slowly 
added BF3.Et2O followed by (2-methyl-but-3-en-2-ol). The reaction mixture was stirred at r.t. 
overnight. The reaction mixture was evaporated under vacuum and partitioned between H2O (35 
ml) and EtOAc (3x15). The combined organic layers were washed with H2O (1x15), dried over 
MgSO4, and concentrated under reduced pressure. Flash chromatography (SiO2, Acetone-Hex = 







Condition d: Prenylation of stilbenoids and dihydrostilbenoids via nucleophilic substitution 
using prenyl bromide and n-BuLi 
To a stirred solution of resveratrol (300mg) or dihydroreveratrol (1g, 750mg) in dry THF 
at −40 °C was added dropwise n-BuLi. After 20 min the reaction was allowed to reach −20 °C, at 
which 3,3-dimethylallyl bromide was added slowly and left to stir for 3 hrs. Then the reaction 
temperature was raised gradually to the room temperature and was stirred for an additional 12 
hrs. The reaction mixture was quenched with saturated aqueous NH4Cl and the water layer was 
extracted three times EtOAc (15 ml). The combined organic layers were dried over Na2SO4 and 
concentrated under with reduced pressure. Column chromatography (SiO2, EtOAc−Hex = 15:85 
to 50:50) provided compounds M2, M3, M6, M7, M10 and M12-M18. 
III.3.4 Spectral data 
 
M2 
IR: 3339.7, 1587.8, 1353.0, 1444.3, 1244.9, 1131.2, 821.9. 1H NMR (400 MHz, MeOD):7.33 (d, 
J = 8.6 Hz, 2H, H-2’, H-6’), 7.14 (d, J = 16.1 Hz, 1H, H-α), 6.84 (d, J = 16.1 Hz, 1H, H-β), 6.78 
(d, J = 8.7 Hz, 2H, H-3’, H-5’), 6.57 (d, J = 2.4 Hz, 1H, H-6), 6.25 (d, J = 2.4 Hz, 1H, H-4), 5.13 
(m, 1H, H-2”), 3.39 (d, J = 6.8, 2H, H-1”), 1.81 (s, 3H, H-4”), 1.69 (s, 3H, H-5”). 13C NMR (100 
MHz, MeOD) δ 156.85 (C-4’), 155.64 (C-5), 155.33 (C-3), 138.29 (C-1), 129.50 (C-1’), 129.31 
(C-β), 129.00 (C-3”), 127.30 (C-2’, C-6’), 124.28 (C-2’), 123.93 (C-α), 117.69 (C-2), 115.08 (C-
3’, C-5’), 102.88 (C-6), 101.20 (C-4), 24.56 (C-4”), 23.84 (C-1”), 16.74 (C-5”). HRMS (ESI) 
calcd for C19H20O3 (MH
+), 297.1485; found 297.1484. 
 
M3 
IR: 3281.9, 1509.6, 1425.7, 1161.1, 1041.8, 965.4. 1H NMR (400 MHz, MeOD) δ 7.34 (d, J = 8.6 
Hz, 2H), 6.92 (d, J = 16.3 Hz, 1H), 6.76 (d, J = 16.3 Hz, 1H), 6.78 (d, J = 8.6 Hz, 2H), 6.48 (s, 
1H), 5.26 (m, 1H), 3.30 (d, J = 7.1 Hz, 2H), 1.78 (s, 3H), 1.68 (s, 3H). 13C NMR (100 MHz, 
MeOD) δ 156.75, 155.62, 155.24, 138.38, 129.58, 129.47, 129.10, 127.39, 124.22, 123.97, 117.86, 
115.14, 103.04, 101.29, 24.64, 23.91, 16.83. HRMS (ESI) calcd for C19H20O3 (MH
+), 297.1485; 
found 297.1486  
 
M4 
IR: 3339.7, 1582.3, 1442.5, 1166.7, 1019.4, 836.8. 1H NMR (400 MHz, acetone-d6) δ 7.47 (d, J 
= 8.6 Hz, 2H), 7.18 (d, J = 16.1 Hz, 1H), 6.96 (d, J = 16.1 Hz, 1H), 6.86 (d, J = 8.6 Hz, 2H), 6.71 
(d, J = 2.4 Hz, 1H), 6.20 (d, J = 2.4 Hz, 1H), 2.78 (t, J = 6.8 Hz, 2H) 1.82 (t, J = 6.8 Hz, 2H), 1.30 
(s, 6H). 13C NMR (100 MHz, acetone-d6) δ 157.31, 156.30, 155.05, 137.95, 129.79, 129.37, 




+), 297.1485; found 297.1488. 
 
M5 
IR: 3308.0, 1547.8, 1511.4, 1422.0, 1116.3, 1053.0, 834.9. 1H NMR (400 MHz, acetone-d6) δ 
7.42 (d, J = 8.6 Hz, 2H), 7.00 (d, J = 16.3 Hz, 1H), 6.86 (d, J = 16.3 Hz, 1H), 6.85 (d, J = 8.5 Hz, 
2H), 6.60 (d, J = 1.4 Hz, 1H), 6.49 (d, J = 1.3 Hz, 1H), 2.67 (t, J = 6.8 Hz, 2H), 1.80 (t, J = 6.8 Hz, 
2H), 1.31 (s, 6H). 13C NMR (100 MHz, acetone-d6) δ 157.13, 155.62, 155.16, 136.88, 129.21, 
127.72, 127.72, 127.45, 125.93, 115.51, 115.51, 108.03, 106.50, 103.89, 73.40, 32.07, 26.07, 
26.07, 17.05. HRMS (ESI) calcd for C19H20O3 (MH
+), 297.1485; found 297.1487. 
 
M6 
IR: 3369.5, 1578.5, 1431.3, 1168.5, 1034.3, 838.1. 1H NMR (500 MHz, acetone-d6) δ 7.39 (d, J 
= 7.9 Hz, 2H), 7.20 (d, J = 16.0 Hz, 1H), 6.85 (d, J = 8.5 Hz, 2H), 6.79 (d, J = 16.1 Hz, 1H), 6.76 
(s, 1H), 5.26 (t, J = 7.0 Hz, 1H), 5.13 (t, J = 6.1 Hz, 1H), 3.48 (d, J = 6.6 Hz, 2H), 3.44 (d, J = 6.9 
Hz, 2H), 1.82 (s, 3H), 1.79 (s, 3H) 1.67 (s, 6H). 13C NMR (125 MHz, acetone-d6) δ 157.11, 153.57, 
153.36, 135.19, 130.85, 129.97, 129.56, 128.79, 127.66, 127.66, 124.26, 124.11, 123.11, 118.07, 
115.52, 115.52, 114.66, 104.12, 25.03, 24.99, 24.70, 22.56, 17.24, 17.09. HRMS (ESI) calcd for 
C24H28O3 (MH
+), 365.2111; found 365.2110. 
 
M7 
IR: 3317.3, 1589.7, 1442.5, 1151.7, 1086.5, 903.5. 1H NMR (500 MHz, acetone-d6) δ 7.38 (d, J 
= 8.5 Hz, 2H), 6.98 (d, J = 16.7 Hz, 1H), 6.87 (d, J = 8.4 Hz, 2H), 6.44 (d, J = 16.6 Hz, 1H), 6.45 
(s, 1H), 5.20 (dt, J = 8.4, 4.2 Hz, 2H), 3.35 (d, J = 4.7 Hz, 4H), 1.65 (s, 6H), 1.63 (s, 6H). 13C 
NMR (100 MHz, acetone-d6) δ 157.06, 153.44, 153.44, 139.55, 133.30, 129.53, 128.95, 128.95, 
127.46, 127.46, 124.90, 124.90, 124.21, 117.55, 117.55, 115.45, 115.45, 101.43, 25.95, 25.95, 
25.08, 25.08, 17.31, 17.31. HRMS (ESI) calcd for C24H28O3 (MH
+), 365.2111; found 365.2111 
 
M8 
IR: 3261.4, 1578.5, 1422.0, 1159.2, 1072.2, 821.9. 1H NMR (400 MHz, acetone-d6) δ 7.40 (d, J 
= 8.6 Hz, 2H), 7.24 (d, J = 16.1 Hz, 1H), 6.85 (d, J = 8.6 Hz, 2H), 6.84 (d, J = 16.3 Hz, 1H), 6.71 
(s, 1H), 5.12 (t, J = 7.0 Hz, 1H), 3.41 (d, J = 7.0 Hz, 2H), 2.68 (t, J = 6.9 Hz, 2H), 1.83 (s, 3H), 1.79 
(t, J = 6.9 Hz, 2H), 1.65 (s, 3H), 1.32 (s, 6H). 13C NMR (100 MHz, acetone-d6) δ 157.08, 153.31, 
152.27, 134.89, 129.61, 128.96, 128.53, 127.65, 124.48, 124.04, 118.85, 115.52, 107.93, 102.33, 
73.36, 31.84, 26.13, 25.06, 24.04, 17.34, 17.27. HRMS (ESI) calcd for C24H28O3 (MH
+), 
365.2111; found 365.2110. 
 
M9 
IR: 3380.2, 15559.9, 1429.4, 1157.3, 1094.0, 838.7. 1H NMR (500 MHz, acetone-d6) δ 7.44 (d, J 
= 8.5 Hz, 2H), 7.20 (d, J = 16.1 Hz, 1H), 6.93 (d, J = 16.1 Hz, 1H), 6.86 (d, J = 8.5 Hz, 2H), 6.63 
(s, 1H), 5.14 (t, J = 6.7 Hz, 1H), 3.49 (d, J = 6.6 Hz, 2H), 2.71 (t, J = 6.8 Hz, 2H), 1.83 (t, J = 6.8 
Hz, 2H), 1.83 (s, 3H), 1.67 (s, 3H), 1.30 (s, 6H). 13C NMR (125 MHz, acetone-d6) δ 157.13, 
152.63, 135.79, 129.79, 129.63, 129.02, 127.73, 127.73, 124.31, 123.72, 117.45, 115.50, 115.50, 
108.11, 105.46, 72.88, 72.88, 32.16, 25.98, 25.98,25.00, 24.50, 17.55, 17.25. HRMS (ESI) calcd 
for C24H28O3 (MH






IR: 3360.2, 1559.9, 1429.4, 1157.3, 1094.0, 838.7. 1H NMR (400 MHz, acetone-d6) δ 7.41 (d, J 
= 8.6 Hz, 2H), 6.96 (d, J = 16.6 Hz, 1H), 6.87 (d, J = 8.6 Hz, 2H), 6.53 (d, J = 16.7 Hz, 1H), 6.27 
(s, 1H), 5.22 (tdd, J = 5.4, 2.9, 1.4 Hz, 1H), 3.38 (d, J = 6.7 Hz, 2H), 2.67 (t, J = 6.7 Hz, 2H), 1.74 
(t, J = 6.7 Hz, 2H), 1.66 (d, J = 1.5 Hz, 3H), 1.65 (d, J = 1.5 Hz, 3H), 1.29 (s, 6H). 13C NMR (100 
MHz, acetone-d6) δ 157.18, 154.08, 152.54, 138.50, 133.60, 129.36, 129.06, 127.52, 127.52, 
124.84, 123.53, 118.34, 115.45, 115.45, 110.40, 102.36, 72.81, 33.10, 26.11, 26.1, 1 25.75, 25.02, 
21.25, 17.27. HRMS (ESI) calcd for C24H28O3 (MH
+), 365.2111; found 365.2130. 
 
M12 
IR: 3295.0, 1593.4, 1448.1, 1131.2, 11131.2, 779.0. 1H NMR (400 MHz, acetone-d6) δ 7.07 (d, J 
= 8.5 Hz, 2H), 6.77 (d, J = 8.4 Hz, 2H), 6.30 (d, J = 2.5 Hz, 1H), 6.26 (d, J = 2.4 Hz, 1H), 5.13 
(tdd, J = 5.4, 2.8, 1.5 Hz, 1H), 3.31 (d, J = 6.6 Hz, 2H), 2.75 (s, 4H), 1.74 (d, J = 1.3 Hz, 3H), 1.66 
(d, J = 1.5 Hz, 3H). 13C NMR (100 MHz, MeOD) δ 155.65, 155.11, 154.96, 142.01, 133.03, 
129.16, 128.88, 128.88, 124.58, 117.64, 114.64, 114.64, 107.23, 99.95, 36.59, 35.44, 24.54, 23.88, 
16.71. HRMS (ESI) calcd for C19H22O3 (MH
+), 299.1642; found 299.1643 
 
M13 
IR: 3233.5, 1589.7, 1438.8, 1115.5, 1034.3, 980.3. 1H NMR (400 MHz, acetone-d6) δ 7.03 (d, J 
= 8.4 Hz, 2H), 6.75 (d, J = 8.5 Hz, 2H), 6.28 (s, 2H), 5.31 (ddt, J = 7.2, 5.8, 1.4 Hz, 1H), 3.34 (d, 
J = 7.2 Hz, 1H), 2.81-2.63 (m, 4H), 1.77 (d, J = 1.3 Hz, 3H), 1.65 (d, J = 1.4 Hz, 3H). 13C NMR 
(100 MHz, acetone-d6) δ 155.80, 155.80, 155.40, 140.47, 132.75, 129.53, 129.21, 129.21, 123.80, 
115.01, 115.01, 112.21, 106.93, 106.93, 37.85, 36.69, 25.07, 22.02, 17.05. HRMS (ESI) calcd for 
C19H22O3 (MH
+), 299.1642; found 299.1642 
 
M14 
IR: 3285.8, 1513.3, 1444.3, 1136.8, 1012.0, 834.9. 1H NMR (400 MHz, MeOD) δ 6.95 (d, J = 8.5 
Hz, 2H), 6.68 (d, J = 8.5 Hz, 2H), 6.23 (d, J = 2.5 Hz, 1H), 6.06 (d, J = 2.5 Hz, 1H), 2.77 – 2.69 
(m, 4H), 2.48 (t, J = 6.8 Hz, 2H), 1.72 (t, J = 6.8 Hz, 1H) 1.25 (s, 6H). 13C NMR (100 MHz, 
MeOD) δ 155.56, 155.04, 154.53, 141.47, 132.68, 129.04, 129.04, 114.63, 114.63, 110.50, 108.01, 
101.25, 73.09, 35.84, 34.67, 32.76, 25.53, 25.53, 18.87. HRMS (ESI) calcd for C19H22O3 (MH
+), 
299.1642; found 299.16.14. 
 
M15 
IR: 3360.33, 1514.68, 1120.1, 1057.36, 830.69. 1H NMR (500 MHz, acetone-d6) 7.05 (d, J = 8.4 
Hz, 2H), 6.77 (d, J = 8.4 Hz, 2H), 6.30 (d, J = 1.6 Hz, 1H), 6.19 (d, J = 1.5 Hz, 0H), 2.82 – 2.73 
(m, 2H), 2.72-2.66 (m, 1H), 2.63 (t, J = 6.8 Hz, 2H), 1.76 (t, J = 6.8 Hz, 2H), 1.28 (s, 6H). 13C 
NMR (125 MHz, acetone-d6 δ 155.40, 155.27, 154.85, 141.01, 132.79, 129.25, 129.25, 115.06, 
115.06, 108.40, 106.19, 105.99, 73.21, 38.01, 36.72, 32.20, 26.15, 26.15, 16.86. HRMS (ESI) 
calcd for C19H22O3 (MH+), 299.1642; found 299.1642. 
 
M16 
IR: 3390.0, 1591.6, 1425.7, 1170.4, 1041.8, 827.5. 1H NMR (400 MHz, acetone-d6) 7.05 (d, J = 
8.5 Hz, 2H), 6.77 (d, J = 8.5 Hz, 1H), 6.35 (s, 1H), 5.26 (dddd, J = 7.1, 5.6, 2.9, 1.5 Hz, 1H), 5.09 
(tq, J = 5.0, 1.5 Hz, 1H), 3.40 (d, J = 7.3 Hz, 2H), 3.34 (d, J = 6.6 Hz, 2H), 2.72 (s, 4H), 1.78 (d, J 
= 1.3 Hz, 3H), 1.75 (d, J = 1.3 Hz, 3H), 1.67 (d, J = 1.5 Hz, 6H). 13C NMR (100 MHz, acetone-
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d6) δ 155.48, 153.49, 153.41, 138.57, 132.91, 130.57, 130.12, 129.13, 129.13, 124.50, 123.45, 
117.63, 115.06, 115.06, 112.79, 108.19, 36.76, 35.55, 25.04, 24.96, 24.72, 22.39, 17.21, 17.07. 
HRMS (ESI) calcd for C24H30O3 (MH
+), 367.2268; found 367.2267 
 
M17 
IR: 3546.6, 1513.3, 1436.9, 1149.9, 825.6. 1H NMR (400 MHz, acetone-d6) 7.11 (d, J = 8.4 Hz, 
2H), 6.80 (d, J = 8.4 Hz, 2H), 6.39 (s, 1H), 5.17-5.10 (m, 2H), 3.37 (d, J = 6.6 Hz, 4H), 2.85 – 2.74 
(m, 2H), 2.68 (dd, J = 11.5, 5.1 Hz, 2H), 1.75 (s, 6H), 1.65 (s, 6H). 13C NMR (100 MHz, acetone-
d6) δ 155.51, 153.56, 153.56, 140.31, 133.24, 129.13, 129.13 129.02, 129.02, 125.27, 125.27, 
117.69, 117.69, 115.18, 115.18, 100.71, 36.19, 32.04, 25.05, 25.05, 24.77, 24.77, 17.33, 17.33. 
HRMS (ESI) calcd for C24H30O3 (MH
+), 367.2268; found 367.2260. 
 
M18 
IR: 3349.0, 1584.1, 1459.3, 1157.3, 1105.2, 827.5. 1H NMR (400 MHz, CDCl3) δ 7.08 (d, J = 8.4 
Hz, 2H), 6.79 (d, J = 8.4 Hz, 1H), 6.22 (s, 1H), 2.86-2.79 (m, 2H), 2.73 – 2.67 (m, 2H), 2.65 (t, J 
= 6.8 Hz, 2H), 1.80 (t, J = 6.8 Hz, 2H), 1.31 (s, 12H). 13C NMR (100 MHz, CDCl3) δ 153.85, 
153.25, 153.25, 138.75, 134.20, 129.44, 129.44, 115.23, 115.23, 111.39, 111.39 103.55, 73.14, 
73.14, 34.31, 33.29, 33.29, 31.18, 26.70, 26.70, 26.70, 26.70, 19.77, 19.77. HRMS (ESI) calcd 
for C24H30O3 (MH
















CHAPTER IV                                                                                                              
ACTIVATION OF PXR BY LICORICE COMPOUNDS 
 
IV.1 Background 
The common perception that a label of ‘natural’ ensures safety, the unpleasant episodes 
and side effects associated with pharmaceutical (synthetic) drugs, along with the long history of 
usage of botanicals as medicines have resulted in an upsurge of herbal medicines in Western 
healthcare. Passage of the education act further fueled the utility of botanicals in drugs, dietary 
supplements, cosmetics or personal care products. As a result, herbal ingredients became part of 
various formularies and the trend shows a strong inclination of consumers to self-medicate with 
botanicals.26 Due to this rapid growth of the market, consumer use in many cases has outpaced 
adequate scientific understanding of the products, opening the door for potential adverse effects. 
Although the efficacy of some botanical drugs has been documented, there is a concern 
regarding the perceived safety of herbal products, particularly with respect to the knowledge of 
botanical drug interaction potential with conventional prescription drugs and its clinical 
significance. Moreover, herb-drug and induced-herb-drug interactions have generally been 
inadequately studied. With the burgeoning use of botanicals, some reports of serious drug 
interactions are appearing in the literature. 131-135 A further risk for consumers, which will 
exacerbate the problems associated with botanical ingredients, is that self-medication might 
delay or prevent a patient from seeking appropriate medical treatment. Botanical drugs comprise 
a plethora of bioactive constituents and often exist as very complex mixtures. Several reports 
indicate that herbal constituents could alter the pharmacokinetics of prescription drugs via direct 
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or inductive pathways.13, 28, 136 This is critically important when it comes to drugs of a 
narrow therapeutic index such as immunosuppressants or chemotherapeutic agents or with those 
intended for a chronic or life-threatening diseases. The incidence of such events has been 
reported and led to therapeutic failure.  
For instance, St. John’s Wort concomitantly used with cyclosporine 
(immunosuppressant) or contraceptives led to the failure of therapy. Other reports described the 
inefficacy of efavirenz (antiviral) consumed with Ginkgo supplements. Direct modulation of 
metabolizing enzymes is one route recognized for the pharmacokinetics interactions between 
conventional drugs and other xenobiotics. This includes CYPs inhibition, both as transient and 
irreversible inhibition. However, these models could not explain the inductive effects acquired 
by consumption of some herbs. Later on, researchers have identified the pivotal role played by 
nuclear receptors in regulating the gene-expression of drug metabolizing enzymes and 
transporters.137-138 The Pregnane X Receptor (PXR), as one of the newly defined nuclear 
receptors, is considered as the master regulator of drug metabolizing enzymes. This includes 
induction of cytochrome P450s and multiple other phase-I and phase-II enzymes and 
transporters.  
Several botanicals and their constituents have been recognized as inducers of PXR such a 
St. John’s Wort, Kava Kava and Gugulipids, Gan Cao.13 Further investigations revealed a wide 
variety of molecules responsible for initiating PXR machinery, which indicates the broad 
substrate acceptability. In conformity with the above, herbal constituents can interact with PXR 
ligand binding domain and have the ability to modulate principal metabolic enzyme and some of 
the energy expenditure checkpoints.139 This situation has raised a huge campaign inclined to 
unveil the potential risk/benefit of intentional long-term herbal consumption.  
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IV.1.1 The role of Pregnane X receptor  
 
One major discovery in the nuclear receptors field has occurred in 1998. The discovery of 
PXR has outlined a new era into understanding the regulatory mechanisms behind xenobiotic 
detoxification as a primary defense mechanism in our bodies. Initially, it was classified as one of 
the orphan receptors “a receptor without a characterized endogenous ligand”, but soon it was 
found to bind a family of diverse chemical subtypes.140 This includes a set of endobiotics such as 
the pregnane steroids as well as other therapeutic drugs. This nuclear receptor (NR1I2) belongs 
to the nuclear receptor subfamily 1 group I, which also includes the vitamin D receptor (VDR) 
and the constitutive androstane receptor (CAR). Similar to the other nuclear receptors, it 
functions as a ligand-induced transcriptional factor, where the binding of a ligand can trigger a 
conformational change of the protein that will switch on a cascade of events leading to a 
controlled and specific genetic induction.137   
It is well established that PXR has a paramount role as a xenosensor, where it regulates 
the expression of many metabolic enzymes and transporters responsible for drug or 
“xenobiotics” disposition. In addition, it has viable but less studied roles in endobiotics synthesis, 
metabolism and homeostasis including bile acids, lipids, glucose, bilirubin, vitamins and other 
steroid hormones. This highlights the diverse and crucial roles of PXR implicated into both drug 
metabolism (efficacy, toxicity, drug interactions, and drug resistance) and disease (metabolic 
syndrome, cancer, and inflammation).141-142 In fact, PXR ligand-activation is paradoxically 
important, in a way to sense these xenobiotics and to dispose them. Alternatively, they may 
influence the systemic or tissue exposure of the other drugs in case of concurrent consumption 
with the PXR activators. In fact, PXR versatile role is reflected by its vast control upon many 
metabolic enzymes and transporters. So far, it is shown to control the target genes of phase-I 
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CYP450 (CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A1, CYP3A4, CYP3A5, 
CYP3A7, CYP4F12, CYP24, and CYP27A1), phase II uridine diphosphate (UDP)-
glucuronosyltransferases (UGT1A1, UGT1A3, UGT1A4, UGT1A6, and UGT1A9), 
sulfotransferases (Sult2a1), glutathione S-transferases (GSTA2, GSTA4). In addition to the 
carboxylesterases and phase III P-glycoprotein (MDR1/ABCB1), multidrug resistance-associated 
protein 1 (ABCC1), multidrug resistance-associated protein 2 (ABCC2), multidrug resistance-
associated protein 3 (ABCC3), and organic anion transporting polypeptide 2 (OATP2).13 
However, induction of PXR is not the ultimate event. Also, it is not necessarily translated 
into the genetic pool of susceptible enzymes and transporters. Instead, responses are selective 
and gradient in nature, which rather come as a result of multiple other dimensions including 
specific tissue, coregulators, epigenetics, and post-translational modifications, specific response 
elements, and other NRs.143 In addition to its roles as a xenobiotic sensor, many studies have 
unveiled the kinetics behind its uncanonical roles. Hence providing the evidence of its function 
as a mediator of chemo-genetics interplay, which delineates the etiology of the environmentally 
induced diseases such as the cardiometabolic disease.  
This can be explained by upregulation or inhibition of vital checkpoints proteins 
(enzymes or factors) in specific diseases networks. One example is the hyperglycemic effects 
corroborated with PXR induction, where PXR induction was found to downregulate the glucose 
transporter 2 and other vital kinases related to gluconeogenesis (glucokinase, dehydrogenase 
kinase isozyme 2, and phosphoenolpyruvate carboxykinase 1).142, 144 Moreover, PXR 
polymorphism, and PXR variants have been correlated to multiple diseases and malignancy such 




4.A.2 The Pregnane X receptor structure 
PXR shares the common features of other NRs required for the transcriptional machinery. 
It consists of five main domains among which the DNA-binding domain (DBD) and the ligand-
binding domain (LBD) are the most important. The former recognizes specific response elements 
that flank the genes controlled by PXR. The ligand-binding domain mainly comprises the 
binding site for ligands in addition to the protein-protein surface interaction. Nevertheless, PXR 
is unique among other NRs by having a large spherical and flexible binding pocket.  
Gene induction is triggered by the ligand-binding event, which will induce a 
conformational change that will release corepressors already bound to PXR in the AF-2 region. 
After ligand activation, PXR heterodimerization with retinoid X receptor (RXRα) will take 
place, which will further stabilize the coactivator binding in the AF-2 region and selectively 
recognizes DNA response elements of specific genes.145 The adopted structural features upon 
ligand binding dictate the following genetic responses by stabilizing and recruiting different 
coregulators and factors and vice versa.   
PXR has a large and flexible hydrophobic pocket wrapped between 12 α-helixes and a 
short region of 5 β-strands. Compared to other NRs, PXR has a wider surface of β-sheets since it 
has an extra two β-strands.  The ligand binding site volume can vary between apo and ligand-
bound crystal structure from 1280-1600 Å3, which is substantially larger than any other NRs. 
The region comprised of residues 198 and 212 can be completely disordered to fit very large 
structures such as Rifampicin.   This further explains its promiscuous behavior and the lack of 
direct antagonists through its ligand-binding site. Thus, it can accommodate a wide variety of 
structures with varying molecular weights (300-800 Daltons). The diversity of the amino acids 
lining this pocket explain the hospitality of such receptor (ten hydrophobic, four polar and four 
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charged amino acids).146-149 Compliance with diversity is essentially one feature that is required 
for its function as a xenobiotic sensor, which allows the detection of a versatile set of chemicals 
that may differ in size or electronic features.150  
However, aside from this sophisticated behavior, several computational studies have 
deduced global features as the primary requirements needed for PXR activation. For instance, 
larger hydrophobic molecules have a better chance to interact with PXR; this includes a 
molecular weight, which is larger than 300 Daltons and hydrophobic features that allow multiple 
hydrophobic interactions and π-π interactions with a list of recognized hydrophobic amino acids 
mainly, those occupying the aromatic sub-pocket surrounded by F288 and W299. Further studies 
recognized S247, Q289, and H407 as indispensable residues for the PXR induction.149, 151-153 
Thus, at least one hydrogen bond interaction with one of the key amino acids is considered as a 
basic requirement for PXR activation.  
The existence of multiple crystal structures of PXR with different ligands has allowed the 
recognition of the characteristic flexible side chains at the binding site. The AF-2 region is 
stabilized via ligand binding, especially by the direct interaction with S247. This region 
recognizes a family of peptides with the LXXLL motif, which is further stabilized by a charge 
clamp interaction with conserved charged amino acids K259 and E427 (Figure 22).149 Although 
many inducers of PXR have been identified, antagonists were more resilient.142 However, more 
recently, the indirect allosteric modulation was recognized as one pathway for PXR 
antagonism.154  
The coregulator site at the AF-2 region constitutes the plausible site for this modulation. 
This key intervention will prevent the coactivators from binding. Ketoconazole among other 
azoles is the representative ligand for PXR antagonism.155 Other naturally occurring and plant-
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derived compounds have been discovered, viz. coumestrol, sesamine and resveratrol.156-157  
IV.1.2 An overview of the applied computational techniques to predict PXR activation 
 
It is increasingly important to screen for drug interaction early in the process of drug 
development to eliminate hits with a high propensity for inducing adverse effects through the 
drug metabolizing enzymes. In fact, computational methods provide a significant research axis 
for pre-screening of hit libraries. In the realm of drug metabolism and excretion, PXR has the 
major influence upon expression of the vital CYPs enzymes and transporters.158-159 However, 
indirect PXR screening is very challenging. It has species-specific selectivity, where animal 
models cannot exclusively tell us about the possible interaction that could happen. For instance, 
rifampicin, which is a potent PXR activator in human, does not induce PXR in rodents. 
Moreover, PXR in vitro models suffer from high variability among different cell lines 
and can lead to contradicting results. The reasons behind this could be related to the cell viability 
or the presence or absence of different transporter machinery that will affect the permeabilities 
and concentrations of the tested compound. Moreover, the origin of the cell-line plays a 
fundamental role in the expressed corepressors/coactivator ratios. For instance, Hela or HepG2 
(cancer cell line) have higher corepressor concentrations compared to normal hepatocytes. 
Hence, extrapolation should be highly dependent on the targeted population. Application of in 
silico models of both structure-based and ligand-based methods not only would provide 
alternative routes but also would fine-tune the screening of the existing methods.160This will 
salvage some of the costs and would keep the more expensive screenings methods such as 
hepatocyte cell-lines or the transgenic mice models (expressing human PXR) for those highly 








Figure 22. (Left) Interaction of SRC-1 (the coactivator peptide in a purple cartoon) with the 
hydrophobic groove in the 1NRL crystal structure. (Middle) the LXXLL motif in SRC-1 is 
buried in the groove with the charge clamp lock with K259 and E427. (Right) Antagonist 
ketoconazole (green sticks) and fluconazole (grey sticks) and coumestrol (pink sticks) docked 
to the SRC-1 site 
 
However, the challenge is not inevitable when applying in silico screening.  The 
promiscuity and flexibility of PXR represent the major obstacle. Nevertheless, previous studies 
have encouraged the application of these approaches coupled to in vitro methods. Most of the 
studies have focused on the ligand-based approaches. For example, one study has applied 
machine-learning methods to predict PXR active ligands and the best predictive ability has 
reached 80% accuracy by applying the support vector machine (SVM) method.161 Other QSAR 
models have employed the pharmacophore modeling, which comprised of hydrophobic and 
hydrogen bonding features similar to the features found in PXR crystal structures.162 Predictions 
based on the LBP and docking have performed well, where one study has used Gold scores to 
classify the compounds from the ToxCast database. They were able to correctly identify 8 out of 
12 agonists and 7 out of 16 PXR non-agonist.160  
Taken together, the application of pre-clinical screening of PXR will significantly reduce 
the costs and can enhance our knowledge about the behavior of such compounds in the presence 
of a very challenging defense mechanism. There is no straightforward method that can give the 
perfect answer. Nevertheless, combining in silico and in vitro screens together will enhance the 

















performance of these models. In this study, we have utilized the structure-based approach 
screening coupled to in vitro analysis to screen a library of Glycyrrhiza compounds. We 
envisaged that docking (compared to the other mentioned in silico methods) would give us direct 
insights for ligand interaction with PXR; a method, which will cope better with the highly 
variable chemical space of PXR activators. Particularly, the number and the class of compounds 
preconceived in the training set for ligand-based methods are usually insufficient to avoid the 
bias. In addition, ligand-based and machine learning approaches are more susceptible to the 
inhomogeneity that is typically encountered within PXR in vitro data.  
IV.1.3 Glycyrrhiza and Herb-drug interaction: An in silico approach   
 
Induction of PXR is identified as one of the major mechanisms for triggering HDI.  
Multiple clinically significant pharmacokinetic interactions between herbs and prescription drugs 
have been reported via PXR. Direct CYP/transporter inhibition is another vital mechanism, 
although not mutually exclusive, but rather a competitive route under in vivo conditions.13, 28, 136 
Licorice herb has been used for centuries in traditional medicine in different parts of the world, 
where it has been found in 85% of the traditional Chinese medicinal prescriptions. Moreover, it 
is increasingly used in the US and Europe as a standardized total extract to alleviate multiple 
ailments, including postmenopausal symptoms. It is also consumed for its chemoprevention and 
hepatoprotective properties.  
Recently, there is more scientific and preclinical experimental evidence, which confirmed 
the efficacy of these ethnobotanical remedies.17, 63, 163 However, these commercialized freely 
accessible herbal supplements have infiltrated the health systems without a rigorous 
understanding of its possible side effects. This situation has triggered an urgent call for more 
rigorous studies of HDI.26 In addition, natural products are indispensable resources for NCEs, 
86 
 
where the optimization of their pharmacokinetics and their drug metabolism properties are at the 
top priority for their success.9 Recent studies have raised the concerns for licorice induced PXR 
activity, and they pointed out to its glycyrrhizin component as the source of induction.164-165 
However, only weak PXR activation has been detected with the in vitro reporter gene assays for 
glycyrrhizin as compared to rifampicin (the positive control). 
Moreover, Glycyrrhiza has been prioritized by the FDA as one of the high-risk herbal 
constituents for inducing the adverse effects.166 The objective of this study is to screen the 
components of different Glycyrrhizae species against potential PXR induction or CYP inhibition 
by application of multiple computational methods. The components with high interaction 
potentials will be further confirmed with cell-based in vitro assays for the assessment of PXR 
induction and the elucidation of the susceptible target genes. The activation of PXR will be 
determined in HepG2 cells that are transiently transfected with the expression vector of PXR and 
the reporter plasmid.  
By the application of such methods, we anticipate bypassing some of the inconveniences 
coupled to the direct in vitro analysis, including interference of endpoint measurements and the 
inadequate supply of the purified diverse component systems. To fill the gaps into our 
knowledge of the possible HDI that could be induced by the secondary metabolites of licorice, 
we have utilized a tandem scheme of both in silico and in vitro risk assessment models. To roll 
out the privileged ingredients with a high propensity for triggering HDI, two clinically relevant 
Glycyrrhiza species (G. glabra and G. uralensis) have been docked to the LBD of PXR crystal 
structure to prioritize their potential interaction. Furthermore, in silico risk assessment of CYP 
enzyme inhibition models commercially available in ADMET predictor have been applied to the 






The top docking scores for licorice compounds are summarized in Tables SI 8 and SI 9. 
Redocking of the cognate ligand in both crystal structures has reproduced the binding mode in 
the native protein structure with relatively good precision (RMSD for SRL and hyperforin were 
found to be 1.0751Å and 1.1987Å, respectively). The docking scores for a group of 
experimentally active compounds were used as a control group to estimate the cut-off value 
(Figure 23 and Table 5). Thus, both SP and XP glide scores were evaluated for a set of active 
known compounds (highly active, moderate and weak) into two different crystal structures, 
1NRL and 1M13. The XP docking scores against 1NRL were capable of reflecting the 
experimental gradient activity of the control group and thus they were used for our screening 
purposes.   
The calculated scores of the known compounds in the control group showed that 
moderately active ones scored in the range of (−9.0 to −9.5 kcal/mol), while high activators 
scored below (−10 kcal/mol). However, earlier studies showed that potent PXR induction 
correlates successfully with a transient transfection assay when the compound (<10 µM) 
achieves (70%) maximum induction relative to (10 µM) rifampicin.167 Thus, in order to reflect 
these observations onto our docking results, we decided to consider the compounds with glide 
scores < −9.5 kcal/mol. In this present study, the docking scores against the LBD suggested a 
high number of licorice components having the potential of inducing PXR activation. According 
to our predefined threshold of PXR agonist, around 60 phenolic compounds in G. glabra and 50 
compounds in G. uralensis have scored below −9.5 kcal/mole. Interestingly, most of these 
compounds belong to the isoflavonoid classes with a higher order of prenyl groups. Moreover, 
88 
 
all the prenylated dihydro stilbenoids reported in both licorice species scored very high, due to 
favorable ligand-protein interactions. 
 
Figure 23. Naturally occurring PXR inducers and 1NRL native ligand SR12813 
 
The visual inspection of the isoflavonoids docking poses revealed the vital hydrophobic 
and π-π interactions of both prenyl groups or their tetrahydropyran (THP) counterparts (the 
cyclized prenyl appendages found in many top-ranked compounds) with the hydrophobic sub-
pocket comprised of F288 and W299 (Figure 24). Representative examples of each category are 
shown in  
Figure 25 (flavonoids and isoflavonoids), Figure 26 (DHS), and Figure 27 (other 
miscellaneous components). In addition, several compounds were also able to interact with at 
least one key residue in the LBD via hydrogen bonding. On the other hand, the docking poses of 
the prenylated stilbenoids did not show a certain pattern of interaction since they have a more 
freely rotatable scaffold and can adopt a variety of conformations. Other prenylated 
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miscellaneous compounds classes (coumarins, chalcones, and pterocarpans) have shown the 
similar potential of interacting with PXR. Examples of the docking pose of some representative 
compounds interacting with PXR LBD is shown in Figure 28. 
 
Table 5. SP and XP glide scores (kcal/mol) for a set of known PXR active compounds (highly 
active, moderate and weak) 
 














−9.82 −10.54 −9.17 −10.15 aHigh activator 
III Enterolactone −7.99 −9.34 −7.22 −8.71 bModerate activator 
IV Hypericin NA NA −7.55 −10.02 bModerate activator 
V Quercetin −6.93 −8.70 −6.76 −9.50 c Weak activator 
VI Genistein −6.66 −8.10 −7.72 −6.58 c Weak activator 
VII Physcion −6.94 −7.71 −6.54 −7.22 c Weak activator 
VIII SR12813 −10.82 −12.34 −8.14 −9.68 a,dHigh activator 
a) >70% maximum induction relative to 10 µM Rifampicin according to transient transfection assay.  
b) 30-70% maximum induction relative to 10 µM Rifampicin according to transient transfection assay.  
c) <30% maximum induction relative to 10 µM Rifampicin according to transient transfection assay.  






















Figure 24. Docking pose (PDB:1NRL) of a number of representative isoflavonoids and 
flavonoids compounds (orange sticks) in the top scoring list of G. glabra and G. uralensis 
showing similar preferable π-π interactions (blue dotted lines) with W299 and F288 






Figure 25. Group 1 (flavonoids and isoflavonoids) of top-scoring compounds from both G. 



















Figure 26. Group 2 (dihydrostilbenoids) of top-scoring compounds from both G. glabra and G. 
uralensis species against PXR LBD (PDB: 1NRL) 
 
 
Figure 27. Group 3 (miscellaneous) of top-scoring compounds from both G. glabra and G. 




   
   
   
   
   
   
   




































Figure 28. Docking pose of representative top scoring compounds in PDB: 1NRL binding 
site (group 1 in magenta sticks, group 2 in green sticks and group 3 in yellow sticks) 
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IV.2.2 In vitro testing  
 
Based on in silico assessment of licorice secondary metabolites, prenylated stilbenoids 
have been identified as one of the top scoring components with a high propensity for PXR 
activation. A library of 18 stilbenoids rich with diverse prenylation patterns (0.78-25 µM), where 
incubated with HepG2 cells transfected with the pSG5‐hPXR (25 µM) and the PCR5 (25 µM) 
plasmid DNA with and without the positive control rifampicin (3.125-25 µM) 
After incubation for 24 hours with the pretreated cells, resveratrol (parent compound) and 
several compounds of both the stilbenoids and the DHS series (M7-10 and M13-18) were able to 
induce PXR with multiple fold induction in a dose-dependent manner (Figure 29, Figure 30 and 
Table 6). Interestingly, compounds M9-M10, M15-M18 showed strong activity, where they 
were evenly or slightly more efficacious than the positive control, rifampicin. The maximum fold 
induction surpassed the positive control (3.8) for compound M10 (4.37 folds), M15-18 (4.22-
5.25 folds) at the same concentration (12.5 µM). Moreover, potent PXR induction was observed 
at the sub-micromolar range for compounds M9, 10, 15, 17 and 18, which maintained at least 
two-fold induction at low concentration as 0.78 µM.  
Furthermore, the significant increase of CYP3A4 mRNA expression of the compounds 
M1, 7, 10, 12, 15, 17, and 18 validates the PXR activation assay (Table 7 and Figure 31). 
Compounds M7, M10, and M15 were able to increase the mRNA levels up to 6 folds with M10 
having the most potent activity. It maintained the 6 fold induction at 1µM concentration. 
Additionally, to exclude any antagonist allosteric modulation of PXR, known for resveratrol, 
select compounds, viz M7, 10, 12, 15, 17, 18 including resveratrol were subjected to competitive 
experiments with rifampicin. None of these compounds were able to antagonize the rifampicin 

















Figure 29. PXR fold induction in transfected HepG2 cells for 
stilbenoids derivatives M1, 7, 8, 9 and 10. The compounds were tested 





















































Figure 30. PXR fold induction in transfected HepG2 cells for DHS 
derivatives M11, and M13-M18. 
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Table 6. PXR activation in HepG2 cells treated with prenylated stilbenoids and DHS for 24 hr. 
The data is included as the means ± standard deviation of three independent experiments 
 
 
Table 7. Increase in the mRNA expression of CYP3A4 in HepG2 cells by the      
synthesized prenylated stilbenoid and DHS derivatives at three different concentrations. 
 
 Fold induction   
Compounds (µM) 10 3 1 
M1 1.66 ± 0.03 1.76 ± 0.20 2.79 ± 0.20 
M7 6.37 ± .053 4.96 ± 0.31 4.64 ± 0.21 
M10 3.96 ± 0.34 5.65 ± 0.29 6.62 ± 0.13 
M12 2.38 ± 0.33 3.46 ± 0.23 2.54 ± 0.22 
M15 6.21 ± 0.79 4.39 ± 0.37 2.34 ± 0.40 
M17 2.15 ± 0.05 1.87 ± 0.10 1.37 ± 016 
M18 1.9 ± 0.10 1.56 ± 0.17 NA 
 
Fold induction 
   
Compounds  
(µM) 
25 12.5 6.25 3.13 1.56 0.78 
M1 1.20 ± 0.02 1.71 ± 0.14 1.75 ± 0.01 0.92 ± 0.05 0.90 ± 0.12 0.73 ± 0.01 
M7 3.16 ± 0.08 2.37 ± 0.01 1.39 ± 0.14  1.06 ± 0.08 0.98 ± 0.08 0.86 ± 0.01 
M8 1.62 ± 0.03 2.54 ± 0.07  2.68 ± 0.01 2.20 ± 0.03 1.76 ± 0.01 1.44 ± 0.04 
M9 3.10 ± 0.00 3.67 ± 0.16 3.74 ± 0.27 3.17 ± 0.22 2.60 ± 0.17 1.87 ± 0.13 
M10 4.80 ± 0.01 4.37 ± 0.44 4.48 ± 0.08 3.40 ±  0.05 2.60 ± 0.59  2.22 ± 0.21 
M11 1.54 ± 0.07 0.94 ± 0.07 0.99 ± 0.02 0.86 ± 0.07 1.07 ± 0.02 0.96 ± 0.11 
M13 1.96 ± 0.21 1.04 ± 0.15  1.05 ± .07 1.07 ± 0.10 1.26 ± 0.02 0.92 ± 0.06 
M14 3.16 ± 0.14 1.98 ± 0.16 1.64 ± 0.22 1.44 ± 0.15 1.49 ± 0.07 0.77 ± 0.09 
M15 4.85 ± 0.39 5.15 ± 0.78  5.37 ± 0.05 4.35 ± 0.26 2.71 ± 0.02 1.95 ± 0.13 
M16 4.91 ± 0.15 4.67 ± 0.51 3.64 ± 0.11 2.71 ± 0.01 1.73 ± 0.22 1.26 ± 0.11 
M17 5.27 ± 0.28 5.24 ± 0.25  4.60 ± 0.04 3.56 ± 0.05 2.47 ± 0.20 1.55 ± 0.20 







IV.2.3 In silico risk assessment of CYP enzyme inhibition models commercially available in 
ADMET predictor 
 
Phytochemicals from both G. glabra and G. uralensis have been evaluated through 
QSAR models utilizing commercially available software product, ADMET Predictor™ 9.0 
(Simulations Plus Inc.) for potential inhibitors of CY1P450s. These models include general 
inhibition models for five recombinant CYPs (1A2, 2C9, 2C19, 2D6, and 3A4). As a result, we 
have classified and compared the putative components in licorice that might influence CYP 





































Increase in the CYP3A4 mRNA expression in HepG2 cells
Figure 31. Increase in the mRNA expression of CYP3A4 in HepG2 cells by the synthesized 
prenylated stilbenoid and DHS derivatives. The compounds were tested at concentrations of 
10 (left), 3 (middle), and 1 (right) μM. Rifampicin (10μM, yellow) was used as a positive 




consumption amongst two major CYPs, 1A2 and 3A4, where many compounds in both species 
(Table 8) were shown to qualify for CYP inhibition with high confidence level (> 79%).  
Table 8. Compounds predicted to have CYP enzyme inhibition with a high confidence level in 
five different CYP inhibition models (CYP3A4, CYP1A2, CYP2C9, CYP2D6, and CYP2C19) 
available in ADMET predictor 
 
 
IV.3 Discussion  
Earlier reports showed weak PXR activation related to its glycyrrhizin component. Many 
manufacturers provide deglycyrrhizinated licorice (DGL licorice) supplements, which are 
labeled to be safe and effective since it avoids the hypertensive crises that could be triggered by 
glycyrrhizin. However, this does not mean that these DGL supplements are void of HDI. In this 
manner, underestimation of a plant material, which can potentially produce hundreds of 
compounds, might be responsible for potentiating HDI. PXR plays a pivotal role in the ADME 
properties of the co-ingested conventional drugs that might change its metabolism, distribution, 
 G. glabra G. uralensis 
CYP3A4_Inh 
1 (80%), 28 (80%), 29 (80%), 67 (80%), 83 
(80%), 108 (80%),  140 (80%), 146 (80%), 158 
(80%), 170 (80%) 
15 (80%), 16 (80%), 17 (80%), 20 (80%), 
32 (80%), 51 (80%), 53 (80%), 55 (80%), 
56 (80%), 61 (80%), 66 (80%), 77 (80%), 
79 (80%), 85 (80%), 111 (80%), 121 (80%), 
122 (80%), 171 (80%), 186 (80%) 
CYP1A2_Inh 
1 (84%), 8 (95%), 9 (95%), 17 (95%), 18 (95%), 
20 (84%), 24 (95%), 31 (79%), 34 (95%), 36 
(95%), 43 (84%), 45 (95%), 48 (95%), 53 (95%), 
54 (95%), 55 (95%) , 56 (95%), 62 (95%), 71 
(95%), 72 (95%), 74 (95%), 76 (95%), 77 (95%), 
88 (95%), 92 (84%), 95 (95%), 101 (84%), 104 
(95%), 106 (84%), 120 (95%), 122 (95%), 130 
(95%), 136 (79%), 139 (95%), 140 (95%), 147 
(84%), 148 (84%), 149 (95%), 160 (95%), 166 
(95%) 
2 (84%), 3 (95%), 5 (79%), 6 (84%), 38 
(95%), 39 (79%), 42 (95%), 60 (95%), 61 
(79%), 64 (84%), 66 (79%), 70 (95%), 85 
(79%), 91 (84%), 108 (95%), 111 (79%), 
114 (95%), 118 (95%), 124 (95%), 148 
(95%), 149 (95%), 157 (84%), 158 (95%), 
159 (95%), 161 (95%), 162 (95%), 179 
(79%) 
CYP2C9_Inh 
19 (77%), 22 (77%), 37 (77%), 52 (77%), 54 
(77%), 112 (77%), 129 (77%) 
5 (77%), 14 (77%), 19 (77%), 20 (77%), 22 
(77%), 24 (77%), 47 (77%), 54 (77%), 57 
(77%), 70 (77%), 83 (77%), 88 (77%), 113 
(77%), 119 (77%), 133 (77%), 149 (77%), 
152 (77%), 161 (77%), 164 (77%), 180 
(77%), 181 (77%) 
CYP2D6_Inh 94 (70%) 50 (70%), 54 (70%) 
CYP2C19_Inh 21 (78%) 94 (77%) 
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and elimination.  
To better understand the pharmacokinetic interaction potential of the licorice plant 
constituents, we have utilized a dual approach by applying integrated in silico structure-based 
PXR screening followed by in vitro testing. The molecular docking into PXR LBD can capture 
the global features, which might later turn on the activation cascade of the target genes. This 
approach is anticipated to increase the efficiency of the in vitro screening for preclinical studies. 
In this work, we have revealed multiple licorice components that essentially possessed high 
docking scores together with excellent interaction with the key amino acids such as S247, W299, 
and H407. A large group of isoflavonoids and stilbenoids common in licorice attained such 
features similar to the known activators. All of the top ranking ligands are prenylated with at 
least one prenyl group, which indicated the highly favorable hydrophobic interactions for PXR. 
This initial result also suggests the vital role of these prenylation patterns as a fingerprint for 
PXR recognition. It also demonstrates the bi-faceted nature that these prenylated patterns might 
bear, since they were shown in previous reports to increase the activity, selectivity, and the 
bioavailability as compared to their unprenylated congeners.  
However, they appear to be a source of liability and should be dealt with caution. In this 
study, we sought to explore the validity of our in silico predictions by the application of in vitro 
screening of a home-designed resveratrol and dihydroresveratrol prenylation products archetypal 
of stilbenoids and dihydrostilbenoids present into different licorice species. Interestingly, these 
experiments manifested the ability of these compounds to induce PXR as predicted. Given the 
fact that PXR activation is highly sensitive for the hydrophobic features, one can surmise that the 
addition of prenyl groups can enhance the interactions with the LBD. The in vitro screening has 
supported this postulate with some of the compounds far more active than the unprenylated 
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counterparts. Some rudimentary SAR could be withdrawn from these results. Both unprenylated 
compounds, resveratrol, and DHR, had very weak but comparable activity against PXR at 25 µM 
concentration in accord with their low docking scores, with resveratrol having better ability in 
maintaining this activity at lower concentrations (6.25 µM). The abolished rigidity in the 
dihydroresveratrol M11 had dramatically affected the pose prediction in the LBD as compared to 
resveratrol M1, which adopted more cis-like conformation to allow multiple polar interactions 
(Figure 32).  
 
 
Figure 32. (Left) The docking pose of M1 (grey sticks) and M11 (purple sticks) in PDB:1NRL 
(white cartoon). (Right) The docking pose of M15 (green sticks) in the same crystal structure. π-
π interactions are shown in blue dotted lines and H-bonds in red dotted lines. 
  
Nevertheless, these interactions failed to increase the docking score (~ −6.5) or the 
activity of the compound as compared to the trans-resveratrol, most likely due to the increased 
entropy experienced with the increase in the number of the rotatable bonds. None of the mono-
prenylated M1 derivatives at positions C2 and C4 (as a straight chain or the cyclized THP), 
















−9.922, −8.262 respectively) generally indicated a lower chance of activation but failed to sense 
the slightly active ones, which is acceptable as we indicated in the validation experiment. 
Compounds M3 (arachidin 2) and its cyclized congener M4 showed cell toxicity in accord with 
previous reports. In contrast, all the mono-prenylated DHS (M12, M13, M14, and M15) were 
active at the 25 µM concentration.  
Interestingly, the more constrained mono-prenylated DHS (the cyclized versions) M14 
and M15 were able to show salient multiple fold activation in the reporter gene assay (up to 4 
folds at 25 µM). Moreover, M15 showed at least 6-fold induction in CYP3A4 mRNA expression 
levels, which has further supported the PXR induction observed in the reporter gene assay. 
According to our cut-off value, these compounds are classified, as moderate activators. Although 
they were not well differentiated as compared to their resveratrol cyclized mono-prenylated 
mates, we noticed that the direction of the docking poses of these compounds were opposite 
(Figure 32, Right). We assumed that the free phenyl moiety of DHS (unprenylated side), which 
resides in the hydrophobic sub-pocket of both F288 and W299 acquire firm π-π interactions 
compared to the benzo-tetrahydropyran side (with the less aromatic character) of the stilbenoid 
posed at the same site. Of note, this might not be the case for some of the natural compounds 
found in licorice where they have a benzo-dehydropyran moiety, which pertains aromatic 
character in both ring systems. We have also examined the double prenylated derivatives 
represented with different patterns. Those compounds have their prenylation in a straight chain 
(M6, M7, M16, and M17), mixed patterns of straight prenyl and cyclized (M8, M9, M10) and 
the double cyclized (M18). Amazingly, as predicted by their higher scores, all the double 
prenylated compounds are PXR actives as verified by their 4-5 fold induction in the reporter 
assay. In addition, these compounds activated the luciferase reporter gene at very low 
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concentrations indicating a higher potency. Moreover, all the tested double prenylated 
compounds were also capable of inducing CYP3A4 mRNA expression.  
 
Figure 33. Docking pose of M10 in green tubes (Left up), M7 in aqua blue (left down) and 
M17 in bluish green tubes (Right up) in PDB: 1NRL (maroon cartoon) showing π-π bonds (blue 
dotted line) with W299 and P288 (orange ball and sticks). (Right down) M7 and M10 overlaid 
docking pose.  
 
However, high levels of mRNA expression are noticed for the tested compounds M7, 
M10 and M15 (up to 6 folds). M7 and M10 have secured π-π interactions with the key residues 
F288 and W299 as shown in Figure 33. These compounds are prenylated at the same positions, 
but the cyclization of one of the prenyl group (M10) did not affect the activity. In contrast, the 
rigidity of the compound seems to have a prominent role at these positions (based on mRNA 
levels), which is apparent by comparing M7 and M10 (stilbenoids) with M17 (DHS).  

































compounds might have a preferred interaction and selectivity toward the AF-2 region rather than 
the LBD especially in the presence of other agonists. Ketoconazole is the prototype of an 
allosteric PXR modifier, which was proposed to interact with the AF-2 region precluding the 
coactivator from binding. Other natural products were also described such as coumestrol and 
resveratrol. However, for resveratrol, controversial conclusions were drawn from different 
studies about its allosteric antagonistic character. To evaluate the ability of resveratrol and the 
other tested compounds to act as pure agonists or allosteric antagonists, selected representative 
compounds of different prenylation patterns were screened in the reporter assay together with 
rifampicin. Our findings revealed that resveratrol and the other derivatives failed to antagonize 
the rifampicin induced PXR in HepG2 cells at the tested concentration range, suggesting that 
these stilbenoids including DHS might be binding at allosteric site.   
These tested synthesized compounds resonated with the DHS present in the licorice 
species except that the latter have the piceatannol as a precursor rather than resveratrol. It is well-
established that piceatannol is a direct metabolite of resveratrol with one extra hydroxy group 
permitting an extra hydrogen bond. Hence, they have achieved higher scores in the initial 
screening. Some of the alerting “in silico identified” compounds found in licorice are species-
specific. For example, the diprenylated DHS U15 and U16 found in Glycyrrhiza uralensis. 
Others belong to the cycloprenylated isoflavenes, which are species-specific markers of G. 
glabra. Moreover, multiple moderately active compounds may synergistically activate PXR and 
dispose of a higher risk for HDI.  
IV.4 Experimental 
IV.4.1 Docking experiments 
 
Both proteins crystal structures PDB: ID 1NRL and 1M13 were prepared using the 
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Protein Preparation Wizard (PrepWizard, Schrodinger 10.3). For both structures, hydrogen atoms 
were added after the deletion of original ones, and the bond orders were assigned. The protein 
structure was checked and the missing residues or loop segments were added using Prime. Non-
hydrogen- bonding water molecules were removed. Only chains B and D for 1NRL and chain A 
for 1M13 were included in the current study. The protonation and tautomeric states of H, Q, S, T, 
and E were adjusted to match a pH of 7.4. Possible orientations of side chain were generated and 
checked. Active site water molecules beyond 5.0 Å from the ligand were deleted. Then, the 
protein-ligand complex was subjected to geometry refinement using an OPLS2005 force field, 
and restrained minimization. The convergence of heavy atoms was set to an RMSD of 0.3 Å. 
Docking grids for both 1NRL and 1M13 were generated with the default settings in Glide using 
the co-crystalized ligands to define the center of the grid box (20 x 20 x 20Å). No constraints 
were included during grid generation. The generated databases of both G. glabra and G. 
uralensis (described in Chapter II) in addition to the generated library of positive controls (Table 
5), which includes  known potent ligands (hyperforin and 4-hydroxytamoxifen) as well as a 
moderate inducer (hypericine and enterolactone) and  the weak activators (genistein and 
physcion) were prepared using LigPrep module. Initially, the 2D structures of these molecules 
were sketched using ChemDraw, converted to 3D structures, and then saved as SD files before 
they were exported to Maestro.  
After 3D structures were loaded, OPLS2005 force field and charges were used in all 
ligand preparation steps. Possible protonation states and ionization states were explored for each 
ligand using Epik at a pH of 7.4. Chirality was determined from 3D structures and compared 
with reported literature. Tautomeric states were generated for chemical groups with possible 
prototrophic tautomerism. Only the lowest energy conformer was kept for each ligand. For 
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validation and comparison purposes, the positive controls were docked in the generated grids of 
both 1NRL and 1M13 using flexible ligand protocol of both SP and XP glide docking. For 
screening of the generated licorice libraries, they were docked into 1NRL using XP flexible 
docking. The compounds, which scored below −9.5 kcal/mol, were kept for further analysis.    
IV.4.2 PXR activation 
 
IV.4.3 Reporter gene assay 
 
PXR activation by the synthesized compounds was measured in HepG2 cell lines 
transiently transfected with 25 μg of pSG5‐hPXR (the expression vector was provided by Dr. 
Steven Kliewer, University of Texas Southwestern Medical Center) and 25 μg of PCR5 plasmid 
DNA (the reporter plasmid was provided by Dr. Christopher Liddle, University of Sydney) by 
electroporation as described earlier. The 96‐well plates were seeded with cells at a density of 
50,000 cells per well. When the cells reach > 90% confluency after 24 hrs, the synthesized 
compounds and the positive control were added at 25, 12.5, 6.25, 3.13, 1.56 and 0.78 μg/mL.  
Subsequently, the media was aspirated after incubation with the test compounds for 48 hrs, and 
40 μL of luciferase reagent (Promega Corporation, Madison, WI, USA) was added to each well. 
After which, the luminescence was measured on Spectramax M5 plate reader (Molecular 
Devices, Sunnyvale, CA, USA). The activation of luciferase in the treated cells was calculated in 
comparison with vehicle-treated cells. 
IV.4.4 RT‐PCR analysis of CYP3A4 
 
CYP3A4 primers qHsaCID0012316 (both the forward and reverse primers) were 
purchased from Bio‐Rad Laboratories (Hercules, CA, USA). HepG2 cells transfected (> 90% 
confluency) as described above, were implanted into 6‐well plate (5 × 105 per well) and they 
were allowed to grow for 24 hrs. Subsequently, cells were treated with three different 
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concentrations of test samples (10, 3 and 1 µM; 10μM for rifampicin (the positive control) for 48 
h. The RNA was extracted using the Quick‐start protocol (Qiagen®) after washing the cells with 
PBS. The concentration of RNA was calculated using a BioTek Take3 plate, which uses the 
A260/A280 ratio to assess the purity. The template used in BioRad's iScript Reverse 
Transcription kit was RNA equal to 0.5μg/ml for initial strand complementary DNA synthesis. 
The resultant complementary DNA strand was fed as the template into BioRad's iTaq Universal 
SYBR Green supermix. RT‐PCR was performed in a 96‐well plate employing a CFX connect 
real-time PCR detector system (Bio‐Rad). The housekeeping gene HPRT1 (qHsaCID0016375) 
was used to normalize the quantification of expressed CYP3A4 genes. The fold induction in 














CHAPTER V                                                                                                             
CONCLUSIONS AND FUTURE DIRECTIONS 
 
The biodiversity offered by NPs and the successful records achieved in the drug 
discovery based on NPs underline their significant roles in this area. Marked therapeutics of 
anticancer, anti-infective, lipid-lowering, antimalarial, and immunosuppressant are either NPs or 
NPs derivatives. Despite the vast developments in the analytical and screening techniques, the 
activity and risk assessment of plant-based therapy is still challenging. The extensive challenges 
of an NP-based discovery made them less present in the pharmaceutical industry paradigms. 
However, the decline in the vital drugs registered or approved by the FDA has changed their 
outlook for screening programs. Although it is an extremely intricate situation, yet 
cheminformatic techniques can offer a variety of solution models to deal with the complexity of 
NPs. Of note, the application of medicinal chemistry roles for filtration of virtual libraries would 
avoid most of the NPs structural features since they break many regular rules practiced in other 
disciplines. 
However, the unique structural features of NPs evolved to recognize natural target 
motives in living systems. The application of in silico tools to search for these untapped NPs 
might unveil unprecedented activities. Moreover, the increase in consumption of herbal 
supplements to alleviate various ailments have outpaced the understanding of their safety or 
efficacy. This situation has created a knowledge gap in the herbal remedy assessments and 
revealed the deficiency for a fit of purpose methodology that could deal with complex mixtures
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 of an herbal supplement. For instance, the preference of a reputable herbal remedy to 
alleviate menopausal symptoms is encouraged by the failure of therapeutic estrogens to 
demonstrate adequate safety under different dosage forms, route of administration, or 
formulations. This trend is further stimulated by the pertained polypharmacology and the 
perceived safety of herbal treatments. One characteristic plant in this category is licorice. Similar 
to other herbal remedies, licorice offers digestive relief, antioxidant, anti-inflammatory, antiviral, 
antibacterial, and chemopreventive properties in addition to its estrogenic nature. However, the 
rise in licorice consumption and self-medication together with prescription drugs and/or over the 
counter medication is a major concern for metabolic disruption as well as HDI. In particular, 
licorice is consumed as an adjuvant therapy together with conventional drugs, and it is present in 
70% of the TCM herbal prescriptions, where it is described as a guide drug. Moreover, many 
medical practitioners believe that it has powerful chemopreventive and antitumor effects. 
Whereas, some of these co-administered drugs are narrow-indexed therapeutics, which are 
commonly consumed by the targeted population of elderly women for chemoprevention in a 
high-risk of breast cancer or with anticancer agents themselves. Hence, there is a great potential 
of unrecognized HDI that could be attributed to other improper causes, which often raise 
questions with no specific rational answers.  
To evaluate the applicability of cheminformatic methods in such a situation, we have 
utilized a platform of ensemble docking and QSAR techniques to study its estrogenic activity. 
Our results allocated a multitude of potential estrogenic components found in licorice diverse 
phenolic metabolome. Many of them are present with different prenylation patterns that could 
alter both hER isoforms. The connection of the plant estrogenic activity to a single entity is an 
oversimplification, which undermines its safety. Deconvolution of the phenolic metabolome of 
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both G. glabra and G. uralensis revealed around 50 unique compounds in each species that 
potentially could alter the hER pathways in different manners of agonism or antagonism, which 
ultimately might lead to endocrine disruption by its chronic use.  
This situation implies the significance of characterization and purification when needed 
for potential phytoalexins or phytoSERMs that might be involved in such activity. The 
application of these techniques was successfully validated by the identification of the already 
known hER active compounds from licorice.  After receiving favorable results thus far, we 
decided to focus onto one of the top scoring components based on both ensemble docking and 
QSAR analysis that have not been yet rigorously explored.  The DHS, tethered with different 
prenylation patterns, showed favorable interactions in both hERs structures that were dependent 
on the position of the prenyl group. To further analyze the effect of the prenylation pattern on 
DHS activity, we aimed to synthesize a small library of prenylated DHS archetypal of those 
found in licorice. Fortunately, a diverse set of prenylation patterns could be achieved in one pot 
reaction as we described in chapter III. For initial screening purposes, we have found that the 
divergent installation of the 
 prenyl group is convenient to provide sufficient quantities for biological testing. Two 
series of stilbenoids (M1-M10) and DHS (M11-M18) were synthesized. Multiple structures 
were synthesized for the same time (M8, M9, M14, M15, M17, and M18). Having this library of 
compounds in hand, the in vitro analysis of estrogenic activity is ongoing and the results will be 
reported in the near future to verify what these patterns might reveal as a unique SERM activity. 
These results would also help us to comprehend the estrogenic activity of licorice plant by 
validation of these methods. Particularly, some of these diprenylated DHS are species-specific 
for G. uralensis.  
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Licorice plant was described to have high potential for exerting HDI. However, different 
mechanisms could be involved in this behavior. Having the induced herb-drug interaction of 
licorice supplements via PXR less studied; we ventured to analyze the potential PXR activation 
by the application of in silico tools. We have coupled the molecular docking experiments with 
the in vitro testing to verify PXR agonists. We have identified many compounds, which are 
potentially capable of triggering PXR; some of these compounds belong to a specific licorice 
species. Interestingly enough, the prenylated DHS was one of the identified alerting classes for 
PXR activation. As a proof of concept, we have further validated our approach by screening the 
DHS synthesized library with the cell-based in vitro luciferase reporter gene assay. As a result, 
this study has unveiled prenylated stilbenoids and DHS as a potential source of PXR activation. 
Furthermore, these results were confirmed by the CYP3A4 mRNA expression, which was 
susceptible to 6 fold activation by multiple tested compounds, especially those of cyclized and 
diprenylated ones similar to glabridin-like metabolites. This situation raised some questions 
about higher prenylation patterns, ubiquitous in nature or intended for lead optimization, as a 
PXR phenotypic alerts.  
To verify other mechanisms of HDI, we have screened the licorice components against 
multiple available QSAR CYP inhibition models. This initial analysis has provided us with a list 
of potentially problematic compounds that might participate in the precipitation of some risks 
upon licorice consumption such as HDIs. Two out of five CYPs, namely CYP3A4 and CYP1A2 
were predicted as a major concern for direct CYP inhibition in both licorice species under 
investigation. However, G. uralensis is predicted to have a higher burden against CYP2C9. It is 
important to note that these predictions are void of pharmacokinetics predictions, and further 




Taken together, the application of cheminformatic tools can provide us with immense 
information that could be the key to untangle the complex mixtures of herbal remedies and their 
activity or safety profiles. Furthermore, there is a continuous need to find new drugs for reluctant 
ailments or resistant therapeutics. NPs are sustainable resources that can supply us with 
compelling untapped structural activities by the application of the appropriate techniques.    
Finally, with the versatile plausible mechanisms of hER interruption that could be exerted 
by the phenolic content of licorice, in addition to the different HDI mechanism discussed in this 
research, we find many concerns regarding licorice plant as a safe surrogate of estrogen. Further 
validation models of endocrine and metabolic disruption should be evaluated. Moreover, our 
research results trigger many questions: Is hERβ antagonism capable of turning on proliferation 
effects via deletion of its negative feedbacks against hERα? Does higher prenylation patterns 
found in many licorice phenolic metabolome exert antagonism against hER-β similar to its 
capacity of counteracting hERα? And if it does what would be the end result in tissues populated 
with both hERs isoforms? Which, if any, of those predicted compounds have preferable SERM 
characteristics? Have our bodies already developed the tools to recognize these prenylation 
patterns and made them self-limiting?  Is it the induction rather than inhibition route of HDI to 
take over in in vivo setting? Faced with all these overwhelming questions, we have more 
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88. Kolšek, K.; Mavri, J.; Sollner Dolenc, M.; Gobec, S.; Turk, S., Endocrine Disruptome  
An Open Source Prediction Tool for Assessing Endocrine Disruption Potential through 
Nuclear Receptor Binding. ACS Publications: 2014. 
89. Ekins, S.; Bugrim, A.; Brovold, L.; Kirillov, E.; Nikolsky, Y.; Rakhmatulin, E.; Sorokina, 
S.; Ryabov, A.; Serebryiskaya, T.; Melnikov, A.; Metz, J.; Nikolskaya, T., Algorithms for 
network analysis in systems-ADME/Tox using the MetaCore and MetaDrug platforms. 
Xenobiotica 2006, 36 (10-11), 877-901. 
90. Alam, S.; Khan, F., Virtual screening, Docking, ADMET and System Pharmacology 
studies on Garcinia caged Xanthone derivatives for Anticancer activity. Sci Rep 2018, 8 
(1), 5524. 
91. Roncaglioni, A.; Piclin, N.; Pintore, M.; Benfenati, E., Binary classification models for 
endocrine disrupter effects mediated through the estrogen receptor. SAR and QSAR in 
Environmental Research 2008, 19 (7-8), 697-733. 
92. Sushko, I.; Novotarskyi, S.; Körner, R.; Pandey, A. K.; Rupp, M.; Teetz, W.; 
Brandmaier, S.; Abdelaziz, A.; Prokopenko, V. V.; Tanchuk, V. Y., Online chemical 
modeling environment (OCHEM): web platform for data storage, model development 
and publishing of chemical information. Journal of computer-aided molecular design 
2011, 25 (6), 533-554. 
118 
 
93. Hecker, M.; Hollert, H., Endocrine disruptor screening: regulatory perspectives and 
needs. Environmental Sciences Europe 2011, 23 (1), 15. 
94. Mansouri, K.; Abdelaziz, A.; Rybacka, A.; Roncaglioni, A.; Tropsha, A.; Varnek, A.; 
Zakharov, A.; Worth, A.; Richard, A. M.; Grulke, C. M., CERAPP: collaborative 
estrogen receptor activity prediction project. Environmental health perspectives 2016, 
124 (7), 1023-1033. 
95. Lavecchia, A.; Cerchia, C., In silico methods to address polypharmacology: current 
status, applications and future perspectives. Drug Discov Today 2016, 21 (2), 288-98. 
96. Ellingson, S. R.; Miao, Y.; Baudry, J.; Smith, J. C., Multi-conformer ensemble docking to 
difficult protein targets. J Phys Chem B 2015, 119 (3), 1026-34. 
97. Tian, S.; Sun, H.; Pan, P.; Li, D.; Zhen, X.; Li, Y.; Hou, T., Assessing an ensemble 
docking-based virtual screening strategy for kinase targets by considering protein 
flexibility. J Chem Inf Model 2014, 54 (10), 2664-79. 
98. Park, S.-J.; Kufareva, I.; Abagyan, R., Improved docking, screening and selectivity 
prediction for small molecule nuclear receptor modulators using conformational 
ensembles. J Comput Aided Mol Des 2010, 24, 459–471. 
99. Zhang, Q.; Ye, M., Chemical analysis of the Chinese herbal medicine Gan-Cao (licorice). 
J Chromatogr A 2009, 1216 (11), 1954-69. 
100. Li, G.; Nikolic, D.; van Breemen, R. B., Identification and Chemical Standardization of 
Licorice Raw Materials and Dietary Supplements Using UHPLC-MS/MS. J Agric Food 
Chem 2016. 
101. Jiang, Y.; Gong, P.; Madak-Erdogan, Z.; Martin, T.; Jeyakumar, M.; Carlson, K.; Khan, 
I.; Smillie, T. J.; Chittiboyina, A. G.; Rotte, S. C., Mechanisms enforcing the estrogen 
receptor β selectivity of botanical estrogens. The FASEB Journal 2013, 27 (11), 4406-
4418. 
102. Mersereau, J. E.; Levy, N.; Staub, R. E.; Baggett, S.; Zogric, T.; Chow, S.; Ricke, W. A.; 
Tagliaferri, M.; Cohen, I.; Bjeldanes, L. F., Liquiritigenin is a plant-derived highly 
selective estrogen receptor β agonist. Molecular and cellular endocrinology 2008, 283 
(1-2), 49-57. 
103. Yamamoto, T.; Sakamoto, C.; Tachiwana, H.; Kumabe, M.; Matsui, T.; Yamashita, T.; 
Shinagawa, M.; Ochiai, K.; Saitoh, N.; Nakao, M., Endocrine therapy-resistant breast 
cancer model cells are inhibited by soybean glyceollin I through Eleanor non-coding 
RNA. Sci Rep 2018, 8 (1), 15202. 
104. Chen, Q.; Tan, H.; Yu, H.; Shi, W., Activation of steroid hormone receptors: Shed light 
on the in silico evaluation of endocrine disrupting chemicals. Science of The Total 
Environment 2018, 631, 27-39. 
105. ADMET Predictor, 9; Simulations Plus, Inc.: Lancaster, CA, USA. 
106. Schaefer, O.; Hümpel, M.; Fritzemeier, K.-H.; Bohlmann, R.; Schleuning, W.-D., 8-
Prenyl naringenin is a potent ERα selective phytoestrogen present in hops and beer. The 
Journal of Steroid Biochemistry and Molecular Biology 2003, 84 (2-3), 359-360. 
107. Muthyala, R. S.; Ju, Y. H.; Sheng, S.; Williams, L. D.; Doerge, D. R.; Katzenellenbogen, 
B. S.; Helferich, W. G.; Katzenellenbogen, J. A., Equol, a natural estrogenic metabolite 
from soy isoflavones: convenient preparation and resolution of R- and S-equols and their 
differing binding and biological activity through estrogen receptors alpha and beta. 
Bioorg Med Chem 2004, 12 (6), 1559-67. 
108. Nomura, T.; Fukai, T.; Akiyama, T., Chemistry of phenolic compounds of licorice 
119 
 
(Glycyrrhiza species) and their estrogenic and cytotoxic activities. Pure Appl. Chem. 
2002, 74, 1199–1206. 
109. Kretzschmar, G.; Zierau, O.; Wober, J.; Tischer, S.; Metz, P.; Vollmer, G., Prenylation 
has a compound specific effect on the estrogenicity of naringenin and genistein. J Steroid 
Biochem Mol Biol 2010, 118 (1-2), 1-6. 
110. Yap, S. P.; Shen, P.; Butler, M. S.; Gong, Y.; Loy, C. J.; Yong, E. L., New estrogenic 
prenylflavone from Epimedium brevicornum inhibits the growth of breast cancer cells. 
Planta Med 2005, 71 (2), 114-9. 
111. Walle, T., Absorption and metabolism of flavonoids. Free Radic Biol Med 2004, 36 (7), 
829-37. 
112. van de Schans, M. G.; Bovee, T. F.; Stoopen, G. M.; Lorist, M.; Gruppen, H.; Vincken, J. 
P., Prenylation and Backbone Structure of Flavonoids and Isoflavonoids from Licorice 
and Hop Influence Their Phase I and II Metabolism. J Agric Food Chem 2015, 63 (49), 
10628-40. 
113. Hwang, C. S.; Kwak, H. S.; Lim, H. J.; Lee, S. H.; Kang, Y. S.; Choe, T. B.; Hur, H. G.; 
Han, K. O., Isoflavone metabolites and their in vitro dual functions: they can act as an 
estrogenic agonist or antagonist depending on the estrogen concentration. J Steroid 
Biochem Mol Biol 2006, 101 (4-5), 246-53. 
114. Pinto, C. L.; Mansouri, K.; Judson, R.; Browne, P., Prediction of Estrogenic Bioactivity 
of Environmental Chemical Metabolites. Chem Res Toxicol 2016, 29 (9), 1410-27. 
115. Chapman, H., Dictionary of Natural Products on DVD (23: 1). CRC Press, Taylor & 
Francis Group, URL: http://dnp. chemnetbase. com: 2014. 
116. Wärnmark, A.; Treuter, E.; Gustafsson, J.-Å.; Hubbard, R. E.; Brzozowski, A. M.; Pike, 
A. C., Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides 
with the coactivator binding site of estrogen receptor α. Journal of Biological Chemistry 
2002, 277 (24), 21862-21868. 
117. Fuchs, S.; Nguyen, H. D.; Phan, T. T.; Burton, M. F.; Nieto, L.; de Vries-van Leeuwen, I. 
J.; Schmidt, A.; Goodarzifard, M.; Agten, S. M.; Rose, R., Proline primed helix length as 
a modulator of the nuclear receptor–coactivator interaction. Journal of the American 
Chemical Society 2013, 135 (11), 4364-4371. 
118. Shiau, A. K.; Barstad, D.; Radek, J. T.; Meyers, M. J.; Nettles, K. W.; Katzenellenbogen, 
B. S.; Katzenellenbogen, J. A.; Agard, D. A.; Greene, G. L., Structural characterization of 
a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nature 
Structural and Molecular Biology 2002, 9 (5), 359. 
119. Manas, E. S.; Xu, Z. B.; Unwalla, R. J.; Somers, W. S., Understanding the selectivity of 
genistein for human estrogen receptor-β using X-ray crystallography and computational 
methods. Structure 2004, 12 (12), 2197-2207. 
120. Schrödinger Release 2015-3: Maestro, 2015-3; Schrödinger, LLC: New York, NY, 2015. 
121. Šmejkal, K., Cytotoxic potential of C-prenylated flavonoids. Phytochemistry Reviews 
2013, 13 (1), 245-275. 
122. Vickery, C. R.; La Clair, J. J.; Burkart, M. D.; Noel, J. P., Harvesting the biosynthetic 
machineries that cultivate a variety of indispensable plant natural products. Curr Opin 
Chem Biol 2016, 31, 66-73. 
123. Kagiyama, I.; Kato, H.; Nehira, T.; Frisvad, J. C.; Sherman, D. H.; Williams, R. M.; 
Tsukamoto, S., Taichunamides: Prenylated Indole Alkaloids from Aspergillus 
taichungensis (IBT 19404). Angew Chem Int Ed Engl 2016, 55 (3), 1128-32. 
120 
 
124. Akinwumi, B. C.; Bordun, K. M.; Anderson, H. D., Biological Activities of Stilbenoids. 
Int J Mol Sci 2018, 19 (3). 
125. Chrząścik, I., Analysis of Biologically Active Stilbene Derivatives. Critical Reviews in 
Analytical Chemistry 2009, 39 (2), 70-80. 
126. Niesen, D. B.; Hessler, C.; Seeram, N. P., Beyond resveratrol: A review of natural 
stilbenoids identified from 2009–2013. J. Berry Res. 2013, 3, 181–196. 
127. Helle, J.; Kraker, K.; Bader, M. I.; Keiler, A. M.; Zierau, O.; Vollmer, G.; Welsh, J.; 
Kretzschmar, G., Assessment of the proliferative capacity of the flavanones 8-
prenylnaringenin, 6-(1.1-dimethylallyl)naringenin and naringenin in MCF-7 cells and the 
rat mammary gland. Mol Cell Endocrinol 2014, 392 (1-2), 125-35. 
128. Gardner, K. D.; Wiemer, D. F., Selective Prenylation of Protected Phenols for Synthesis 
of Pawhuskin A Analogues. J Org Chem 2016, 81 (4), 1585-92. 
129. Nicolaou, K.; Lister, T.; Denton, R. M.; Gelin, C. F., Total synthesis of artochamins F, H, 
I, and J through cascade reactions. Tetrahedron 2008, 64 (21), 4736-4757. 
130. Park, B. H.; Lee, H. J.; Lee, Y. R., Total synthesis of chiricanine A, arahypin-1, trans-
arachidin-2, trans-arachidin-3, and arahypin-5 from peanut seeds. J Nat Prod 2011, 74 
(4), 644-9. 
131. Choi, J. G.; Eom, S. M.; Kim, J.; Kim, S. H.; Huh, E.; Kim, H.; Lee, Y.; Lee, H.; Oh, M. 
S., A Comprehensive Review of Recent Studies on Herb-Drug Interaction: A Focus on 
Pharmacodynamic Interaction. J Altern Complement Med 2016, 22 (4), 262-79. 
132. Yuan, Y.; Yang, H.; Kong, L.; Li, Y.; Li, P.; Zhang, H.; Ruan, J., Interaction between 
rhein acyl glucuronide and methotrexate based on human organic anion transporters. 
Chem Biol Interact 2017, 277, 79-84. 
133. Alsanad, S. M.; Williamson, E. M.; Howard, R. L., Cancer patients at risk of herb/food 
supplement-drug interactions: a systematic review. Phytother Res 2014, 28 (12), 1749-55. 
134. Mouly, S.; Lloret-Linares, C.; Sellier, P. O.; Sene, D.; Bergmann, J. F., Is the clinical 
relevance of drug-food and drug-herb interactions limited to grapefruit juice and Saint-
John's Wort? Pharmacol Res 2017, 118, 82-92. 
135. Ghosh, N.; Ghosh, R. C.; Kundu, A.; Mandal, S. C., Herb and Drug Interaction. 2018, 
467-490. 
136. Cui, Z.; Kang, H.; Tang, K.; Liu, Q.; Cao, Z.; Zhu, R., Screening Ingredients from Herbs 
against Pregnane X Receptor in the Study of Inductive Herb-Drug Interactions: 
Combining Pharmacophore and Docking-Based Rank Aggregation. Biomed Res Int 2015, 
2015, 657159. 
137. Tirona, R. G.; Kim, R. B., Nuclear receptors and drug disposition gene regulation. J 
Pharm Sci 2005, 94 (6), 1169-86. 
138. Brewer, C. T.; Chen, T., PXR variants: the impact on drug metabolism and therapeutic 
responses. Acta Pharm Sin B 2016, 6 (5), 441-449. 
139. Xu, C.; Huang, M.; Bi, H., PXR- and CAR-mediated herbal effect on human diseases. 
Biochim Biophys Acta 2016, 1859 (9), 1121-1129. 
140. Yan, J.; Xie, W., A brief history of the discovery of PXR and CAR as xenobiotic 
receptors. Acta Pharm Sin B 2016, 6 (5), 450-452. 
141. Zhou, C., Novel functions of PXR in cardiometabolic disease. Biochimica et Biophysica 
Acta (BBA)-Gene Regulatory Mechanisms 2016, 1859 (9), 1112-1120. 
142. Banerjee, M.; Robbins, D.; Chen, T., Targeting xenobiotic receptors PXR and CAR in 
human diseases. Drug discovery today 2015, 20 (5), 618-628. 
121 
 
143. Wei, Y.; Tang, C.; Sant, V.; Li, S.; Poloyac, S. M.; Xie, W., A Molecular Aspect in the 
Regulation of Drug Metabolism: Does PXR-Induced Enzyme Expression Always Lead to 
Functional Changes in Drug Metabolism? Curr Pharmacol Rep 2016, 2 (4), 187-192. 
144. Hassani-Nezhad-Gashti, F.; Rysä, J.; Kummu, O.; Näpänkangas, J.; Buler, M.; Karpale, 
M.; Hukkanen, J.; Hakkola, J., Activation of nuclear receptor PXR impairs glucose 
tolerance and dysregulates GLUT2 expression and subcellular localization in liver. 
Biochemical pharmacology 2018, 148, 253-264. 
145. Chai, S. C.; Cherian, M. T.; Wang, Y.-M.; Chen, T., Small-molecule modulators of PXR 
and CAR. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms 2016, 
1859 (9), 1141-1154. 
146. Watkins, R. E.; Maglich, J. M.; Moore, L. B.; Wisely, G. B.; Noble, S. M.; Davis-Searles, 
P. R.; Lambert, M. H.; Kliewer, S. A.; Redinbo, M. R., 2.1 Å Crystal Structure of Human 
PXR in Complex with the St. John’s Wort Compound Hyperforin. Biochemistry 2003, 42 
(6), 1430-1438. 
147. Khan, J. A.; Camac, D. M.; Low, S.; Tebben, A. J.; Wensel, D. L.; Wright, M. C.; Su, J.; 
Jenny, V.; Gupta, R. D.; Ruzanov, M., Developing adnectins that target SRC co-activator 
binding to PXR: a structural approach toward understanding promiscuity of PXR. 
Journal of molecular biology 2015, 427 (4), 924-942. 
148. Motta, S.; Callea, L.; Tagliabue, S. G.; Bonati, L., Exploring the PXR ligand binding 
mechanism with advanced Molecular Dynamics methods. Scientific reports 2018, 8 (1), 
16207. 
149. Watkins, R. E.; Davis-Searles, P. R.; Lambert, M. H.; Redinbo, M. R., Coactivator 
Binding Promotes the Specific Interaction Between Ligand and the Pregnane X Receptor. 
Journal of Molecular Biology 2003, 331 (4), 815-828. 
150. Ngan, C.-H.; Beglov, D.; Rudnitskaya, A. N.; Kozakov, D.; Waxman, D. J.; Vajda, S., 
The structural basis of pregnane X receptor binding promiscuity. Biochemistry 2009, 48 
(48), 11572-11581. 
151. Honkakoski, P.; Sueyoshi, T.; Negishi, M., Drug-activated nuclear receptors CAR and 
PXR. Annals of medicine 2003, 35 (3), 172-182. 
152. Östberg, T.; Bertilsson, G.; Jendeberg, L.; Berkenstam, A.; Uppenberg, J., Identification 
of residues in the PXR ligand binding domain critical for species specific and constitutive 
activation. European journal of biochemistry 2002, 269 (19), 4896-4904. 
153. Banerjee, M.; Chai, S. C.; Wu, J.; Robbins, D.; Chen, T., Tryptophan 299 is a conserved 
residue of human pregnane X receptor critical for the functional consequence of ligand 
binding. Biochemical pharmacology 2016, 104, 131-138. 
154. Ekins, S.; Chang, C.; Mani, S.; Krasowski, M. D.; Reschly, E. J.; Iyer, M.; Kholodovych, 
V.; Ai, N.; Welsh, W. J.; Sinz, M.; Swaan, P. W.; Patel, R.; Bachmann, K., Human 
pregnane X receptor antagonists and agonists define molecular requirements for different 
binding sites. Mol Pharmacol 2007, 72 (3), 592-603. 
155. Gao, Y. D.; Olson, S. H.; Balkovec, J. M.; Zhu, Y.; Royo, I.; Yabut, J.; Evers, R.; Tan, E. 
Y.; Tang, W.; Hartley, D. P.; Mosley, R. T., Attenuating pregnane X receptor (PXR) 
activation: a molecular modelling approach. Xenobiotica 2007, 37 (2), 124-38. 
156. Wang, H.; Li, H.; Moore, L. B.; Johnson, M. D.; Maglich, J. M.; Goodwin, B.; Ittoop, O. 
R.; Wisely, B.; Creech, K.; Parks, D. J.; Collins, J. L.; Willson, T. M.; Kalpana, G. V.; 
Venkatesh, M.; Xie, W.; Cho, S. Y.; Roboz, J.; Redinbo, M.; Moore, J. T.; Mani, S., The 
phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X 
122 
 
receptor. Mol Endocrinol 2008, 22 (4), 838-57. 
157. Smutny, T.; Pavek, P., Resveratrol as an Inhibitor of Pregnane X Receptor (PXR): 
Another Lesson in PXR Antagonism. Journal of Pharmacological Sciences 2014, 126 
(2), 177-178. 
158. Xiao, L.; Nickbarg, E.; Wang, W.; Thomas, A.; Ziebell, M.; Prosise, W. W.; Lesburg, C. 
A.; Taremi, S. S.; Gerlach, V. L.; Le, H. V.; Cheng, K. C., Evaluation of in vitro PXR-
based assays and in silico modeling approaches for understanding the binding of a 
structurally diverse set of drugs to PXR. Biochem Pharmacol 2011, 81 (5), 669-79. 
159. Matter, H.; Anger, L. T.; Giegerich, C.; Güssregen, S.; Hessler, G.; Baringhaus, K.-H., 
Development of in silico filters to predict activation of the pregnane X receptor (PXR) by 
structurally diverse drug-like molecules. Bioorganic & medicinal chemistry 2012, 20 
(18), 5352-5365. 
160. Kortagere, S.; Krasowski, M. D.; Reschly, E. J.; Venkatesh, M.; Mani, S.; Ekins, S., 
Evaluation of computational docking to identify pregnane X receptor agonists in the 
ToxCast database. Environ Health Perspect 2010, 118 (10), 1412-7. 
161. Han, L.; Ma, X.; Lin, H.; Jia, J.; Zhu, F.; Xue, Y.; Li, Z.; Cao, Z.; Ji, Z.; Chen, Y., A 
support vector machines approach for virtual screening of active compounds of single 
and multiple mechanisms from large libraries at an improved hit-rate and enrichment 
factor. Journal of Molecular Graphics and Modelling 2008, 26 (8), 1276-1286. 
162. Chen, C.-N.; Shih, Y.-H.; Ding, Y.-L.; Leong, M. K., Predicting activation of the 
promiscuous human pregnane X receptor by pharmacophore ensemble/support vector 
machine approach. Chemical research in toxicology 2011, 24 (10), 1765-1778. 
163. Yang, R.; Wang, L.-q.; Yuan, B.-c.; Liu, Y., The pharmacological activities of licorice. 
Planta medica 2015, 81 (18), 1654-1669. 
164. Feng, X.; Ding, L.; Qiu, F., Potential drug interactions associated with glycyrrhizin and 
glycyrrhetinic acid. Drug metabolism reviews 2015, 47 (2), 229-238. 
165. Wang, Y.-G.; Zhou, J.-M.; Ma, Z.-C.; Li, H.; Liang, Q.-D.; Tan, H.-L.; Xiao, C.-R.; 
Zhang, B.-L.; Gao, Y., Pregnane X receptor mediated-transcription regulation of CYP3A 
by glycyrrhizin: a possible mechanism for its hepatoprotective property against 
lithocholic acid-induced injury. Chemico-biological interactions 2012, 200 (1), 11-20. 
166. Johnson, E. J.; Gonzalez-Perez, V.; Tian, D.-D.; Lin, Y. S.; Unadkat, J. D.; Rettie, A. E.; 
Shen, D. D.; McCune, J. S.; Paine, M. F., Selection of Priority Natural Products for 
Evaluation as Potential Precipitants of Natural Product–Drug Interactions: A NaPDI 
Center Recommended Approach. Drug Metabolism and Disposition 2018, 46 (7), 1046-
1052. 
167. Jacobs, M. N.; Nolan, G. T.; Hood, S. R., Lignans, bacteriocides and organochlorine 
compounds activate the human pregnane X receptor (PXR). Toxicol Appl Pharmacol 
2005, 209 (2), 123-33. 
168. Manda, V. K.; Ibrahim, M. A.; Dale, O. R.; Kumarihamy, M.; Cutler, S. J.; Khan, I. A.; 
Walker, L. A.; Muhammad, I.; Khan, S. I., Modulation of CYPs, P-gp, and PXR by 
Eschscholzia californica (California poppy) and its alkaloids. Planta medica 2016, 82 
(06), 551-558. 
169. Fukai, T.; Cai, B.-S.; Maruno, K.; Miyakawa, Y.; Konishi, M.; Nomura, T., "Phenolic 
constituents of Glycyrrhiza species". An isoprenylated flavanone from Glycyrrhiza glabra 
and rec-assay of licorice phenols. Phytochemistry 1998, 49 (7), 2005-2013. 
170. Li, K.; Ji, S.; Song, W.; Kuang, Y.; Lin, Y.; Tang, S.; Cui, Z.; Qiao, X.; Yu, S.; Ye, M., 
123 
 
Glycybridins A-K, bioactive phenolic compounds from Glycyrrhiza glabra. J. Nat. Prod. 
2017, 80 (2), 334-346. 
171. Kitagawa, I.; Chen, W. Z.; Hori, K.; Harada, E.; Yasuda, N.; Yoshikawa, M.; Ren, J., 
Chemical Studies of Chinese Licorice-Roots. I. Elucidation of five new flavonoid 
constituents from the roots of Glycyrrhiza glabra L. collected in Xinjiang. Chem. Pharm. 
Bull. 1994, 42 (5), 1056-62. 
172. Bhardwaj, D. K.; Murari, R.; Seshadri, T. R.; Singh, R., Liqcoumarin, a novel coumarin 
from Glycyrrhiza glabra. Phytochemistry 1976, 15 (7), 1182-3. 
173. Siracusa, L.; Saija, A.; Cristani, M.; Cimino, F.; D'Arrigo, M.; Trombetta, D.; Rao, F.; 
Ruberto, G., Phytocomplexes from liquorice (Glycyrrhiza glabra L.) leaves - Chemical 
characterization and evaluation of their antioxidant, anti-genotoxic and anti-inflammatory 
activity. Fitoterapia 2011, 82 (4), 546-556. 
174. Denisova, S.; Galkin, E.; Murinov, Y. I., Isolation and GC-MS determination of 
flavonoids from Glycyrrhiza glabra root. Chemistry of natural compounds 2006, 42 (3), 
285-289. 
175. Canonica, L.; Danielli, B.; Russo, G.; Bonati, A., Triterpenes from Glycyrrhiza glabra IV. 
18α-Hydroxyglycyrrhetic acid. Gazz Chim Ital 1967, 97, 769-786. 
176. Elgamal, M.; Fayez, M., Structure of glabric acid A: further triterpenoid constituent of 
glycyrrhiza glabra L. Acta Chimica Academiae Scientarium Hungaricae 1968, 58 (1), 75. 
177. Canonica, L.; Danielli, B.; Manitto, P.; Russo, G.; Bombardelli, E.; Bonati, A., 
Glycyrrhiza glabra triterpenes VIL 24-Hydroxyliquiritic acid (30, 24-dihydroxy-11-oxo-
olean-12-en-29-oic acid) and liquiridolic acid (3β, 21α, 24-trihydroxy-olean-12-en-29-oic 
acid). Gazz Chim Ital 1968, 98, 712-728. 
178. Canonica, L.; Danieli, B.; Manitto, P.; Russo, G., Triterpenes of Glycyrrhiza glabra. III. 
Structure of isogabrolide. Gazzetta Chimica Italiana 1966, 96 (6), 843-51. 
179. Wang, Y.; Yang, L.; He, Y. Q.; Wang, C. H.; Welbeck, E. W.; Bligh, S. A.; Wang, Z. T., 
Characterization of fifty‐one flavonoids in a Chinese herbal prescription Longdan Xiegan 
Decoction by high‐performance liquid chromatography coupled to electrospray ionization 
tandem mass spectrometry and photodiode array detection. Rapid Communications in 
Mass Spectrometry: An International Journal Devoted to the Rapid Dissemination of Up‐
to‐the‐Minute Research in Mass Spectrometry 2008, 22 (12), 1767-1778. 
180. Li, J.-R.; Wang, Y.-Q.; Deng, Z.-Z., Two new compounds from Glycyrrhiza glabra. J. 
Asian Nat. Prod. Res. 2005, 7 (4), 677-680. 
181. Biondi, D. M.; Rocco, C.; Ruberto, G., Dihydrostilbene derivatives from Glycyrrhiza g 
labra leaves. Journal of natural products 2005, 68 (7), 1099-1102. 
182. Asada, Y.; Li, W.; Yoshikawa, T., The first prenylated biaurone, licoagrone from hairy 
root cultures of Glycyrrhiza glabra. Phytochemistry 1999, 50 (6), 1015-1019. 
183. Hayashi, H.; Yasuma, M.; Hiraoka, N.; Ikeshiro, Y.; Yamamoto, H.; Yeşilada, E.; Sezik, 
E.; Honda, G.; Tabata, M., Flavonoid variation in the leaves of Glycyrrhiza glabra. 
Phytochemistry 1996, 42 (3), 701-704. 
184. Hayashi, H.; Hanaoka, S.; Tanaka, S.; Fukui, H.; Tabata, M., Glycyrrhetinic acid 24-
hydroxylase activity in microsomes of cultured licorice cells. Phytochemistry 1993, 34 
(5), 1303-1307. 
185. Elgamal, M. H. A.; El-Tawil, B. A. H., Constituents of local plants. XVIII. 28-
Hydroxyglycyrrhetic acid, a new triterpenoid isolated from the roots of Glycyrrhiza 
glabra. Planta Med. 1975, 27 (2), 159-63. 
124 
 
186. Ofir, R.; Tamir, S.; Khatib, S.; Vaya, J., Inhibition of serotonin re-uptake by licorice 
constituents. Journal of molecular neuroscience 2003, 20 (2), 135-140. 
187. Chin, Y.-W.; Jung, H.-A.; Liu, Y.; Su, B.-N.; Castoro, J. A.; Keller, W. J.; Pereira, M. A.; 
Kinghorn, A. D., Anti-oxidant Constituents of the Roots and Stolons of Licorice 
(Glycyrrhiza glabra). J. Agric. Food Chem. 2007, 55 (12), 4691-4697. 
188. Kuroda, M.; Mimaki, Y.; Honda, S.; Tanaka, H.; Yokota, S.; Mae, T., Phenolics from 
Glycyrrhiza glabra roots and their PPAR-gamma ligand-binding activity. Bioorg Med 
Chem 2010, 18 (2), 962-70. 
189. Suman, A.; Ali, M.; Alam, P., New prenylated isoflavanones from the roots of 
Glycyrrhiza glabra. Chem. Nat. Compd. 2009, 45 (4), 487-491. 
190. Li, W.; Asada, Y.; Yoshikawa, T., Flavonoid constituents from Glycyrrhiza glabra hairy 
root cultures. Phytochemistry 2000, 55 (5), 447-456. 
191. Bogatkina, V. F.; Murav'ev, I. A.; Stepanova, E. F.; Kir'yalov, N. P., Triterpine 
compounds from the above ground part of a licorice plant Khimiya Prirodnykh Soedinenii 
1975, 11 (1), 101-102. 
192. Bharadwaj, D. K.; Murari, R.; Seshadri, T. R.; Singh, R., Occurrence of 2-
methylisoflavones in Glycyrrhiza glabra. Phytochemistry 1976. 
193. Mitscher, L. A.; Park, Y. H.; Clark, D.; Beal, J. L., Antimicrobial agents from higher 
plants. Antimicrobial isoflavanoids and related substances from Glycyrrhiza glabra L. 
var. typica. J. Nat. Prod. 1980, 43 (2), 259-69. 
194. Fukai, T.; Tantai, L.; Nomura, T., Isoprenoid-substituted flavonoids from Glycyrrhiza 
glabra. Phytochemistry 1996, 43 (2), 531-532. 
195. Montoro, P.; Maldini, M.; Russo, M.; Postorino, S.; Piacente, S.; Pizza, C., Metabolic 
profiling of roots of liquorice (Glycyrrhiza glabra) from different geographical areas by 
ESI/MS/MS and determination of major metabolites by LC-ESI/MS and LC-
ESI/MS/MS. Journal of pharmaceutical and biomedical analysis 2011, 54 (3), 535-544. 
196. Canonica, L.; Russo, G.; Bonati, A., Triterpenes of Glycyrrhiza glabra. I. Two new 
lactones with an oleanane structure. Gazz Chim Ital 1966, 96, 772-785. 
197. Kim, H. K.; Park, Y.; Kim, H. N.; Choi, B. H.; Jeong, H. G.; Lee, D. G.; Hahm, K.-S., 
Antimicrobial mechanism of β-glycyrrhetinic acid isolated from licorice, Glycyrrhiza 
glabra. Biotechnology letters 2002, 24 (22), 1899-1902. 
198. Li, W.; Asada, Y.; Yoshikawa, T., Antimicrobial flavonoids from Glycyrrhiza glabra 
hairy root cultures. Planta Med 1998, 64 (8), 746-7. 
199. Chen, J.-J.; Cheng, M.-J.; Shu, C.-W.; Sung, P.-J.; Lim, Y.-P.; Cheng, L.-Y.; Wang, S.-
L.; Chen, L.-C., A New Chalcone and Antioxidant Constituents of Glycyrrhiza glabra. 
Chem. Nat. Compd. 2017, 53 (4), 632-634. 
200. Sadaf, N.; Erum, S.; Khalida, B.; Barlow, D., Ligand-based screening of chemical 
constituents of Glycyrrhiza glabra in search of inhibitors of xanthine oxidase. 
International Journal of Biology and Biotechnology 2012, 9 (3), 257-262. 
201. Litvinenko, V.; Nadezhina, T., flavonoids of the above-ground part of Glycyrrhiza glabra 
L. Rastitel Resursy 1972. 
202. Bhardwaj, D.; Singh, R., 'Glyzaglabrin', a new isoflavone from Glycyrrhiza glabra. 
Current science 1977. 
203. Biondi, D. M.; Rocco, C.; Ruberto, G., New Dihydrostilbene Derivatives from the Leaves 
of Glycyrrhiza g labra and Evaluation of Their Antioxidant Activity. Journal of Natural 
Products 2003, 66 (4), 477-480. 
125 
 
204. Canonica, L.; Danielli, B.; Manitto, P.; Russo, G.; Bombardelli, E., Glycyrrhiza glabra 
triterpenes V. Glycyrrhetol and 21α-hydroxyisoglabrolide. Gazz Chim Ital 1967, 97, 
1347-1358. 
205. Elgamal, M.; Hady, F. A.; Hanna, A.; Mahran, G.; Duddeck, H., A further contribution to 
the triterpenoid constituents of Glycyrrhiza glabra L. Zeitschrift für Naturforschung C 
1990, 45 (9-10), 937-941. 
206. Birari, R. B.; Gupta, S.; Mohan, C. G.; Bhutani, K. K., Antiobesity and lipid lowering 
effects of Glycyrrhiza chalcones: experimental and computational studies. Phytomedicine 
2011, 18 (8-9), 795-801. 
207. Kinoshita, T.; Tamura, Y.; Mizutani, K., The isolation and structure elucidation of minor 
isoflavonoids from licorice of Glycyrrhiza glabra origin. Chem. Pharm. Bull. 2005, 53 
(7), 847-849. 
208. Rafi, M. M.; Vastano, B. C.; Zhu, N.; Ho, C.-T.; Ghai, G.; Rosen, R. T.; Gallo, M. A.; 
DiPaola, R. S., Novel polyphenol molecule isolated from licorice root (Glycrrhiza glabra) 
induces apoptosis, G2/M cell cycle arrest, and Bcl-2 phosphorylation in tumor cell lines. 
Journal of agricultural and food chemistry 2002, 50 (4), 677-684. 
209. Hoton-Dorge, M., Identification of some flavonoid aglycone extracts of Glycyrrhiza 
glabra roots Journal de Pharmacie de Belgique 1974, 29 (6), 560-72. 
210. Simmler, C.; Anderson, J. R.; Gauthier, L.; Lankin, D. C.; McAlpine, J. B.; Chen, S.-N.; 
Pauli, G. F., Metabolite profiling and classification of DNA-authenticated licorice 
botanicals. Journal of natural products 2015, 78 (8), 2007-2022. 
211. Ji, S.; Li, Z.; Song, W.; Wang, Y.; Liang, W.; Li, K.; Tang, S.; Wang, Q.; Qiao, X.; Zhou, 
D.; Yu, S.; Ye, M., Bioactive Constituents of Glycyrrhiza uralensis (Licorice): Discovery 
of the Effective Components of a Traditional Herbal Medicine. J Nat Prod 2016, 79 (2), 
281-92. 
212. Kuroda, M.; Mimaki, Y.; Honda, S.; Tanaka, H.; Yokota, S.; Mae, T., Phenolics from 
Glycyrrhiza glabra roots and their PPAR-γ ligand-binding activity. Bioorg. Med. Chem. 
2010, 18 (2), 962-970. 
213. Shul'ts, E.; Petrova, T.; Shakirov, M.; Chernyak, E.; Tolstikov, G., Flavonoids of Roots 
ofGlycyrrhiza uralensisGrowing in Siberia. Chemistry of Natural Compounds 2000, 36 
(4), 362-368. 
214. Wei, G. H.; Yang, X. Y.; Zhang, J. W.; Gao, J. M.; Ma, Y. Q.; Fu, Y. Y.; Wang, P., 
Rhizobialide: a new stearolactone produced by Mesorhizobium sp. CCNWGX022, a 
rhizobial endophyte from Glycyrrhiza uralensis. Chemistry & biodiversity 2007, 4 (5), 
893-898. 
215. Li, S.; Li, W.; Wang, Y.; Asada, Y.; Koike, K., Prenylflavonoids from Glycyrrhiza 
uralensis and their protein tyrosine phosphatase-1B inhibitory activities. Bioorg. Med. 
Chem. Lett. 2010, 20 (18), 5398-5401. 
216. Ryu, Y. B.; Kim, J. H.; Park, S.-J.; Chang, J. S.; Rho, M.-C.; Bae, K.-H.; Park, K. H.; 
Lee, W. S., Inhibition of neuraminidase activity by polyphenol compounds isolated from 
the roots of Glycyrrhiza uralensis. Bioorg. Med. Chem. Lett. 2010, 20 (3), 971-974. 
217. Jia, S.; Ma, C.; Li, Y.; Hao, J., Glycosides of phenolic acid and flavonoids from the 
leaves of Glycyrrhiza uralensis Ficsh. Yao xue xue bao= Acta pharmaceutica Sinica 
1992, 27 (6), 441-444. 
218. Han, Y. N.; Chung, M. S., A pyrrolo-pyrimidine alkaloid fromGlycyrrhiza uralensis. 
Archives of Pharmacal Research 1990, 13 (1), 103-104. 
126 
 
219. Hatano, T.; Takagi, M.; Ito, H.; Yoshida, T., Acylated flavonoid glycosides and 
accompanying phenolics from licorice. Phytochemistry 1998, 47 (2), 287-293. 
220. Yahara, S.; Nishioka, I., Flavonoid glucosides from licorice. Phytochemistry 1984, 23 
(9), 2108-9. 
221. KITAGAWA, I.; ZHOU, J. L.; SAKAGAMI, M.; UCHIDA, E.; YOSHIKAWA, M., 
Licorice-saponins F3, G2, H2, J2, and K2, five new oleanene-triterpene oligoglycosides 
from the root of Glycyrrhiza uralensis. Chemical and pharmaceutical bulletin 1991, 39 
(1), 244-246. 
222. Gafner, S.; Bergeron, C.; Villinski, J. R.; Godejohann, M.; Kessler, P.; Cardellina, J. H.; 
Ferreira, D.; Feghali, K.; Grenier, D., Isoflavonoids and coumarins from Glycyrrhiza 
uralensis: antibacterial activity against oral pathogens and conversion of isoflavans into 
isoflavan-quinones during purification. Journal of natural products 2011, 74 (12), 2514-
2519. 
223. Fukai, T.; WANG, Q.-H.; Nomura, T., Four new prenylated flavonoids from aerial parts 
of Glycyrrhiza uralensis. Heterocycles 1989, 29 (7), 1369-1378. 
224. Zheng, Y.-F.; Qi, L.-W.; Cui, X.-B.; Peng, G.-P.; Peng, Y.-B.; Ren, M.-T.; Cheng, X.-L.; 
Li, P., Oleanane-type triterpene glucuronides from the roots of Glycyrrhiza uralensis 
Fischer. Planta medica 2010, 76 (13), 1457-1463. 
225. Zhu, D.; Song, G.; Jian, F.; Chang, X.; Guo, W., Chemical constituents of Glycyrrhiza 
uralensis Fisch - structures of isolicoflavonol and glycycoumarin. Huaxue Xuebao 1984, 
42 (10), 1080-4. 
226. Shu, Y.; Zhao, Y.; Zhang, R., Isolation and structural identification of triterpene 
sapogenins from Glycyrrhiza uralensis Fisch. Yaoxue Xuebao 1985, 20 (3), 193-7. 
227. Gao, C.; Qiao, L.; Jia, Q.; Zhang, Z., Study and identification of the chemical structure of 
a new component in Glycyrrhiza uralensis Fisch by NMR method. Bopuxue Zazhi 1990, 
7 (1), 11-16. 
228. Fukai, T.; Nishizawa, J.; Yokoyama, M.; Nomura, T., Phenolic constituents of 
Glycyrrhiza species. Five new isoprenoid-substituted flavonoids, kanzonols F-J, from 
Glycyrrhiza uralensis. Heterocycles 1993, 36 (11), 2565-76. 
229. Song, W.; Si, L.; Ji, S.; Wang, H.; Fang, X. M.; Yu, L. Y.; Li, R. Y.; Liang, L. N.; Zhou, 
D.; Ye, M., Uralsaponins M-Y, antiviral triterpenoid saponins from the roots of 
Glycyrrhiza uralensis. J Nat Prod 2014, 77 (7), 1632-43. 
230. Kitagawa, I.; Hori, K.; Uchida, E.; Chen, W. Z.; Yoshikawa, M.; Ren, J., Saponin and 
sapogenol. L. On the constituents of the roots of Glycyrrhiza uralensis Fischer from 
Xinjiang, China. Chemical structures of licorice-saponin L3 and isoliquiritin apioside. 
Chem. Pharm. Bull. 1993, 41 (9), 1567-72. 
231. Fukai, T.; Nishizawa, J.; Nomura, T., Variations in the chemical shift of the 5-hydroxyl 
proton of isoflavones; two isoflavones from licorice. Phytochemistry 1994, 36 (1), 225-
228. 
232. He, J.; Chen, L.; Heber, D.; Shi, W.; Lu, Q.-Y., Antibacterial Compounds from 
Glycyrrhiza u ralensis. Journal of natural products 2006, 69 (1), 121-124. 
233. Shibano, M.; Henmi, A.; Matsumoto, Y.; Kusano, G.; Miyase, T.; Hatakeyama, Y., 
Studies on the index compounds for HPLC analysis of Glycyrrhiza uralensis. 
Heterocycles 1997, 10 (45), 2053-2060. 
234. Jia, S.; Liu, D.; Zheng, X.; Zhang, Y.; Li, Y., Two new isoprenyl flavonoids from the 
leaves of Glycyrrhiza uralensis Fisch. Yao xue xue bao= Acta pharmaceutica Sinica 
127 
 
1993, 28 (1), 28-31. 
235. Jia, S.; Liu, D.; Wang, H.; Suo, Z., Isolation and identification of gancaonin P-3'-
methylether from the leaves of Glycyrrhiza uralensis Fisch. Yao xue xue bao= Acta 
pharmaceutica Sinica 1993, 28 (8), 623-625. 
236. Tao, W.-W.; Duan, J.-A.; Yang, N.-Y.; Tang, Y.-P.; Liu, M.-Z.; Qian, Y.-F., 
Antithrombotic phenolic compounds from Glycyrrhiza uralensis. Fitoterapia 2012, 83 
(2), 422-425. 
237. Ye, R.; Fan, Y.-H.; Ma, C.-M., Identification and enrichment of α-glucosidase-inhibiting 
dihydrostilbene and flavonoids from Glycyrrhiza uralensis leaves. Journal of agricultural 
and food chemistry 2017, 65 (2), 510-515. 
238. Kitagawa, I.; Zhou, J. L.; Sakagami, M.; Taniyama, T.; Yoshikawa, M., Licorice-
saponins A3, B2, C2, D3, and E2, five new oleanene-type triterpene oligoglycosides from 
Chinese Glycyrrhizae radix. Chemical and Pharmaceutical Bulletin 1988, 36 (9), 3710-
3713. 
239. Yuldashev, M., Flavonoids of the epigeal part ofGlycyrrhiza uralensis. Chemistry of 
natural compounds 1998, 34 (4), 508-509. 
240. Wang, J.; Zhang, J.; Gao, W.; Wang, Q.; Yin, S.; Liu, H.; Man, S., Identification of 
triterpenoids and flavonoids, step-wise aeration treatment as well as antioxidant capacity 
of Glycyrrhiza uralensis Fisch. cell. Industrial crops and products 2013, 49, 675-681. 
241. Fukai, T.; Wang, Q. H.; Takayama, M.; Nomura, T., Structures of five new prenylated 
flavonoids, gancaonins L, M, N, O, and P from aerial parts of Glycyrrhiza uralensis. 
Heterocycles 1990, 31 (2), 373-82. 
242. Han, Y. N.; Chung, M. S.; Kim, T. H.; Han, B. H., Two tetrahydroquinoline alkaloids 
fromGlycyrrhiza uralensis. Archives of Pharmacal Research 1990, 13 (1), 101-102. 
243. Villinski, J. R.; Bergeron, C.; Cannistra, J. C.; Gloer, J. B.; Coleman, C. M.; Ferreira, D.; 
Azelmat, J.; Grenier, D.; Gafner, S., Pyrano-isoflavans from Glycyrrhiza uralensis with 
antibacterial activity against Streptococcus mutans and Porphyromonas gingivalis. 
Journal of natural products 2014, 77 (3), 521-526. 
244. Fukai, T.; Marumo, A.; Kaitou, K.; Kanda, T.; Terada, S.; Nomura, T., Anti-Helicobacter 
pylori flavonoids from licorice extract. Life sciences 2002, 71 (12), 1449-1463. 
245. Feng, K.-P.; Chen, R.-D.; Li, J.-H.; Tao, X.-Y.; Liu, J.-M.; Zhang, M.; Dai, J.-G., 
Flavonoids from the cultured cells of Glycyrrhiza uralensis. Journal of Asian natural 
products research 2016, 18 (3), 253-259. 
246. Fukai, T.; Nishizawa, J.; Yokoyama, M.; Tantai, L.; Nomura, T., Five new isoprenoid-
substituted flavonoids, kanzonols M, P and R, from two Glycyrrhiza species. 
Heterocycles 1994, 38 (5), 1089-1098. 
247. Kim, H. J.; Seo, S. H.; Lee, B.-g.; Lee, Y. S., Identification of tyrosinase inhibitors from 
Glycyrrhiza uralensis. Planta medica 2005, 71 (08), 785-787. 
248. Eerdunbayaer; Orabi, M. A.; Aoyama, H.; Kuroda, T.; Hatano, T., Structures of two new 
flavonoids and effects of licorice phenolics on vancomycin-resistant Enterococcus 
species. Molecules 2014, 19 (4), 3883-97. 
249. Qiao, X.; Song, W.; Ji, S.; Wang, Q.; Guo, D. A.; Ye, M., Separation and characterization 
of phenolic compounds and triterpenoid saponins in licorice (Glycyrrhiza uralensis) using 
mobile phase-dependent reversed-phasexreversed-phase comprehensive two-dimensional 




250. Kuroda, M.; Mimaki, Y.; Sashida, Y.; Mae, T.; Kishida, H.; Nishiyama, T.; Tsukagawa, 
M.; Konishi, E.; Takahashi, K.; Kawada, T.; Nakagawa, K.; Kitahara, M., Phenolics with 
PPAR-γ ligand-Binding activity obtained from licorice (Glycyrrhiza uralensis Roots) and 
ameliorative effects of glycyrin on genetically diabetic KK-Ay mice. Bioorg. Med. Chem. 




















(a) Hydrogen bond acceptor (b) Hydrogen bond donor (c) Hydrophilic (d) Hydrophobic (e) Total surface 
 
 
        





















ACCPTR A DONOR B PHIL C PHOB D METAL SURF E 
1GWR 128.45 185.70 318.23 247.90 0 654.24 
2P15 191.43 397.62 587.40 340.33 0 1039.75 
3ERT 188.00 427.37 602.56 299.20 0 1496.72 
4J24 87.60 204.93 276.69 223.40 0 564.67 
1X7J 96.15 172.19 284.55 266.36 0 628.82 







Ligand/PDB 1GWR 2P15 3ERT 1X7J 4J24 1L2J 
 
1GWR-Nativelig −10.91 −10.78 −8.65 −9.81 −10.81 −9.42 0 
2P15-Nativelig NA −14.44 NA NA NA NA 0.51 
3ERT-Nativelig NA −10.77 −11.37 NA NA NA 1.90 
1X7J-Nativelig −10.06 −9.81 −9.38 −10.55 −9.43 −9.43 0.29 
4J24-Nativelig −10.91 −10.78 −8.65 −9.81 −10.81 −9.42 0 
1L2J-Nativelig −11.09 −11.17 −9.36 −11.08 −11.33 −11.92 0.40 
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SI 3. Compounds from Glycyrrhiza glabra 
 
No. Name (G. glabra) M. Formula CAS Class Ref. 
G1 Prenyllicoflavone A= 
Licoflavone B 
C25 H26 O4 91433-17-9 diprenyl-flavone 
169 
G2 3-Hydroxyglabrol C25 H28 O5 74148-41-7 Flavanone-3-ol 169-170 
G3 Glabrol C25 H28 O4 59870-65-4 diprenylflavanone 169-170 
G4 6''-O-Acetylliquiritin C23 H24 O10 166531-17-5 Flavanone-glucoside DNP 
G5 Liquiritoside =Liquiritin C21 H22 O9 551-15-5 flavanone glycoside 171 
G6 Liqcoumarin C12 H10 O4 36695-19-9 Coumarin 172 
G7 Glucoliquiritin apioside C32 H40 O18 157226-47-6 flavanone glycoside 46, 171 
G8 Pinocembroside C21 H22 O9 75829-43-5P flavanone glycoside 173 
G9 Pallidiflorin C16 H12 O4 133086-79-0 isoflavone 174 
G10 Liquiritigenin C15 H12 O4 578-86-9 Flavanone 170 
G11 17991-67-2 C30 H46 O5 17991-67-2 saponin 175 
G12 Glabric acid C30 H46 O5 22327-86-2 saponin 176 
G13 24-Hydroxyliquiritic acid C30 H46 O5 20528-69-2 saponin 177 
G14 Isoglabrolid C30 H44 O4 10376-64-4 saponin 178 
G15 Liquiritin apioside C26 H30 O13 74639-14-8 flavanone glycoside 171 
G16 Glabroside C26 H30 O13 152246-80-5 flavanone glycoside 179 
G17 Eicosanyl (E)-caffeate C29 H48 O4 28593-90-0 miscellaneous  DNP 
G18 Glychionide B C22 H20 O11 51059-44-0 flavone glycoside 180 
G19 862389-76-2 C21 H24 O4 862389-76-2 prenyl stillbenoid 173 
G20 Isoglabranin C20 H20 O4 55051-77-9 6-prenylflavanone 181 
G21 525585-31-3 C19 H22 O3 525585-31-3 prenyl stillbenoid 173 
G22 kanzonol D C25 H24 O4 155233-20-8 prenyl-flavone 182 
G23 3,3',5'-Trihydroxy-4-
methoxybibenzyl 
C15 H16 O4 60640-97-3 stillbenoid 
173 
G24 7-O-Methylgenistein or 
Prunetin 
C16 H12 O5 552-59-0 isoflavone 
183 
G25 98063-17-3 C31 H48 O4 98063-17-3 saponin DNP 
G26 24-Hydroxyglycyrrhetinic acid C30 H46 O5 52911-55-4 saponin 184 
G27 28-Hydroxyglycyrrhetic acid C30 H46 O5 56061-86-0 saponin 185 
G28 Uralstilbene C24H30O4 677709-69-2 diprenyl-stilbene DNP  
G29 139101-68-1 C21 H26 O9 139101-68-1 stillbenoid glycoside DNP  
G30 525585-32-4 C20 H24 O4 525585-32-4 prenyl stillbenoid 173 
G31 2'-O-Methylglabridin C21 H22 O4 211099-37-5 pyran-isoflavan 186 
G32 4'-O-Methylglabridin C21 H22 O4 68978-09-6 pyrano-isoflavane 170 
G33 525585-33-5 C19 H22 O4 525585-33-5 prenyl stillbenoid 173 
G34 Isoglycyrol C21 H18 O6 23013-86-7 pyran-coumestan 54 
G35 Glabridin C20 H20 O4 59870-68-7 pyrano-isoflavane 170, 187 
G36 Gancaonin F C21 H16 O6 126716-33-4 miscellaneous 169 
G37 Licoflavone A C20 H18 O4 61153-77-3P prenyl-flavone 171, 188 
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G38 Glabrene C20 H18 O4 60008-03-9 pyrano-Isoflavene 170, 188 
G39 Arachidic alcohol C20 H42 O1 629-96-9 miscellaneous DNP 
G40 525585-30-2 C24 H30 O4 525585-30-2 diprenyl stillbenoid 173 
G41 525585-29-9 C24 H30 O3 525585-29-9 diprenyl stillbenoid 173 
G42 1201180-35-9 C25 H28 O4 1201180-35-9 prenyl-pyrano-isoflavanone 189 
G43 Shinflavanone C25 H26 O4 157414-03-4 pyrano-prenyl-flavanone 170-171 
G44 Licoagrocarpin C21 H22 O4 202815-29-0 prenyl-pterocarpan 170 
G45 Xambioona C25 H24 O4 82345-36-6 dipyrano-flavanone 188 
G46 Glycyrrhizin C42 H62 O16 1405-86-3 saponin glycoside 171 
G47 Glycycoumarin C21 H20 O6 94805-82-0P coumarin 46 
G48 Glyinflanin B C20 H18 O5 142750-23-0 miscellaneous 190 
G49 3,4-Didehydroglabridin C20 H18 O4 214283-58-6 pyrano-isoflavene 170 
G50 Glabrocoumarin C20 H16 O5 866021-47-8 Coumarin 188 
G51 Glabrone =Eurycarpin B C20 H16 O5 60008-02-8 pyrano-Isoflavone 170 
G52 56262-33-0 C30 H46 O4 56262-33-0 saponin 191 
G53 Glabrocoumarone B 
=Glyinflanin H 
C19 H16 O4 164123-54-0 pyrano-1-benzofuran 
170 
G54 Glyzarin C18 H14 O4 62820-28-4 isoflavone 170 
G55 2-Methyl-7-acetoxyisoflavone C18 H14 O4 3211-63-0 isoflavone 192 
G56 7-Methoxy-2-methylisoflavone C17 H14 O3 19725-44-1 isoflavone 192 
G57 7-Hydroxy-2-methylisoflavone C16 H12 O3 2859-88-3 isoflavone 192 
G58 11-Deoxoglycyrrhetinic acid C30 H48 O3 564-16-9 saponin 53 
G59 14884-88-9 C30 H46 O3 14884-88-9 saponin DNP  
G60 Glyinflanin A C25 H28 O5 142542-83-4 propanedione 190 
G61 Hispaglabridin A C25 H28 O4 68978-03-0 prenyl-pyrano-Isoflavane 170 
G62 944257-60-7 C25 H26 O4 944257-60-7 dipyrano-chalcone 187 
G63 Hispaglabridin B C25 H26 O4 68978-02-9 dipyrano-Isoflavane 170 
G64 Licoagroside B C18 H24 O12 325144-72-7 miscellaneous 190 
G65 3'-Methoxyglabradin C21 H22 O5 74046-05-2 pyran-isoflavan 193 
G66 944257-63-0 C65 H108 O8 944257-63-0 neolignan lipid esters 187 
G67 Kanzonol T C25 H26 O7 181476-22-2 pyrano-prenyl-isoflavone           194 
G68 Kanzonol Z C25 H26 O5 220860-37-7 pyrano-prenyl-Flavanone-3-
ol 
170 
G69 Kanzonol V C24 H24 O4 184584-65-4 prenyl-pyrano-benzofuran 169 
G70 Isoglycycoumarin C21 H20 O6 117038-82-1 coumarin DNP 
G71 FCO69-H C21 H18 O5 FCO69-H prenyl-isoflavene DNP 
G72 Kanzonol B C20 H18 O4 155233-19-5 pyrano-chalcone 170 
G73 Kanzonol W C20 H16 O5 184584-82-5 pyrano-Arylcoumarin 170 
G74 isoderon  C20 H16 O5 121747-89-5 pyrano-isoflavone            DNP 
G75 Glabrocoumarone A  C19 H16 O4 178330-48-8 pyrano-1-benzofuran 170 
G76 944257-62-9 C63 H104 O8 944257-62-9 neolignan lipid esters 187 
G77 944257-61-8 C61 H100 O8 944257-61-8 neolignan lipid esters 187 
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G78 1201180-37-1 C36 H58 O7 1201180-37-1 saponin glycosides 189 
G79 Glycyrrhetol C30 H48 O3 14226-18-7 saponin 195 
G80 Liquiritic acid C30 H46 O4 10379-72-3 saponin 196 
G81 18α-Glycyrrhetinic acid C30 H46 O4 1449-05-4 saponin 197 
G82 18β-Glycyrrhetinic acid= 
Enoxolone 
C30 H46 O4 471-53-4 saponin 
46 
G83 Kanzonol Y C25 H30 O5 184584-87-0 diprenyldihydrochalcone 170 
G84 Licoagrodin C45 H44 O9 325144-66-9 miscellaneous 190 
G85 Licoagrochalcone D C21 H22 O5 325144-69-2 chalcone 190 
G86 Licochalcone A C21 H22 O4 58749-22-7 prenylated Chalcone 171 
G87 Licoagrodione C20 H20 O6 220860-12-8 miscellaneous 198 
G88 Methoxyphaseollin C21 H20 O5 157226-48-7 pyrano-pterocarpin 171 
G89 Licoagrochalcone B C21 H20 O4 325144-67-0 pyrano-chalcone 199 
G90 phaseolinisoflavin C20 H20 O4 40323-57-7 pyran-isoflavan 193 
G91 Isoglabrone C20 H16 O5 1115012-65-1 pyrano-Isoflavone 170 
G92 Licochalcone B C16 H14 O5 58749-23-8P chalcone 188 
G93 Deoxyglabrolide C30 H46 O3 10379-62-1 saponin 199 
G94 Licoricidin C26 H32 O5 30508-27-1 diprenyl-isoflavan 200 
G95 Licoagroside A C23 H24 O12 30508-27-1 isoflavonoids glycosides              190 
G96 Licocoumarin A C25 H26 O5 222034-74-4 coumarin DNP 
G97 Kanzonol R C22 H26 O5 156250-73-6 prenyl-Isoflavan 169 
G98 Glyasperin K C22 H24 O6 156162-03-7 prenyl-isoflavanone DNP 
G99 licoagrochalcone C C21 H22 O5 325144-68-1 chalcone 190 
G100 Morachalcone A C20 H20 O5 76472-88-3P prenyl-chalcone 188 
G101 Isolicoflavonol C20 H18 O6 94805-83-1 prenyl-3-OH-flavone DNP 
G102 Isomucronulatol C17 H18 O5 64474-51-7 isoflavan 200 
G103 Folerogenin C16 H14 O6 35815-06-6 3-OH-flavanone 201 
G104 glyzaglabrin C16 H10 O6 65242-64-0 isoflavone 202 
G105 Liquiridiolic acid C30 H48 O5 20528-70-5 saponin 177 
G106 Licoflavanone =3'-
Prenylnaringenin 
C20 H20 O5 119240-82-3 prenyl-flavanone 
173 
G107 6-Prenylnaringenin C20 H20 O5 68236-13-5 prenyl-flavanone 169 
G108 Gancaonin L C20 H18 O6 129145-50-2P prenyl-Isoflavone 188 
G109 Licoagrochalcone A C20 H20 O4 202815-28-9 prenyl-Chalcone 170 
G110 Licoagroaurone C20 H18 O5 325144-70-5 prenyl-Benzofuranone 190 
G111 Erythrinin B =Wighteone C20 H18 O5 51225-30-0 prenyl isoflavone 203 
G112 8-Prenylgenistein 
=Lupiwighteone 
C20 H18 O5 104691-86-3 prenyl-Isoflavone 
170 
G113 163121-02-6 C15 H12 O4 163121-02-6 chalcone DNP 
G114 18184-25-3 C30 H44 O5 18184-25-3 saponin 204 
G115 10401-33-9 C30 H44 O4 10401-33-9 saponin 205 
G116 Licuraside C26 H30 O13 29913-71-1 chalcone glycoside 171 
G117 Kanzonol X =Tenuifolin B C25 H30 O4 182745-37-5 diprenyl-Isoflavane 170 
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G118 Isoliquiritin C21 H22 O9 5041-81-6 chalcone glycoside 171 
G119 Neoisoliquiritigenin C21 H22 O9 59122-93-9 chalcone glycoside 171 
G120 Glychionide A C21 H18 O11 119152-50-0 flavone glycoside 180 
G121 Licochalcone C C21 H22 O4 144506-14-9 prenyl chalcone 199 
G122 Calycosin C16 H12 O5 20575-57-9 isoflavone 55 
G123 (−)-Naringenin C15 H12 O5 480-41-1 Flavanone 173 
G124 Formononetin=Biochanin B C16 H12 O4 485-72-3  Isoflavone 47 
G125 Isoliquiritigen C15 H12 O4 961-29-5 Chalcone 170 
G126 Kumatakenin B C15 H10 O4 2196-14-7 flavone 206 
G127 Glicoricone C21 H20 O6 161099-37-2 prenyl-isoflavone DNP 
G128 R)-(−)-Vestitol C16 H16 O4 35878-41-2P isoflavan 188 
G129 4',7-Dihydroxyflavone 7-D-
glucoside 
C21 H20 O9 20633-86-7 flavone-glycoside 
54 
G130 1217305-76-4 C21 H20 O5 1217305-76-4 benzaldehyde-pyrano-
isoflavan 
188 
G131 1217305-78-6 C20 H20 O5 1217305-78-6 prenyl-Flavanone-3-ol 188 
G132 201157-06-4 C16 H16 O5 201157-06-4 isoflavan 188 
G133 Echinatin =Retrochalcone C16 H14 O4 34221-41-5P chalcone  171, 188 
G134 131319-67-0 C15 H14 O5 131319-67-0 dihydrochalcone 188 
G135 938190-29-5 C25 H28 O5 938190-29-5 diprenyl-chalcone 188 
G136 151135-83-0 C25 H26 O5 151135-83-0 prenyl-pyrano-chalcone 188 
G137 Euchrenone a5 C25 H26 O4 125140-20-7 pyrano-prenyl-flavanone 188 
G138 905708-40-9 C21 H22 O6 905708-40-9 prenyl-chalcone 188 
G139 3'-Hydroxy-4'-O-
methylglabridin 
C21 H22 O5 175554-11-7 pyrano-isoflavane 
188 
G140 938190-32-0 C21 H20 O5 938190-32-0 prenyl-isoflavone 188 
G141 Glabroisoflavanone B C21 H20 O5 866021-46-7 isoflavanone 207 
G142 Glabroisoflavanone A C20 H18 O5 204700-00-5 isoflavanone 207 
G143 400900-10-9 C21 H24 O10 400900-10-9 chalcone glycoside 208 
G144 131319-67-0 C15 H14 O5 131319-67-0 dihydrochalcone 188 
G145 Rocymosin B C21 H24 O10 150036-01-4 chalcone glycoside DNP  
G146 Glabraisoflavanone B C30 H38 O5 1201428-07-0 prenyl flavanone 189 
G147 p-Hydroxychalcone C15 H12 O2 20426-12-4 chalcone 209 
G148 Shinpterocarpin C20 H18 O4 157414-04-5 pyrano-pterocarpan 188 
G149 Cordifolin C16 H14 O5 53219-84-4 chalcone DNP 
G150 Licoagrone C45 H42 O10 228099-12-5 miscellaneous DNP 
G151 3-Methyl-3-hepten-2-one C8 H14 O1 39899-08-6 miscellaneous DNP 
G152 8-Prenylphaseollinisoflavan C25 H28 O4 175554-12-8 prenyl-pyrano-isoflavane 170 
G153 DHY67-Q C25 H28 O6 DHY67-Q Diprenyl-isoflavanone 
 
DNP 
G154 Glyasperin B C21 H22 O6 142488-54-8 prenyl-isoflavanone DNP 
G155 135432-48-3 C26 H30 O13 135432-48-3 flavanone glycoside 210 
G156 Abyssinone II =3'-
Prenylliquiritigenin 




G157 Isoviolanthin C27 H30 O14 40788-84-9 flavone C-glycoside 211 
G158 1217888-51-1 C25 H30 O6 1217888-51-1 miscellaneous 212 
G159 4''-Hydroxyglabridin C20 H20 O5 938190-33-1P pyrano-isoflavan 188 
G160 O-Methylshinpterocarpin C21 H20 O4 157479-38-4P pyrano-pterocarpan 171, 188 
G161 938190-31-9 C14 H16 O4 938190-31-9 
 
188 
G162 1217888-54-4 C14 H16 O3 1217888-54-4 
 
188 
G163 938190-35-3 C20 H22 O6 938190-35-3 prenyl-dihydrochalcone 188 
G164 905708-41-0 C21 H20 O6 905708-41-0 pyrano-isoflavanone-3-ol 188 
G165 Ononin 6''-O-acetate C24 H24 O10 120727-10-8 isoflavone-glucoside NCNPR 
G166 Isoliquiritigenin-4'-Me-ether C16 H14 O4 32274-67-2 chalcone NCNPR 




G168 Resorcinol C6 H6 O2 Gg2-ZA13  phenolic NCNPR 
G169 ZA15-Gg C21 H22 O7 ZA15-Gg arylcoumarine NCNPR 
G170 ZA19-Gg C20 H18 O6 ZA19-Gg Prenyl-isoflavone NCNPR 
G171 Erythbidin A C20 H20 O4 210050-83-2 pyran-isoflavan NCNPR 
G172 ZA20-Gg C27 H26 O9 ZA20-Gg miscellaneous NCNPR 
G173 ZA41-Gg C36 H38 O16 ZA41-Gg miscellaneous NCNPR 
G174 ZA21-Gg C20 H18 O5 ZA21-Gg arylcoumarine NCNPR 
G175 GDY88-C C25 H28 O6 GDY88-C diprenylisoflavanone DNP 
G176 Erybacin B C19 H18 O5 1314877-89-8  170 

























SI 4. Compounds from Glycyrrhiza uralensis 
 
No. Name (G. uralensis) M. Formula CAS Class Ref 
U1 Licorice glycoside C2 C36 H38 O16 202657-55-4 flavanone glycoside DNP 
U2 342433-16-3 C22 H24 O9 342433-16-3 flavanone glycoside 213 
U3 Rhizobialide C18 H32 O3 928213-29-0 stearolactone 214 
U4 Neoliquiritin C21 H22 O9 5088-75-5 flavanone glycoside 50 
U5 Cyclolicocoumarone C20 H20 O5 1253641-17-6 pyrano-benzofuran 215 
U6  Kumatakenin C17 H14 O6 3301-49-3 flavone-3-ol 216 
U7 Uralenneoside C12 H14 O8 143986-30-5 miscellaneous 217 
U8 Licorice glycoside D2 C35 H36 O15 202657-65-6 flavanone glycoside 53 
U9 76884-47-4 C8 H10 N2 O1 76884-47-4  pyrrolo-pyrimidine 218 
U10 Licorice glycoside D1 C35 H36 O15 202657-63-4 flavanone glycoside 53 
U11 Licorice glycoside E C35 H35 N1 O14 202657-66-7 miscellaneous 219 
U12 Liquiritigenin 7,4'-
diglucoside 
C27 H32 O14 93446-18-5 flavanone glycoside 
220 
U13 134250-13-8 C42 H64 O16 134250-13-8 saponin glycosides 221 
U14 Glycycarpan C26 H32 O6 1346768-08-8 prenyl-pyran-pterocarpan 222 
U15 Gancaonin R C24 H30 O4 134958-53-5 diprenyl-dihydrostillbenoid 169 
U16 Gancaonin S C24 H30 O4 134958-54-6 diprenyl-dihydrostillbenoid 169 
U17 Gancaonin U C24 H28 O4 134958-56-8 diprenyl-
Dihydrophenancerene 
169 
U18 Glycyrin C22 H22 O6 66056-18-6 coumarin 216 
U19 Gancaonin I C21 H22 O5 126716-36-7 prenylated-benzofuran 211 
U20 Gancaonin D C21 H20 O7 124596-88-9 prenyl-isoflavone 223 
U21 Licoricesaponin G2 C42 H62 O17 118441-84-2 saponin glycoside 50 
U22 Glycybenzofuran C21 H22 O5 1253641-15-4 prenylated-benzofuran 215 
U23 Licocoumarone C20 H20 O5 118524-14-4 prenylated-benzofuran 215 
U24 Gancaonin C C20 H18 O6 124596-87-8 prenyl-isoflavone 223 
U25 Gancaonin V C19 H20 O4 134958-57-9 prenyl-Dihydrophenancerene 169 
U26 Uralsaponin A C42 H62 O16 103000-77-7 saponin glycoside 224 
U27 Licorice glycoside C1 C36 H38 O16 202657-31-6 flavanone glycoside 225 
U28 24-Hydroxyglycyrrhetic 
acid 
C31 H48 O5 18184-26-4 saponin 
226 
U29 Glyuranolide C31 H44 O6 123914-44-3 saponin-lactone 227 
U30 Licoricesaponin A3 C48 H72 O21 118325-22-7 saponin glycoside 50 
U31 Glypallidifloric acid C30 H46 O3 17991-81-0 saponin DNP 
U32 Kanzonol L C30 H32 O6 156281-31-1 diprenyl-pyrano-isoflavone DNP 
U33 Licobichalcone C32 H26 O10 637338-06-8 biflavonoid DNP 
U34 Kanzonol I C27 H32 O5 152546-94-6 prenyl-pyran-isoflavan 228 
U35 Kanzonol H C26 H32 O5 152511-46-1 prenyl-pyran-isoflavan 228 
U36 Kanzonol J C26 H30 O5 152511-47-2 dipyrano-isoflavan 228 
U37 Kanzonol F C26 H28 O5 152511-44-9 prenyl-pyran-pterocarpan 228 
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U38 Kanzonol M C23 H26 O6 156250-70-3 prenyl-isoflavan DNP 
U39 Kanzonol N C22 H24 O6 156250-71-4 prenyl-isoflavan DNP 
U40 Uralsaponin B C42 H62 O16 105038-43-5 saponin glycoside 211 
U41 Glicophenone C20 H22 O6 303175-66-8 
 
211 
U42 Glycyrrhizol B C21 H18 O5 877373-01-8 pterocarpan DNP 
U43 Licoricesaponin B2 C42 H64 O15 118536-86-0 saponin glycoside 229 
U44 22-Dehydroxyuralsaponin 
C 
C42 H64 O15 134250-15-0 saponin glycoside 
224 
U45 Licoricesaponin K2 C42 H62 O16 135815-61-1 saponin glycoside 230 
U46 134449-15-3 C42 H62 O15 134449-15-3 saponin glycoside 229 
U47 Licoricesaponin C2 C42 H62 O15 118525-49-8 saponin glycoside 53 
U48 Uralsaponin W C42 H62 O15 1616062-88-4 saponin glycoside 229 
U49 18β-Glycyrrhetic acid 
methyl ester 
C31 H48 O4 1477-44-7 saponin 
226 
U50 Licorisoflavan A  C27 H34 O5 129314-37-0 diprenyl-isoflavan 216 
U51 Kanzonol G C26 H30 O6 152511-45-0 diprenyl-isoflavanone 228 
U52 1-Methoxyficifolinol C26 H30 O5 129280-35-9 diprenyl-pterocarpan 228 
U53 Kanzonol K C26 H28 O6 156281-30-0 diprenyl-isoflavan 231 
U54 Glycyrrhizol A C26 H28 O5 877373-00-7 pterocarpan 232 
U55 Isoangustone A C25 H26 O6 129280-34-8 diprenylated-isoflavone 211 
U56 Glyurallin B C25 H26 O6 199331-53-8 diprenylated-isoflavone 233 
U57 Gancaonin Q C25 H26 O5 134958-52-4 diprenyl-flavone 169 
U58 22β-Acetoxyglycyrrhizin C44 H64 O18 938042-17-2 saponin glycoside 211 
U59 150853-98-8 C21 H20 O7 150853-98-8 prenyl-flavone 234 
U60 gancaonin P-3'-methyl 
ether 
C21 H20 O7 151776-21-5 prenyl-3-OH-flavone 
235 
U61 Uralene C21 H20 O7 150853-99-9 prenyl-flavone 234 
U62 Glycryrurol C21 H20 O7 1415339-39-7 miscellaneous 236 
U63 Licoleafol C20 H20 O7 677709-68-1 prenyl flavanone 237 
U64 Uralenol C20 H18 O7 139163-15-8 prenyl-isoflavone-3-ol 211 
U65 Gancaonin P C20 H18 O7 129145-54-6 prenyl-flavone-3-ol 169 
U66 Neouralenol C20 H18 O7 C20 H18 O7 prenyl-3-OH-flavone DNP  
U67 119418-01-8 C44 H64 O16 119418-01-8 saponin glycoside 238 
U68 Phaseol C20 H16 O5 88478-02-8 coumestan DNP  
U69 Isotrifoliol C16 H10 O6  329319-08-6 coumestan 236 
U70 Galangin C15 H10 O5  548-83-4 3-OH-flavone 239 
U71 Licorice glycoside A C36 H38 O16 202657-28-1 chalcone-glycoside 53 
U72 Licorice glycoside B C35 H36 O15 202657-29-2 chalcone-glycoside 240 
U73 166531-18-6 C31 H44 O5 166531-18-6 saponin DNP 
U74 24-Hydroxyglabrolide C30 H44 O5 98063-18-4 saponin-lactone 226 
U75 Isoliquiritin apioside= 
Neolicuroside 
C26 H30 O13 120926-46-7 chalcone glycoside 
216 
U76 118536-87-1 C50 H76 O21 118536-87-1 saponin 238 
U77 Sigmoidin A C25 H28 O6 87746-48-3 diprenyl-flavanone DNP 
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U78 Gancaonin E C25 H28 O6 124596-89-0 diprenyl-flavanone 169 
U79 782503-66-6 C25 H26 O6 782503-66-6 diprenyl-flavone DNP 
U80 Vestitol 7-O-glucoside C22 H26 O9 202533-15-1 flavan glycoside DNP 
U81 Licoricone C22 H22 O6 51847-92-8 prenyl-isoflavone 211 
U82 952481-52-6 C21 H20 O9 952481-52-6 flavone glycoside DNP 
U83 Topazolin C21 H20 O6 109605-79-0 prenyl-flavone-3-ol 211 
U84 Gancaonin N C21 H20 O6 129145-52-4 prenyl-isoflavone 241 
U85 Gancaonin B C21 H20 O6 124596-86-7 prenyl-isoflavone DNP 
U86 Glycyrol C21 H18 O6 23013-84-5 prenyl-coumestan 216 
U87 Licoflavonol C20 H18 O6 60197-60-6 prenyl-flavone-3-ol 216 
U88 Gancaonin O C20 H18 O6 129145-53-5 prenyl-flavone 169 
U89 AlloLicoisoflavone b C20 H16 O6 117204-81-6 pyrano-isoflavone 211 
U90 60169-66-6 C11 H15 N1 60169-66-6 tetrahydroquinoline 242 
U91 28971-03-1 C10 H13 N1 28971-03-1 tetrahydroquinoline 242 
U92 Uralsaponin C C42 H64 O16 1262326-46-4 saponin glycoside 211 
U93 166531-19-7 C32 H48 O6 166531-19-7 saponin  DNP 
U94 Uralenolide C30 H44 O4 111150-27-7 saponin  DNP 
U95 Licoriquinone A C27 H32 O6 1346768-10-2  Isoflavan-Quinone 222 
U96 Licoriquinone B C26 H30 O6 1346768-14-6  Isoflavan-Quinone 243 
U97 Uralsaponin F C44 H64 O19 1208004-79-8 saponin glycoside 211 
U98 Edudiol C21 H22 O5 63343-94-2 prenyl-pterocarpan 222 
U99 1-Methoxyphaseollidin C21 H22 O5 65428-13-9 prenyl-pterocarpan 244 
U100 Gancaonin A C21 H20 O5 27762-99-8 prenyl-isoflavone 223 
U101 Gancaonin G C21 H20 O5 126716-34-5 prenyl-isoflavone 243 
U102 Gancaonin M C21 H20 O5 129145-51-3 prenyl-isoflavone 241 
U103 646508-72-7 C43 H62 O17 646508-72-7 saponin glycoside DNP 
U104 Glyurallin A C21 H22 O5 213130-81-5 pterocarpan DNP 
U105 Isobavachalcone C20 H20 O4 20784-50-3 prenyl-chalcone 245 
U106 Licoisoflavone a C20 H18 O6 66056-19-7 prenyl-isoflavone 211 
U107 Uralsaponin E C42 H60 O17 1262489-45-1 saponin glycoside 224 
U108 Kanzonol Q C15 H16 O4 17053-75-7 miscellaneous 246 
U109 Uralsaponin D C42 H58 O18 1262489-44-0 1262489-44-0 DNP 
U110 2',4',5,7-Tetrahydroxy-
3',8-diprenylisoflavanone 
C25 H28 O6 141846-47-1 diprenyl-isoflavanone 
247 
U111 Gancaonin H C25 H24 O6 126716-35-6 prenyl-pyrano-isoflavone DNP 
U112 Kanzonol P C22 H24 O5 156250-72-5 prenyl-pterocarpan 228 
U113 1680176-18-4 C20 H20 O5 1680176-18-4 prenyl-benzofuran 248 
U114 1177433-19-0 C21 H18 O6 1177433-19-0 coumestan 248 
U115 Demethylglycyrol C20 H16 O6 1680176-22-0 coumestan 249 
U117 1680176-21-9 C19 H18 O5 1680176-21-9 prenyl-benzofuran 248 
U118 Semilicoisoflavone B C20 H16 O6 129280-33-7 pyrano-isoflavone 211 
U119 Isokaempferide  C16 H12 O6 1592-70-7 flavone-3ol 215 
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U120 6468-37-7 C16 H12 O4 6468-37-7 Coumarin 248 
U121 6,8-Diprenylorobol C25 H26 O6 66777-70-6 diprenyl-isoflavone 248 
U122 6,8-Diprenylgenistein C25 H26 O5 51225-28-6 diprenyl isoflavone 211 
U123 Glyasperin D C22 H26 O5 142561-10-2 prenyl-isoflavan 216 
U124 23013-88-9 C23 H22 O6 23013-88-9 prenyl-coumestan 216 
U125 1680176-23-1 C22 H22 O6 1680176-23-1 prenyl-isoflavone 216 
U126 1680176-20-8 C21 H20 O6 1680176-20-8 coumarine 216 
U127 1680176-17-3 C21 H20 O6 1680176-17-3 prenyl-isoflavone 216 
U128 Licoarylcoumarin C21 H20 O6 125709-31-1 prenyl-coumarin 211 
U129 Uralsaponin X C50 H74 O22 1616062-89-5 saponin glycoside 229 
U130 Uralsaponin U C42 H62 O17 1616062-86-2 saponin glycoside 229 
U131 Uralsaponin N C42 H62 O17 1616062-79-3 saponin glycoside 229 
U132 Licoricesaponin H2 C42 H62 O16 118441-85-3 saponin glycoside 230 
U133 Uralsaponin V C42 H62 O15 1616062-87-3 saponin glycoside 229 
U134 Uralsaponin O C42 H60 O16 1616062-80-6 saponin glycoside 229 
U135 Licoricesaponin E2 C42 H60 O16 119417-96-8 saponin glycoside 230 
U136 Araboglycyrrhizin C41 H62 O14 1622142-49-7 saponin glycoside 216 
U137 22β-
Acetoxyglycrrhetaldehyde 
C32 H48 O5 1614257-31-6 saponin 
229 
U138 Uralsaponin S C48 H74 O20 1616062-84-0 saponin glycoside 229 
U139 Uralsaponin R C48 H74 O20 1616062-83-9 saponin glycoside 229 
U140 Uralsaponin T C48 H74 O19 1616062-85-1 saponin glycoside 229 
U141 Uralsaponin Y C48 H70 O20 1616062-90-8 saponin glycoside 229 
U142 Uralsaponin Q C47 H72 O19 1616062-82-8 saponin glycoside 229 
U143 Uralsaponin M C44 H64 O18 1616062-78-2 saponin glycoside 229 
U144 Uralsaponin P C42 H64 O16 1616062-81-7 saponin glycoside 229 
U145 Licoricesaponin J2 C42 H64 O16 938042-18-3 saponin glycoside 211 
U146 Isoliquiritigenin 4,4'-di-
O-glucopyranoside 
C27 H32 O14 69262-36-8 chalcone glycoside 
211 
U147 Glycyuralin B C21 H22 O5 1879910-23-2 prenyl-pterocarpan 211 
U148 Ononin=Formononetin 7-
O-glucoside 
C22 H22 O9 486-62-4 isoflavone glycoside 
211 
U149 Apigenin 4'-O-glucoside C21 H20 O10 20486-34-4 flavone glycoside 211 
U150 Sophoraflavone B C21 H20 O9 22052-75-1 flavone glycoside 211 
U151 Daidzin C21 H20 O9 552-66-9 isoflavone glycoside 211 
U152 Glycyuralin E C21 H22 O6 1879910-26-5 prenylated-benzofuran 211 
U153 Glycyuralin F C20 H20 O7 1879910-27-6 hydroxyprenyl-isoflavone 211 
U154 Syringic acid glucoside C15 H20 O10 33228-65-8 phenolic-glycoside 211 
U155 Luteone C20 H18 O6 41743-56-0 prenyl isoflavone 211 
U156 Vicenin= Apigenin 6,8-di-
C-glucoside 
C27 H30 O15 23666-13-9 flavone-glycoside 
220 
U157 Homobutein C16 H14 O5 34000-39-0 chalcone 211 
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U158 Pratensein C16 H12 O6 2284-31-3 isoflavone 211 
U159 Isomedicarpin C16 H14 O4 74560-05-7 pterocarpan 211 
U160 7-Methoxy-2',4'-
dihydroxyisoflavone 
C16 H12 O5 7622-53-9 isoflavone 
211 
U161 Apigenin 7-O-methyl 
ether  
C16 H12 O5 437-64-9 flavone 
211 
U162 Biochanin A C16 H12 O5 491-80-5 isoflavone 211 
U163 Isoviolanthin C27 H30 O14 40788-84-9 flavone C-glycoside 211 
U164 Kaempferol C15 H10 O6 520-18-3 flavone-3-ol 211 
U165 Daidzein C15 H10 O4 486-66-8 isoflavone 211 
U166 4-Methoxy-2H-pyran-2-
one 
C6 H6 O3 100047-51-6 simple lactone  
211 
U167 Schaftoside  C26 H28 O14 51938-32-0 flavone C-glycoside 211 
U168 Isoschaftoside C26 H28 O14 52012-29-0 flavone C-glycoside 211 
U169 Glycyuralin A C26 H34 O6 1879910-22-1 prenyl-pyran-isoflavan 211 
U170 Glycyuralin C C26 H32 O6 1879910-24-3 hydroxyprenyl-pyran-
isoflavan 
211 
U171 Angustone a C25 H26 O6 90686-13-8 diprenyl-isoflavone 211 
U173 no trivial name C43 H62 O16 1874227-82-3 saponin glycoside 211 
U174 Dehydroglyasperin D C22 H24 O5 517885-72-2 prenyl-dehydroisoflavan 211 
U175 Glyasperin C C21 H24 O5 142474-53-1 prenyl-isoflavan 211 
U176 Dehydroglyasperin C C21 H22 O5 199331-35-6 prenyl-dehydroisoflavan 250  
U177 Glicophenone C20 H22 O6 303175-66-8 
 
211 
U178 7-O-Methylluteone C21 H20 O6 122290-50-0 prenylated-isoflavone 211 
U179 1307578-72-8 C21 H20 O6 1307578-72-8 prenyl-flavone-3-ol 211 
U180 no trivial name C42 H62 O15 1874227-83-4 saponin glycoside 211 
U181 Glyurallin a C21 H20 O5 199331-36-7 prenyl pterocarpan 211 
U182 Hirtellanine C21 H18 O6 1369378-20-0 pyrano-isoflavone 211 
U183 11b-Hydroxy-11b,1-
dihydromedicarpin 
C16 H16 O5 210537-04-5  pterocarpan! 
211 
U184 1622179-42-3 C33 H38 O19 1622179-42-3 flavone C-glycoside 211 
U185 Glycyroside C27 H30 O13 125310-04-5 isoflavone glycoside 211 
U186 2'-Hydroxy-
isolupalbigenin 
C25 H26 O6 121747-94-2 diprenyl-isoflavone 
211 
U187 Isolupalbigenin C25 H26 O5 162616-70-8 diprenyl-isoflavone 211 
U189 ZA13-Gu C20 H16 O7 ZA13-Gu miscellaneous NCNPR 
U190 Conferol A C16 H16 O5 1172120-53-4 isoflavanol NCNPR 















































1 G163 α 2p15 −10.79 −105.92 
2 G28 α 2p15 −10.43 −105.86 
3 G106 α 2p15 −10.54 −105.34 
4 G3 α 2p15 −11.04 −105.11 
5 G40 α 2p15 −10.83 −104.52 
6 G138 α 2p15 −10.55 −101.07 
7 G156 α 2p15 −10.38 −100.18 
8 G112 α 2p15 −10.41 −97.60 
9 G38 α 2p15 −10.87 −96.96 
10 G174 α 2p15 −10.84 −96.31 
11 G163 β 1L2J −11.35 −96.15 
12 G33 α 2p15 −10.49 −95.93 
13 G108 α 2p15 −10.53 −95.76 
14 G2 β 1L2J −10.45 −95.35 
15 G28 β 1L2J −10.54 −94.89 
16 G21 α 2p15 −10.47 −94.64 
17 G50 α 2p15 −10.95 −94.43 
18 G127 α 2p15 −10.80 −93.82 
19 G158 β 1L2J −11.73 −93.19 
20 G47 α 2p15 −10.82 −93.11 
21 G30 α 2p15 −10.37 −93.06 
22 G40 β 1L2J −10.43 −91.87 
23 G170 α 2p15 −10.30 −90.75 
24 G154 α 2p15 −10.32 −90.73 
25 G75 β 1X7J −10.74 −90.66 
26 G38 β 1X7J −10.92 −90.10 
27 G111 β 1L2J −10.58 −89.09 
28 G99 β 1L2J −11.00 −88.50 
29 G100 β 1X7J −11.06 −86.56 
30 G171 α 1GWR −10.33 −85.01 
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SI 6. Glycyrrhiza uralensis top scoring compounds sorted by MM−GBSA 
 







1 U77 α 2p15 −11.05 −122.91 
2 U15 α 2p15 −11.49 −111.57 
3 U16 β 1L2J −11.03 −111.36 
4 U191 α 2p15 −10.84 −105.61 
5 U78 α 2p15 −10.19 −105.11 
6 U25 α 2p15 −9.92 −100.44 
7 U22 α 2p15 −10.26 −100.04 
8 U86 β 1L2J −10.58 −98.73 
9 U23 β 1L2J −11.14 −98.39 
10 U24 α 2p15 −10.39 −98.18 
11 U176 β 1L2J −10.33 −97.53 
12 U57 β 1L2J −10.22 −96.81 
13 U66 α 2p15 −11.15 −95.79 
14 U63 α 1GWR −11.88 −95.75 
15 U127 α 2p15 −10.66 −93.42 
16 U175 β 1L2J −10.85 −92.92 
17 U117 β 1L2J −10.91 −92.15 
18 U115 β 1L2J −10.47 −91.79 
19 U177 α 2p15 −10.12 −91.71 
20 U62 β 1L2J −10.15 −91.59 
21 U77 β 1L2J −10.47 −91.24 
22 U88 β 1L2J −10.72 −91.07 
23 U119 β 1X7J −10.15 −89.28 
24 U127 β 1L2J −10.30 −88.71 
25 U105 β 1X7J −10.23 −88.66 
26 U189 α 2p15 −9.95 −86.80 
27 U105 α 1GWR −10.28 −84.87 
28 U165 β 1X7J −10.49 −84.09 
29 U69 β 1X7J −10.59 −83.22 













SI 7. Predicted RBA for top 20 compounds in both G. glabra and G. uralensis that scored 
(>70%) confidence in estro_filter as calculated in ADMET Predictor™. 
 
Rank No. Estro_Filter Estro_RBA Rank No. Estro_Filter Estro_RBA 
1 G94 Toxic (97%) 758.16 1 U35 Toxic (97%) 330.74 
2 G117 Toxic (97%) 699.12 2 U169 Toxic (89%) 268.66 
3 G41 Toxic (97%) 364.00 3 U175 Toxic (97%) 184.89 
4 G152 Toxic (97%) 138.98 4 U170 Toxic (76%) 133.40 
5 G96 Toxic (97%) 108.12 5 U147 Toxic (73%) 93.40 
6 G61 Toxic (97%) 98.37 6 U176 Toxic (97%) 75.16 
7 G97 Toxic (97%) 56.62 7 U123 Toxic (97%) 75.05 
8 G49 Toxic (97%) 42.985 8 U191 Toxic (97%) 46.29 
9 G175 Toxic (76%) 37.22 9 U15 Toxic (97%) 46.17 
10 G21 Toxic (97%) 36.00 10 U22 Toxic (97%) 39.45 
11 G40 Toxic (97%) 34.13 11 U16 Toxic (97%) 39.10 
12 G69 Toxic (89%) 33.32 12 U110 Toxic (76%) 38.06 
13 G38 Toxic (97%) 25.32 13 U174 Toxic (89%) 36.04 
14 G28 Toxic (76%) 16.33 14 U98 Toxic (97%) 31.45 
15 G174 Toxic (97%) 12.44 15 U187 Toxic (73%) 31.26 
16 G3 Toxic (73%) 10.55 16 U117 Toxic (97%) 29.87 
17 G159 Toxic (97%) 10.034 17 U104 Toxic (76%) 29.17 
18 G47 Toxic (97%) 8.77 18 U99 Toxic (97%) 28.60 
19 G19 Toxic (97%) 8.40 19 U23 Toxic (97%) 27.93 























                 SI 8. Glycyrrhiza glabra top-scoring compounds against PXR (1NRL) crystal 












1 G158 −13.36 −82.20 33 G106 −10.06 −67.56 
2 G136 −12.59 −57.69 34 G101 −10.02 −66.64 
3 G146 −12.53 −72.39 35 G159 −9.98 −45.66 
4 G172 −12.52 −70.72 36 G159 −9.98 −9.98 
5 G83 −12.33 −88.91 37 G137 −9.98 −9.98 
6 G163 −12.18 −75.52 38 G68 −9.97 −9.97 
7 G96 −11.95 −80.85 39 G140 −9.94 −9.94 
8 G33 −11.91 −66.11 40 G94 −9.91 −9.91 
9 G135 −11.69 −74.52 41 G110 −9.96 −9.96 
10 G60 −11.58 −87.77 42 G170 −9.89 −9.89 
11 G1 −11.54 −41.99 43 G97 −9.88 −9.88 
12 G28 −11.26 −74.99 44 G30 −9.84 −9.84 
13 G40 −11.09 −69.09 45 G71 −9.83 −9.83 
14 G42 −10.99 −72.37 46 G134 −9.82 −9.82 
15 G164 −10.99 −60.34 47 G100 −9.84 −9.84 
16 G152 −10.91 −35.20 48 G131 −9.74 −9.74 
17 G141 −10.80 −62.74 49 G19 −9.70 −9.70 
18 G99 −10.87 −74.75 50 G111 −9.69 −9.69 
19 G64 −10.72 −80.71 51 G32 −9.69 −9.69 
20 G117 −10.72 −58.66 52 G65 −9.67 −9.67 
21 G41 −10.56 −67.82 53 G62 −9.65 −9.65 
22 G2 −10.47 −65.61 54 G53 −9.60 −9.60 
23 G48 −10.42 −71.42 55 G102 −9.60 −9.60 
24 G109 −10.46 −77.76 56 G138 −9.63 −9.63 
25 G61 −10.28 −20.10 57 G132 −9.58 −9.58 
26 G98 −10.25 −68.26 58 G139 −9.56 −9.56 
27 G108 −10.24 −66.42 59 G35 −9.55 −9.55 
28 G21 −10.21 −57.29 60 G88 −9.54 −9.54 
29 G90 −10.21 −41.13 61 G91 −9.54 −9.54 
30 G142 −10.21 −64.10 62 G69 −9.52 −9.52 
31 G144 −10.12 −63.78 63 G154 −9.50 −9.50 








SI 9. Glycyrrhiza uralensis  top-scoring compounds against PXR (1NRL) 







Rank No XP score 
Emodel 
score 
1 U77 −12.26 −61.88 29 U54 −10.07 −53.88 
2 U186 −12.18 −75.86 30 U34 −10.04 −52.24 
3 U121 −11.72 −62.73 31 U128 −10.04 −61.43 
4 U79 −11.32 −34.46 32 U106 −10.03 −67.06 
5 U52 −11.16 −20.64 33 U191 −10.00 −66.84 
6 U187 −11.06 −73.77 34 U88 −9.99 −70.15 
7 U111 −11.00 −16.83 35 U105 −10.03 −58.39 
8 U51 −10.88 −63.85 36 U60 −9.95 −73.45 
9 U189 −10.87 −54.86 37 U117 −9.92 −60.62 
10 U57 −10.72 −44.33 38 U178 −9.86 −66.60 
11 U64 −10.71 −73.32 39 U18 −9.85 −68.63 
12 U55 −10.69 −69.68 40 U84 −9.83 −65.02 
13 U171 −10.67 −34.90 41 U155 −9.78 −63.13 
14 U78 −10.66 −63.91 42 U81 −9.77 −61.65 
15 U35 −10.60 −43.01 43 U126 −9.76 −67.29 
16 U110 −10.60 −58.17 44 U36 −9.76 −52.58 
17 U85 −10.53 −63.83 45 U189 −9.76 −70.68 
18 U59 −10.46 −75.87 46 U153 −9.71 −67.16 
19 U16 −10.45 −73.07 47 U170 −9.70 −10.11 
20 U38 −10.47 −80.33 48 U19 −9.67 −64.20 
21 U65 −10.40 −70.29 49 U174 −9.66 −73.89 
22 U152 −10.37 −70.27 50 U179 −9.66 −68.80 
23 U15 −10.34 −73.23 51 U50 −9.65 −19.40 
24 U41 −10.44 −78.57 52 U63 −9.64 −70.95 
25 U17 −10.21 −61.27 53 U41 −9.79 −76.19 
26 U169 −10.21 −4.63 54 U87 −9.53 −68.63 
27 U39 −10.27 −78.75 55 U25 −9.52 −53.86 









                                                            SPECTRAL DATA 
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Resveratrol prenylation products (M2-M10) 
 
1H NMR (MeOD, 400MHz) spectrum of M2. 
 










IR spectrum of compound M2 
 





1H NMR (MeOD, 400MHz) spectrum of M3 
 







IR spectrum of compound M3 
 










1H NMR (acetone-d6, 400 MHz) spectrum of M4 
 





IR spectrum of compound M4 
 










1H NMR (acetone-d6, 400 MHz) spectrum of M5 
 







IR spectrum of compound M5 
 




1H NMR (acetone-d6, 500 MHz)  spectrum of M6 
 








IR spectrum of compound M6 
 






1H NMR (acetone-d6, 500 MHz)  spectrum of compound M7 
 








IR spectrum of compound M7 
 




1H NMR (acetone-d6, 400 MHz) spectrum of M8 
 






HSQC spectrum of compound M8 
 























IR spectrum of compound M8 
 




1H NMR (acetone-d6, 500 MHz)spectrum of M9 
 





HSQC spectrum of compound M9 
 




NOESY spectrum of compound M9 
 






IR spectrum of compound M9 
 









1H NMR (acetone-d6, 400 MHz) spectrum of M10 
 





IR spectrum of compound M10 
 








         DHS  prenylation products (M12-M18) 
 
1H NMR (acetone-d6, 400 MHz) spectrum of M12 
 





IR spectrum of compound M12 
 










1H NMR (acetone-d6, 100 MHz) spectrum of M13 
 






IR spectrum of compound M13 
 




















IR spectrum of compound M14 
 




1H NMR (acetone-d6, 500 MHz) spectrum of compound M15 
 







IR spectrum of compound M15 
 














1H NMR (acetone-d6, 400 MHz) spectrum of M16 
 





IR spectrum of compound M16 
 











1H NMR (acetone-d6, 400 MHz) spectrum of M17 
 





IR spectrum of compound M17 
 
 








1H NMR (CDCl3, 400 MHz) spectrum of compound M18 
 







IR spectrum of compound M18 
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